[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "vicuna-7b_response": "Acrokeratosis paraneoplastica is a skin condition that is sometimes associated with the presence of malignancies in the upper respiratory or digestive systems. It is characterized by the development of thick, rough, and scaly patches on the skin, particularly on the hands and feet. The condition is also known as Bazex's syndrome, named after the French dermatologist who first described it in 1897. The patient described in the provided document has been diagnosed with enduring and dedifferentiated carcinoma of the parotid gland, which is a type of cancer that originates in the salivary glands located in the neck, and metastatic cervical lymph nodes, which are clusters of immune cells that have spread to the neck from a cancerous tumor. The patient's case is an example of a paraneoplastic syndrome, which is a group of symptoms that occur as a result of a cancerous tumor, but are not directly caused by the tumor itself.",
    "vicuna-7b_fact_raw": "1. Acrokeratosis paraneoplastica is associated with malignancies in the upper respiratory or digestive systems.\n2. The condition involves the development of thick, rough, and scaly patches on the skin, particularly on the hands and feet.\n3. Acrokeratosis paraneoplastica is also known as Bazex's syndrome.\n4. Bazex's syndrome was first described by a French dermatologist in 1897.\n5. A paraneoplastic syndrome is a group of symptoms that occur as a result of a cancerous tumor but are not directly caused by the tumor itself.",
    "vicuna-7b_fact": [
      "Acrokeratosis paraneoplastica is associated with malignancies in the upper respiratory or digestive systems.",
      "The condition involves the development of thick, rough, and scaly patches on the skin, particularly on the hands and feet.",
      "Acrokeratosis paraneoplastica is also known as Bazex's syndrome.",
      "Bazex's syndrome was first described by a French dermatologist in 1897.",
      "A paraneoplastic syndrome is a group of symptoms that occur as a result of a cancerous tumor but are not directly caused by the tumor itself."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Bazex's syndrome was first described by a French dermatologist, Andre Bazex, in the 1960s.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "vicuna-7b_response": "Weaver syndrome is a childhood overgrowth syndrome that is similar to Sotos syndrome in terms of its characteristic facial appearance, advanced bone age, and developmental delay. However, Weaver syndrome has its own distinctive facial gestalt. Recently, a 2.2-Mb chromosome 5q35 microdeletion, encompassing NSD1, was reported as the major cause of Sotos syndrome, with intragenic NSD1 mutations identified in a minority of cases. In this study, the authors evaluated 75 patients with childhood overgrowth for intragenic mutations and large deletions of NSD1. The patients were scored into four groups based on their phenotype prior to molecular analysis. The authors detected three deletions and 32 mutations in NSD1 that are likely to impair its functions. The truncating mutations were spread throughout NSD1, but there was evidence of clustering of missense mutations in highly conserved functional domains between exons 13 and 23. The authors found that the presence of an NSD1 alteration was strongly correlated with the clinical phenotype, with 28 of 37 (76%) patients in group 1 having NSD1 mutations or deletions, whereas none of the patients in group 4 had abnormalities of NSD1. Three patients with Weaver syndrome had NSD1 mutations, all between amino acids 2142 and 2184. The authors conclude that intragenic mutations of NSD1 are the major cause of Sotos syndrome and account for some Weaver syndrome cases but rarely occur in other childhood overgrowth phenotypes.",
    "vicuna-7b_fact_raw": "1. Weaver syndrome is a childhood overgrowth syndrome that shares characteristics with Sotos syndrome, such as facial appearance, advanced bone age, and developmental delay.\n2. A 2.2-Mb chromosome 5q35 microdeletion encompassing NSD1 is the major cause of Sotos syndrome, and intragenic NSD1 mutations are identified in a minority of cases.\n3. A study evaluated 75 patients with childhood overgrowth for intragenic mutations and large deletions of NSD1, who were scored into four groups based on phenotype.\n4. The study detected three deletions and 32 mutations in NSD1, with a strong correlation between the presence of an NSD1 alteration and the clinical phenotype of Sotos syndrome.\n5. Three patients with Weaver syndrome had NSD1 mutations, specifically between amino acids 2142 and 2184.",
    "vicuna-7b_fact": [
      "Weaver syndrome is a childhood overgrowth syndrome that shares characteristics with Sotos syndrome, such as facial appearance, advanced bone age, and developmental delay.",
      "A 2.2-Mb chromosome 5q35 microdeletion encompassing NSD1 is the major cause of Sotos syndrome, and intragenic NSD1 mutations are identified in a minority of cases.",
      "A study evaluated 75 patients with childhood overgrowth for intragenic mutations and large deletions of NSD1, who were scored into four groups based on phenotype.",
      "The study detected three deletions and 32 mutations in NSD1, with a strong correlation between the presence of an NSD1 alteration and the clinical phenotype of Sotos syndrome.",
      "Three patients with Weaver syndrome had NSD1 mutations, specifically between amino acids 2142 and 2184."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: A 2.2-Mb chromosome 5q35 microdeletion encompassing NSD1 is the major cause of Sotos syndrome, and intragenic NSD1 mutations are identified in the majority of cases, not a minority.\n3. UNKNOWN (The statement doesn't provide a complete context to verify the study design or findings.)\n4. UNKNOWN (As with the previous statement, the specific study and its findings are not provided, making it difficult to verify the truthfulness of this statement.)\n5. FALSE [correction]: Typically, mutations in the EZH2 gene, not NSD1, are associated with Weaver syndrome.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "vicuna-7b_response": "The JASPAR database is a leading open-access database of matrix profiles describing the DNA-binding patterns of transcription factors (TFs) and other proteins interacting with DNA in a sequence-specific manner. The latest release of the JASPAR database, the fourth major release, is the largest expansion of the core database to date. The new entries include the first batch of profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments, and 177 yeast TF binding profiles. The introduction of a yeast division brings the convenience of JASPAR to an active research community.\nThe binding models are refined by newer data, and the JASPAR database now uses versioning of matrices. In this release, 12% of the older models were updated to improved versions. Classification of TF families has been improved by adopting a new DNA-binding domain nomenclature. A curated catalog of mammalian TFs is provided, extending the use of the JASPAR profiles to additional TFs belonging to the same structural family.\nThe changes in the database set the system ready for more rapid acquisition of new high-throughput data sources. Additionally, three new special collections provide matrix profile data produced by recent alternative high-throughput approaches. The JASPAR database continues to be a valuable resource for the scientific community studying transcriptional regulation.",
    "vicuna-7b_fact_raw": "1. The JASPAR database is an open-access database that provides DNA-binding patterns of transcription factors (TFs) and other DNA-interacting proteins.\n2. As of the latest release mentioned, the JASPAR database had undergone four major releases.\n3. The latest major release of JASPAR included the first batch of profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments.\n4. The recent update of the JASPAR database includes the addition of 177 yeast TF binding profiles.\n5. In the mentioned release of the JASPAR database, 12% of the older models were updated to improved versions.",
    "vicuna-7b_fact": [
      "The JASPAR database is an open-access database that provides DNA-binding patterns of transcription factors (TFs) and other DNA-interacting proteins.",
      "As of the latest release mentioned, the JASPAR database had undergone four major releases.",
      "The latest major release of JASPAR included the first batch of profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments.",
      "The recent update of the JASPAR database includes the addition of 177 yeast TF binding profiles.",
      "In the mentioned release of the JASPAR database, 12% of the older models were updated to improved versions."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The exact number of major releases is not provided, and it could be more or less than four. The statement cannot be addressed properly without additional information.\n3. TRUE: This statement is likely to be true as JASPAR frequently updates with profiles derived from newer techniques like ChIP-seq and ChIP-chip.\n4. UNKNOWN: Without knowing the specific release referred to, it's impossible to confirm whether 177 yeast TF binding profiles were added in that update.\n5. UNKNOWN: Similarly, without the context of the particular release, we cannot confirm the percentage of models that were updated.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "vicuna-7b_response": "The viral KP4 protein, also known as the P protein of parainfluenza virus 5 (PIV5), is an essential cofactor of the viral RNA-dependent RNA polymerase. The P protein is phosphorylated at specific sites, which can positively or negatively regulate viral gene expression. Sumoylation, a process that adds small ubiquitin-like modifier (SUMO) to proteins posttranslationally, plays an important role in regulating protein function. In this study, the researchers found that the P protein of PIV5 was sumoylated with SUMO1 in both transfected and infected cells. The K254 residue of the P protein is within a consensus sumoylation motif. Mutation of the P protein at K254 to arginine (P-K254R) reduced PIV5 minigenome activity, as well as the sumoylation level of the P protein. Incorporation of K254R into a recombinant PIV5 (rPIV5-P-K254R) resulted in a virus that grew to a lower titer and had lower levels of viral RNA synthesis and protein expression than wild-type PIV5, suggesting that sumoylation of the P protein at K254 is important for PIV5 growth. The researchers propose that sumoylation of the P protein at K254 regulates PIV5 gene expression through a host protein.",
    "vicuna-7b_fact_raw": "1. The KP4 protein, also known as the P protein of parainfluenza virus 5 (PIV5), is a cofactor of the viral RNA-dependent RNA polymerase.\n2. The P protein is phosphorylated at specific sites, affecting viral gene expression.\n3. Sumoylation plays a significant role in regulating the function of the P protein of PIV5.\n4. Mutation of K254 to arginine in the P protein reduces PIV5 minigenome activity and the level of sumoylation of the P protein.\n5. The recombinant PIV5 with the K254R mutation in the P protein grew to a lower titer compared to the wild-type virus.",
    "vicuna-7b_fact": [
      "The KP4 protein, also known as the P protein of parainfluenza virus 5 (PIV5), is a cofactor of the viral RNA-dependent RNA polymerase.",
      "The P protein is phosphorylated at specific sites, affecting viral gene expression.",
      "Sumoylation plays a significant role in regulating the function of the P protein of PIV5.",
      "Mutation of K254 to arginine in the P protein reduces PIV5 minigenome activity and the level of sumoylation of the P protein.",
      "The recombinant PIV5 with the K254R mutation in the P protein grew to a lower titer compared to the wild-type virus."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The KP4 protein is actually a fungal toxin produced by Ustilago maydis and is not related to parainfluenza virus 5 (PIV5). The P protein is indeed a cofactor of the viral RNA-dependent RNA polymerase in PIV5.\n2. TRUE\n3. TRUE - Based on the context provided, it is understood that sumoylation is significant in regulating the function of the P protein of PIV5, although additional context would be necessary for a detailed confirmation.\n4. TRUE - If the context indicates that this is a known effect of mutating K254 to arginine, then this statement can be considered true. However, such a specific detail would need verification from scientific studies on the PIV5 P protein.\n5. TRUE - This statement is specific and suggests a result from an experiment or study comparing the recombinant PIV5 with the K254R mutation with the wild-type virus. Assuming it is based on experimental evidence, it is considered true. However, without access to the original data or publication, it is impossible to verify this claim independently.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "vicuna-7b_response": "Yes, DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies. The patent application WO2008106213 describes the beneficial effects of DITPA, including stimulating weight loss in overweight mammals, lowering triglycerides, and treating metabolic syndrome in humans. The human clinical studies employing DITPA have focused on obese adults and have shown weight reduction and improvement in metabolic abnormalities.",
    "vicuna-7b_fact_raw": "1. DITPA is a thyroid hormone analog used in experimental and clinical studies.\n2. The patent application WO2008106213 describes the beneficial effects of DITPA.\n3. DITPA use includes stimulating weight loss in overweight mammals.\n4. DITPA is used for lowering triglycerides.\n5. Clinical studies with DITPA have shown weight reduction and improvement in metabolic abnormalities in obese adults.",
    "vicuna-7b_fact": [
      "DITPA is a thyroid hormone analog used in experimental and clinical studies.",
      "The patent application WO2008106213 describes the beneficial effects of DITPA.",
      "DITPA use includes stimulating weight loss in overweight mammals.",
      "DITPA is used for lowering triglycerides.",
      "Clinical studies with DITPA have shown weight reduction and improvement in metabolic abnormalities in obese adults."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "vicuna-7b_response": "The COUGER tool is a device used in dentistry for sharpening scalers and curettes. It is typically used by dental hygienists and dentists to maintain the sharpness of their instruments, which are used for removing plaque and tartar from teeth. The COUGER tool is powered by a rotary stone, which is used to grind the sides of the blade to create a sharp edge. The tool is designed to make the sharpening process easier and more efficient, and it is recommended to be used on a regular basis to extend the life of the instruments. The COUGER tool is not a standalone device, it is typically used in conjunction with other dental instruments and materials.",
    "vicuna-7b_fact_raw": "1. The COUGER tool is used in dentistry to sharpen scalers and curettes.\n2. Dental hygienists and dentists use the COUGER tool to maintain the sharpness of their instruments.\n3. The COUGER tool uses a rotary stone to grind the sides of the blade.\n4. The tool is designed to make the sharpening process more efficient.\n5. The COUGER tool is recommended to be used regularly to extend the life of dental instruments.",
    "vicuna-7b_fact": [
      "The COUGER tool is used in dentistry to sharpen scalers and curettes.",
      "Dental hygienists and dentists use the COUGER tool to maintain the sharpness of their instruments.",
      "The COUGER tool uses a rotary stone to grind the sides of the blade.",
      "The tool is designed to make the sharpening process more efficient.",
      "The COUGER tool is recommended to be used regularly to extend the life of dental instruments."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The Cavitron Ultrasonic Scaling device (often referred to as Cavitron) rather than COUGER is used widely in dentistry, but not specifically for sharpening scalers and curettes. However, without a widely recognized tool known as COUGER in dentistry, this statement cannot be confirmed. There are various other tools and devices used for sharpening dental instruments, like sharpening stones or automatic sharpeners.\n2. FALSE [correction]: Since the COUGER tool is not a recognized standard tool in dentistry for maintaining the sharpness of instruments, this statement appears to be false. Dental hygienists and dentists typically use sharpening stones or other devices to maintain the sharpness of their instruments.\n3. FALSE [correction]: While rotary stones are indeed used for grinding and sharpening in some contexts, it is unclear what the COUGER tool is, and if it's not a recognized tool in the dental industry, this statement cannot be confirmed as true.\n4. UNKNOWN: Without clear information on what the COUGER tool is, it's impossible to verify the intent of its design regarding the efficiency of the sharpening process.\n5. UNKNOWN: Since the COUGER tool is not identified as a standard dental device, it's impossible to confirm if it's recommended for regular use to extend the life of dental instruments. Regular maintenance of dental instruments is standard practice, but the use of a specific tool named COUGER cannot be verified.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "vicuna-7b_response": "Yes, there are drugs for Tick-borne Encephalitis. According to the information provided, a drug called cytoflavin is suggested as a treatment option for neuroinfections, including tick-borne encephalitis, with a modifying effect on NO. The drug was found to significantly reduce general brain, focal brain, and neuropsychological disorders, as well as the endogenous hyperproduction of NO metabolites in patients who received cytoflavin compared to those who did not receive the drug. The recommended dose is 10.0 ml administered intravenously in drops once a day for 7-10 days.",
    "vicuna-7b_fact_raw": "1. Cytoflavin is suggested as a treatment option for neuroinfections, including tick-borne encephalitis.\n2. Cytoflavin has a modifying effect on Nitric Oxide (NO).\n3. The drug cytoflavin was found to reduce general brain, focal brain, and neuropsychological disorders in patients with tick-borne encephalitis.\n4. Cytoflavin can reduce the endogenous hyperproduction of NO metabolites in patients.\n5. The recommended dose of cytoflavin for tick-borne encephalitis is 10.0 ml administered intravenously once a day for 7-10 days.",
    "vicuna-7b_fact": [
      "Cytoflavin is suggested as a treatment option for neuroinfections, including tick-borne encephalitis.",
      "Cytoflavin has a modifying effect on Nitric Oxide (NO).",
      "The drug cytoflavin was found to reduce general brain, focal brain, and neuropsychological disorders in patients with tick-borne encephalitis.",
      "Cytoflavin can reduce the endogenous hyperproduction of NO metabolites in patients.",
      "The recommended dose of cytoflavin for tick-borne encephalitis is 10.0 ml administered intravenously once a day for 7-10 days."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe statements regarding the effects of cytoflavin, such as its modifying effect on Nitric Oxide (NO) and its potential to reduce the endogenous hyperproduction of NO metabolites, are generally consistent with the drug's intended effects, based on medical literature concerning antioxidants and their mechanisms. However, the specific treatment recommendations and outcomes for patients with tick-borne encephalitis, such as the detailed efficacy and the recommended dose, require specialized medical knowledge or access to clinical study data that is not universally documented. Therefore, unless the given statements can be directly validated with current medical guidelines or research findings, the actual recommended use and efficacy for tick-borne encephalitis, as well as the specific recommended dose, would remain UNKNOWN.",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "vicuna-7b_response": "The University of California, Santa Cruz Genome Browser Database is a genome browser database that provides annotation for the genomes of 13 vertebrate and 19 invertebrate species. The database includes assembly data, genes and gene predictions, mRNA and EST alignments, and comparative genomics, regulation, expression and variation data. The Genome Browser displays a wide variety of annotations at all scales from the single nucleotide level up to a full chromosome and includes powerful visualization and querying capabilities for mining the data. The database is optimized for fast interactive performance and new features include VisiGene, phyloGif, a redesigned Custom Track feature, an expanded SNP annotation track, and many new display options. The Genome Browser, other tools, downloadable data files, and documentation can be found at <http://genome.ucsc.edu/>.",
    "vicuna-7b_fact_raw": "1. The University of California, Santa Cruz Genome Browser Database provides annotation for the genomes of 13 vertebrate and 19 invertebrate species.\n2. The database includes assembly data, genes and gene predictions, mRNA and EST alignments, comparative genomics, regulation, expression, and variation data.\n3. The Genome Browser displays annotations ranging from the single nucleotide level to a full chromosome.\n4. New features of the Genome Browser include VisiGene, phyloGif, a redesigned Custom Track feature, and an expanded SNP annotation track.\n5. The Genome Browser and related tools, data files, and documentation are accessible at http://genome.ucsc.edu/.",
    "vicuna-7b_fact": [
      "The University of California, Santa Cruz Genome Browser Database provides annotation for the genomes of 13 vertebrate and 19 invertebrate species.",
      "The database includes assembly data, genes and gene predictions, mRNA and EST alignments, comparative genomics, regulation, expression, and variation data.",
      "The Genome Browser displays annotations ranging from the single nucleotide level to a full chromosome.",
      "New features of the Genome Browser include VisiGene, phyloGif, a redesigned Custom Track feature, and an expanded SNP annotation track.",
      "The Genome Browser and related tools, data files, and documentation are accessible at http://genome.ucsc.edu/."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: The exact number of species whose genomes are annotated in the UCSC Genome Browser Database can vary over time, and without knowing the current database content, it's not possible to verify the numbers stated.\n2. TRUE: The UCSC Genome Browser Database does indeed include a wide array of data including assembly data, genes and gene predictions, mRNA and EST alignments, comparative genomics, regulation, expression, and variation data.\n3. TRUE: The Genome Browser is designed to display annotations at various scales, including the single nucleotide level and up to full chromosomes.\n4. UNKNOWN: The features of the Genome Browser are updated over time, and without a specific timestamp or version reference, it's difficult to confirm whether these features are new or former updates.\n5. TRUE: The Genome Browser and its related tools, data files, and documentation are typically accessed via the URL provided.",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "vicuna-7b_response": "EZH2 gene mutations are associated with Weaver syndrome. Weaver syndrome is a rare genetic disorder characterized by short stature, intellectual disability, and distinctive facial features such as a broad forehead, low-set and malformed ears, and a small jaw. Other features may include webbed neck, abnormalities of the genitals, and a wide space between the big toes. The condition is caused by mutations in the EZH2 gene, which encodes a protein involved in regulating the expression of other genes. The mutations lead to an accumulation of the histone-lysine N-methyltransferase EZH2 protein, which results in the dysregulation of gene expression and the development of the characteristic features of Weaver syndrome.",
    "vicuna-7b_fact_raw": "1. EZH2 gene mutations are associated with Weaver syndrome.\n2. Weaver syndrome is characterized by short stature and intellectual disability.\n3. Distinctive facial features of Weaver syndrome include a broad forehead, low-set and malformed ears, and a small jaw.\n4. Weaver syndrome may feature abnormalities such as a webbed neck, genital abnormalities, and a wide space between the big toes.\n5. Mutations in the EZH2 gene cause an accumulation of the histone-lysine N-methyltransferase EZH2 protein.",
    "vicuna-7b_fact": [
      "EZH2 gene mutations are associated with Weaver syndrome.",
      "Weaver syndrome is characterized by short stature and intellectual disability.",
      "Distinctive facial features of Weaver syndrome include a broad forehead, low-set and malformed ears, and a small jaw.",
      "Weaver syndrome may feature abnormalities such as a webbed neck, genital abnormalities, and a wide space between the big toes.",
      "Mutations in the EZH2 gene cause an accumulation of the histone-lysine N-methyltransferase EZH2 protein."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is characterized by rapid growth during childhood, advanced bone age, and distinctive facial features. It is not typically characterized by short stature; instead, affected individuals may be taller than average.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the EZH2 gene typically lead to a reduction or absence of functional histone-lysine N-methyltransferase EZH2 protein, not an accumulation.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "vicuna-7b_response": "Human pregnancy zone protein (PZP) undergoes a dimer-to-tetramer transition. PZP forms dimeric/tetrameric species of 360/720 kDa. PZP binds proteinases, causing a transition to a new conformational state. Three different conformational states exist for PZP and its derivatives. Access to discriminating immunochemical tools allows for an evaluation of the relative abundance of the different complexes in vivo.",
    "vicuna-7b_fact_raw": "1. Human pregnancy zone protein (PZP) undergoes a dimer-to-tetramer transition.\n2. PZP forms dimeric and tetrameric species of 360 and 720 kDa, respectively.\n3. PZP binds proteinases and transitions to a new conformational state.\n4. There are three different conformational states of PZP and its derivatives.\n5. Discriminating immunochemical tools can evaluate the relative abundance of the different PZP complexes in vivo.",
    "vicuna-7b_fact": [
      "Human pregnancy zone protein (PZP) undergoes a dimer-to-tetramer transition.",
      "PZP forms dimeric and tetrameric species of 360 and 720 kDa, respectively.",
      "PZP binds proteinases and transitions to a new conformational state.",
      "There are three different conformational states of PZP and its derivatives.",
      "Discriminating immunochemical tools can evaluate the relative abundance of the different PZP complexes in vivo."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the highly specific nature of the statements about Human pregnancy zone protein (PZP), I have assessed them to the best of my ability. However, without knowledge of the current and specific scientific literature on PZP conformations (statement 4) and the available immunochemical tools for evaluating PZP complexes in vivo (statement 5), their truthfulness cannot be determined and thus are labeled as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "vicuna-7b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is troponin I (TnI). TnI is a key regulatory protein in muscle contraction and is involved in the interaction between actin and myosin in skeletal and cardiac muscle. TnI has been shown to interact with PLN and play a role in the regulation of intracellular Ca2+ in heart muscle cells. The interaction between TnI and PLN has been shown to occur at multiple sites within the cytoplasmic and membrane domains. TnI has also been shown to have anti-apoptotic properties and may play a role in the protection of heart muscle cells from cell death.",
    "vicuna-7b_fact_raw": "1. Troponin I (TnI) interacts with phospholamban (PLN).\n2. TnI is an anti-apoptotic protein.\n3. TnI is involved in muscle contraction and the interaction between actin and myosin in skeletal and cardiac muscle.\n4. The interaction between TnI and PLN plays a role in the regulation of intracellular Ca2+ in heart muscle cells.\n5. TnI may protect heart muscle cells from cell death.",
    "vicuna-7b_fact": [
      "Troponin I (TnI) interacts with phospholamban (PLN).",
      "TnI is an anti-apoptotic protein.",
      "TnI is involved in muscle contraction and the interaction between actin and myosin in skeletal and cardiac muscle.",
      "The interaction between TnI and PLN plays a role in the regulation of intracellular Ca2+ in heart muscle cells.",
      "TnI may protect heart muscle cells from cell death."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Troponin I (TnI) is known to be involved in the regulation of cardiac muscle contraction and interacts with other proteins, including tropomyosin and other components of the troponin complex that are important in this process. While TnI primarily interacts with actin and other troponin subunits, the statement as given doesn't provide enough context to specifically say it interacts with phospholamban (PLN), which is typically regulated by the phosphorylation status. PLN's primary known interaction is with the SERCA pump. Without additional context, this statement's accuracy is uncertain, yet a direct interaction between TnI and PLN is not well established in the literature.\n   \n2. FALSE [correction]: Troponin I is not typically characterized as an anti-apoptotic protein. Its main function is related to muscle contraction. Anti-apoptotic proteins are those that prevent apoptosis, which is the process of programmed cell death, such as members of the Bcl-2 family.\n\n3. TRUE: TnI is indeed involved in muscle contraction and is part of the troponin complex that regulates the interaction between actin and myosin in skeletal and cardiac muscle.\n\n4. FALSE [correction]: The interaction of Troponin I (TnI) with Troponin C (TnC), which is another subunit of the troponin complex, and tropomyosin on the actin filament plays a role in the regulation of intracellular Ca2+ concentration in heart muscle cells. Phospholamban (PLN) regulates the intracellular Ca2+ concentration through its role in inhibiting the sarcoplasmic reticulum Ca2+-ATPase (SERCA) pump, but not directly through interaction with TnI.\n\n5. TRUE: There is some evidence to suggest that TnI has a role in cardioprotection under certain conditions, which may include helping to protect heart muscle cells from cell death (apoptosis). However, this is a complex area of study and the mechanisms are not fully understood.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "vicuna-7b_response": "Based on the information provided in Document-0, there is no clear evidence that vitamin D supplementation reduces the incidence of falls in older people in clinical trials. The trial mentioned in the document only included elderly women living at home who had fallen during the previous year and found that regular exercise reduced the incidence of falls resulting in injury, but routine vitamin D supplementation did not.\nIt's worth noting that vitamin D has been studied for its potential to prevent falls in older adults, but the results of these studies have been mixed. Some studies have found that vitamin D supplementation may reduce the risk of falls, while others have found no significant effect.\nTherefore, while vitamin D may have potential as a preventive measure for falls in older adults, the evidence is not yet clear-cut, and more research is needed to determine its effectiveness.",
    "vicuna-7b_fact_raw": "1. Vitamin D supplementation was studied for its potential to prevent falls in older adults.\n2. Trials included elderly women living at home who had fallen during the previous year.\n3. Regular exercise reduced the incidence of falls resulting in injury in the trial mentioned.\n4. The trial found that routine vitamin D supplementation did not reduce the incidence of falls.\n5. The results of studies on the effect of vitamin D supplementation on fall prevention have been mixed.",
    "vicuna-7b_fact": [
      "Vitamin D supplementation was studied for its potential to prevent falls in older adults.",
      "Trials included elderly women living at home who had fallen during the previous year.",
      "Regular exercise reduced the incidence of falls resulting in injury in the trial mentioned.",
      "The trial found that routine vitamin D supplementation did not reduce the incidence of falls.",
      "The results of studies on the effect of vitamin D supplementation on fall prevention have been mixed."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "vicuna-7b_response": "Based on the information provided, there is no direct association between Jarid2 and miR-155 in Th17 cells. However, the study suggests that miR-155 inhibition can regulate the differentiation and function of Th17 cells by regulating the expression of Jarid2 and Notch1. The study found that miR-155 inhibition reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes (MLNs) and the level of the Th17 cell-associated cytokines IL-6, IL-17A, IL-17F and IL-21 in colon tissues. Additionally, the study found that Jarid2 was significantly elevated by miR-155 inhibition and Notch1 expression was inversely correlated with Jarid2 by using Immunohistochemistry and western blot. Therefore, it can be concluded that miR-155 inhibition can regulate the differentiation and function of Th17 cells by regulating the expression of Jarid2 and Notch1.",
    "vicuna-7b_fact_raw": "1. miR-155 inhibition can regulate the differentiation and function of Th17 cells by affecting the expression of Jarid2 and Notch1.\n2. The study found that miR-155 inhibition reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes.\n3. Inhibition of miR-155 decreased the level of Th17 cell-associated cytokines IL-6, IL-17A, IL-17F, and IL-21 in colon tissues.\n4. Jarid2 expression was significantly elevated by miR-155 inhibition.\n5. Notch1 expression was inversely correlated with Jarid2 as determined by Immunohistochemistry and western blot.",
    "vicuna-7b_fact": [
      "miR-155 inhibition can regulate the differentiation and function of Th17 cells by affecting the expression of Jarid2 and Notch1.",
      "The study found that miR-155 inhibition reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes.",
      "Inhibition of miR-155 decreased the level of Th17 cell-associated cytokines IL-6, IL-17A, IL-17F, and IL-21 in colon tissues.",
      "Jarid2 expression was significantly elevated by miR-155 inhibition.",
      "Notch1 expression was inversely correlated with Jarid2 as determined by Immunohistochemistry and western blot."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - miR-155 is known to be involved in the regulation of immune responses, including the differentiation and function of Th17 cells, through various mechanisms, including the expression of genes such as Jarid2 and Notch1.\n2. TRUE - Studies have demonstrated that miR-155 can play a role in immune cell differentiation; thus, inhibition of miR-155 could plausibly reduce the proportion of Th17 cells in immune organs like the spleen and mesenteric lymph nodes.\n3. TRUE - Given that Th17 cells are a source of cytokines such as IL-6, IL-17A, IL-17F, and IL-21, it's reasonable that inhibition of miR-155 which affects Th17 cell differentiation and function could decrease the levels of these cytokines in affected tissues.\n4. TRUE - It's consistent with scientific understanding that if miR-155 normally suppresses Jarid2 expression, its inhibition would lead to increased levels of Jarid2.\n5. UNKNOWN - While the statement about the relationship between Notch1 and Jarid2 could be plausible given the complexity of gene regulation, specific experimental results are required to confirm such correlational findings. The techniques mentioned, Immunohistochemistry and western blot, are often used to determine protein levels and localization, but without specific data or published findings, it's not possible to confirm this statement's accuracy.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "vicuna-7b_response": "The human hoxD cluster contains 39 genes.",
    "vicuna-7b_fact_raw": "1. The human hoxD cluster contains 39 genes.",
    "vicuna-7b_fact": [
      "The human hoxD cluster contains 39 genes."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The human hoxD cluster contains 9 genes.",
    "vicuna-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "vicuna-7b_response": "Phosphorylation consensus motifs for Casein Kinase 1 (CK1) are:\n1. S/T-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "vicuna-7b_response": "The ASPH gene in humans encodes for two proteins, hAspH and bAspH. hAspH is a 757-amino acid protein with a molecular weight of 85 kDa, while bAspH is a 719-amino acid protein with a molecular weight of 80 kDa. Both proteins have a similar catalytic domain, but there are significant differences in the N-terminal portion of hAspH compared to bAspH. In vitro transcription and translation of the hAspH cDNA yielded a 56-kDa protein, while Western blot analyses of membrane fractions from MG63 cells showed a protein of the same M(r). These results suggest that there is a posttranslational cleavage of the catalytic C terminus in the lumen of the endoplasmic reticulum.",
    "vicuna-7b_fact_raw": "1. The ASPH gene in humans encodes for two proteins: hAspH and bAspH.\n2. The hAspH protein consists of 757 amino acids and has a molecular weight of 85 kDa.\n3. The bAspH protein consists of 719 amino acids and has a molecular weight of 80 kDa.\n4. There are significant differences in the N-terminal portion of hAspH compared to bAspH.\n5. In vitro transcription and translation of the hAspH cDNA yielded a 56-kDa protein.",
    "vicuna-7b_fact": [
      "The ASPH gene in humans encodes for two proteins: hAspH and bAspH.",
      "The hAspH protein consists of 757 amino acids and has a molecular weight of 85 kDa.",
      "The bAspH protein consists of 719 amino acids and has a molecular weight of 80 kDa.",
      "There are significant differences in the N-terminal portion of hAspH compared to bAspH.",
      "In vitro transcription and translation of the hAspH cDNA yielded a 56-kDa protein."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: Without further information on the gene ASPH and its associated proteins, I cannot ascertain the truth of this statement. ASPH commonly refers to Aspartate Beta-Hydroxylase; however, the designations \"hAspH\" and \"bAspH\" are not standard nomenclature, and thus the statement cannot be verified.\n\n2. UNKNOWN: Similarly, without external sources or scientific literature, it's unclear whether the hAspH protein consists of 757 amino acids and has a molecular weight of 85 kDa. This information needs to be referenced from a reliable source.\n\n3. UNKNOWN: The statement about the bAspH protein is also uncertain without proper references regarding its amino acid count and molecular weight.\n\n4. UNKNOWN: The statement addressing the N-terminal differences between hAspH and bAspH cannot be verified here, as it needs specific scientific evidence or data for support.\n\n5. UNKNOWN: Finally, the outcome of in vitro transcription and translation of the hAspH cDNA resulting in a 56-kDa protein is not verifiable without the respective research data or publication. This statement requires empirical evidence to be confirmed or corrected.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "vicuna-7b_response": "The FDA approved empagliflozin for the treatment of type 2 diabetes in July 2014.",
    "vicuna-7b_fact_raw": "1. Empagliflozin was approved by the FDA in July 2014.\n2. Empagliflozin is used for the treatment of type 2 diabetes.",
    "vicuna-7b_fact": [
      "Empagliflozin was approved by the FDA in July 2014.",
      "Empagliflozin is used for the treatment of type 2 diabetes."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "vicuna-7b_response": "Based on the information provided, it appears that the loss of the protein Lon1 in the plant Arabidopsis has not been specifically studied. However, the study mentioned in Document-0 used 15N labeling approaches to characterize protein degradation rates and determinants in Arabidopsis. The study found that protein half-lives in Arabidopsis vary from several hours to several months, and that protein complex membership and specific protein domains are strong predictors of degradation rate. The study also identified rapidly degrading subunits in a variety of protein complexes in plastids and calculated the protein turnover energy costs in different leaves and their key determinants within the proteome. Therefore, it can be inferred that the loss of Lon1 in Arabidopsis could potentially affect protein degradation rates and energy costs in different leaves, but more specific research would be needed to determine the exact impact of Lon1 loss on these processes.",
    "vicuna-7b_fact_raw": "1. The protein half-lives in Arabidopsis can range from several hours to several months.\n2. Protein complex membership and specific protein domains are strong predictors of protein degradation rates in Arabidopsis.\n3. Rapidly degrading subunits have been identified in a variety of protein complexes in plastids within Arabidopsis.\n4. The study calculated the protein turnover energy costs in different leaves of Arabidopsis.\n5. Key determinants within the proteome for protein turnover energy costs in Arabidopsis leaves have been identified.",
    "vicuna-7b_fact": [
      "The protein half-lives in Arabidopsis can range from several hours to several months.",
      "Protein complex membership and specific protein domains are strong predictors of protein degradation rates in Arabidopsis.",
      "Rapidly degrading subunits have been identified in a variety of protein complexes in plastids within Arabidopsis.",
      "The study calculated the protein turnover energy costs in different leaves of Arabidopsis.",
      "Key determinants within the proteome for protein turnover energy costs in Arabidopsis leaves have been identified."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: This statement is consistent with information from scientific studies indicating that protein half-lives in Arabidopsis and other organisms can vary widely.\n2. TRUE: Protein complex membership and specific protein domains are known factors that can influence the degradation rates of proteins. Studies in proteomics often identify such features as predictors of protein stability and degradation.\n3. TRUE: There have been studies identifying rapidly degrading subunits in various protein complexes in plastids within Arabidopsis. This is a common area of research in plant biology and proteomics.\n4. UNKNOWN: Without specific context or details about the study in question, it is difficult to determine the accuracy of this statement. Studies on protein turnover in plants do often measure energy costs, but whether this particular study calculated the energy costs in different leaves is not specified.\n5. UNKNOWN: Similarly, without specific details from the study, it is difficult to ascertain whether key determinants within the proteome for protein turnover energy costs in Arabidopsis leaves have been identified. While research in this area is plausible, the statement's truth is not verifiable with the information provided.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "vicuna-7b_response": "Yes, a linker histone exists in the yeast genome. The study found that increased expression of Hho1, the yeast linker histone, resulted in a severe growth defect, despite only subtle changes in chromatin structure. Further, this growth defect was rescued by mutations that increase histone acetylation. Consistent with this, genome-wide analysis of linker histone occupancy revealed an inverse correlation with histone tail acetylation in both yeast and mouse embryonic stem cells. These results suggest that histone acetylation negatively regulates linker histone binding in S. cerevisiae and other organisms and provide important insight into how chromatin structure is regulated and maintained to both facilitate and repress transcription.",
    "vicuna-7b_fact_raw": "1. A linker histone, known as Hho1, exists in the yeast genome.\n2. Increased expression of Hho1 in yeast results in a severe growth defect.\n3. Mutations that increase histone acetylation can rescue the growth defect caused by increased expression of Hho1 in yeast.\n4. There is an inverse correlation between linker histone occupancy and histone tail acetylation in both yeast and mouse embryonic stem cells.\n5. Histone acetylation negatively regulates linker histone binding in S. cerevisiae (yeast) and possibly other organisms.",
    "vicuna-7b_fact": [
      "A linker histone, known as Hho1, exists in the yeast genome.",
      "Increased expression of Hho1 in yeast results in a severe growth defect.",
      "Mutations that increase histone acetylation can rescue the growth defect caused by increased expression of Hho1 in yeast.",
      "There is an inverse correlation between linker histone occupancy and histone tail acetylation in both yeast and mouse embryonic stem cells.",
      "Histone acetylation negatively regulates linker histone binding in S. cerevisiae (yeast) and possibly other organisms."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Hho1 is a known linker histone in the yeast Saccharomyces cerevisiae.\n2. TRUE: Elevated levels of Hho1 have been reported to result in growth defects in yeast, although the specific biological context can be important for the outcome.\n3. TRUE: Mutations that increase histone acetylation are known to counteract the effects of chromatin compaction caused by linker histones. This can lead to the rescue of growth defects associated with high levels of linker histones such as Hho1, by providing a more open and transcriptionally active chromatin state.\n4. TRUE: Generally, there is an inverse correlation between linker histone binding and histone tail acetylation, as acetylated histones are associated with a less compact chromatin structure which reduces the affinity for linker histones.\n5. TRUE: Histone tail acetylation is associated with reduced chromatin compaction and can thus negatively regulate the binding of linker histones like Hho1. While this is well-established in yeast, it is also a widespread mechanism and likely affects other organisms as well.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "vicuna-7b_response": "Based on the information provided, there is evidence to suggest that tomato juice may have beneficial effects on lipid metabolism, but the addition of polyphenols does not appear to provide additional beneficial cardiovascular effects. The study found that tomato juice consumption led to a significant reduction in total cholesterol and LDL-C levels in the control group, but not in the experimental group that was supplemented with polyphenol-enriched tomato juice. However, it is important to note that the study was conducted on subjects with stage 1 hypertension and the results may not be generalizable to all populations. Further research is needed to confirm the potential cardiovascular benefits of tomato juice and to determine the optimal dosage and form of tomato consumption for cholesterol-lowering effects.",
    "vicuna-7b_fact_raw": "1. Tomato juice consumption led to a significant reduction in total cholesterol and LDL-C levels in a control group.\n2. The addition of polyphenols to tomato juice did not provide additional beneficial cardiovascular effects in an experimental group.\n3. The study was conducted on subjects with stage 1 hypertension.\n4. The results of the study on tomato juice and its effects on lipid metabolism may not be generalizable to all populations.",
    "vicuna-7b_fact": [
      "Tomato juice consumption led to a significant reduction in total cholesterol and LDL-C levels in a control group.",
      "The addition of polyphenols to tomato juice did not provide additional beneficial cardiovascular effects in an experimental group.",
      "The study was conducted on subjects with stage 1 hypertension.",
      "The results of the study on tomato juice and its effects on lipid metabolism may not be generalizable to all populations."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n\nSince the specific study on tomato juice and polyphenols is not provided, and details of the design and results are not given, statements 1, 2, and 3 cannot be verified without additional information. Statement 4 is generally true for most studies, as the results are often specific to the population that was studied and may not be applicable to all groups.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "vicuna-7b_response": "Hsp70 and Hsp110 are both heat shock proteins (HSPs) that play a role in regulating the stability of mRNA. Hsp70 is a well-known protein chaperone that has been shown to interact with AU-rich elements (AREs) in the 3' untranslated region (3'UTR) of mRNA. These AREs are targets for factors that control transcript longevity and translational efficiency. Hsp70 has been shown to form direct, high-affinity complexes with ARE substrates and to bind and stabilize endogenous ARE-containing mRNAs, such as vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (Cox-2). The binding and stabilization of these mRNAs is mediated by ARE-like sequences in the proximal 3'UTR. The stabilization of these mRNAs may contribute to the cytoprotective effects of Hsp70 following cellular stress, but it may also provide a novel mechanism linking constitutively elevated Hsp70 expression to the development of aggressive neoplastic phenotypes.\nHsp110 is another HSP that has been shown to affect mRNA stability. It has been shown to interact with ARE-like RNA substrates in vitro and to bind and stabilize ARE-containing mRNAs, such as VEGF and Cox-2. The mechanism by which Hsp110 stabilizes these mRNAs is similar to that of Hsp70. The stabilization of these mRNAs by Hsp110 may also contribute to the cytoprotective effects of Hsp110 following cellular stress, but it may also provide a novel mechanism linking constitutively elevated Hsp110 expression to the development of aggressive neoplastic phenotypes.\nIn summary, Hsp70 and Hsp110 are both HSPs that play a role in regulating the stability of mRNA. They interact with ARE-like sequences in the 3'UTR of mRNA and bind and stabilize ARE-containing mRNAs, such as VEGF and Cox",
    "vicuna-7b_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins that play a role in regulating the stability of mRNA.\n2. Hsp70 interacts with AU-rich elements in the 3' untranslated region of mRNA.\n3. Hsp70 can form direct, high-affinity complexes with ARE substrates.\n4. Hsp110 can bind and stabilize ARE-containing mRNAs in vitro.\n5. Both Hsp70 and Hsp110 binding and stabilization of mRNAs may contribute to cytoprotective effects following cellular stress.",
    "vicuna-7b_fact": [
      "Hsp70 and Hsp110 are heat shock proteins that play a role in regulating the stability of mRNA.",
      "Hsp70 interacts with AU-rich elements in the 3' untranslated region of mRNA.",
      "Hsp70 can form direct, high-affinity complexes with ARE substrates.",
      "Hsp110 can bind and stabilize ARE-containing mRNAs in vitro.",
      "Both Hsp70 and Hsp110 binding and stabilization of mRNAs may contribute to cytoprotective effects following cellular stress."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Hsp70 is a heat shock protein that plays a role in protein folding, assembly, and translocation across membranes but is not typically known for regulating the stability of mRNA. Hsp110 is related to the Hsp70 family and functions as a nucleotide exchange factor for Hsp70 chaperones, but it is not primarily associated with mRNA stability either.\n2. FALSE [correction]: While Hsp70 has a variety of functions related to protein maintenance, it does not typically interact with AU-rich elements in the 3' untranslated region of mRNA. These elements are often bound by other proteins that regulate mRNA stability.\n3. FALSE [correction]: Hsp70 is known for forming complexes with non-native polypeptides, aiding in their folding and preventing aggregation rather than forming direct, high-affinity complexes with mRNA AU-rich elements (ARE) substrates.\n4. UNKNOWN: Without specific evidence provided in the context, it is unclear whether Hsp110 can bind and stabilize ARE-containing mRNAs in vitro. This is not a widely recognized function of Hsp110.\n5. FALSE [correction]: While both Hsp70 and Hsp110 have roles in the cellular response to stress, including cytoprotection, their known mechanisms of action are primarily related to protein homeostasis rather than binding and stabilization of mRNAs. Cytoprotective effects are more often attributed to their capacity to refold denatured proteins and prevent protein aggregation.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "vicuna-7b_response": "The human skeletal muscle expresses Type 2 deiodinase (D2), which is a low K(m) iodothyronine deiodinase that catalyzes the removal of a single iodine from the phenolic ring of T4 or rT3. D2 is a selenoenzyme, as evidenced by the presence of two in-frame UGA codons, the synthesis of a 31-kDa 75Selabeled protein in D2 cDNA-transfected cells, and the requirement for a 3'-selenocysteine incorporation sequence element for its translation. Unlike D1 and D3, we were not able to covalently label overexpressed D2 with N-bromoacetyl [125I]T3 or -T4. The expression of D2 in muscle suggests that it could play a role in peripheral, as well as intracellular, T3 production.",
    "vicuna-7b_fact_raw": "1. Human skeletal muscle expresses Type 2 deiodinase (D2).\n2. D2 catalyzes the removal of a single iodine from the phenolic ring of T4 or rT3.\n3. D2 is a selenoenzyme, which requires a 3'-selenocysteine incorporation sequence element for its translation.\n4. Two in-frame UGA codons are present in D2, indicating its selenoprotein nature.\n5. The presence of D2 in muscle suggests it may play a role in peripheral and intracellular T3 production.",
    "vicuna-7b_fact": [
      "Human skeletal muscle expresses Type 2 deiodinase (D2).",
      "D2 catalyzes the removal of a single iodine from the phenolic ring of T4 or rT3.",
      "D2 is a selenoenzyme, which requires a 3'-selenocysteine incorporation sequence element for its translation.",
      "Two in-frame UGA codons are present in D2, indicating its selenoprotein nature.",
      "The presence of D2 in muscle suggests it may play a role in peripheral and intracellular T3 production."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: D2 contains a single in-frame UGA codon, which is a selenocysteine insertion sequence (SECIS) element, not two.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "vicuna-7b_response": "Inflammatory caspases are a group of proteases that play a crucial role in inflammation and cell death. They are essential effectors of inflammation and are involved in the regulation of intestinal homeostasis, inflammation, and tumorigenesis. Caspases-1 and -12 are two of the most important inflammatory caspases.\nCaspase-1 is activated in response to pro-inflammatory cytokines and is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1beta (IL-1beta). Caspase-1 is also involved in the processing and activation of the pro-inflammatory cytokine IL-18. Caspase-1(-/-) mice exhibit defects in mucosal tissue repair and succumb rapidly after dextran sulfate sodium administration. These defects are rescued by administration of exogenous IL-18 and are partially reproduced in mice deficient in the inflammasome adaptor ASC.\nCaspase-12 is involved in the activation of the inflammasome, which is a complex that includes the inflammasome adaptor protein ASC, caspase-1, and the pro-inflammatory cytokines IL-1beta and IL-18. Caspase-12(-/-) mice are resistant to acute colitis and show signs of enhanced repair. However, these mice are more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS.\nThe inflammatory caspases are critical in the induction of inflammation in the gut after injury, which is necessary for tissue repair and maintenance of immune tolerance. The balance between inflammation and tissue repair is crucial for the maintenance of intestinal homeostasis. Dysregulation of the inflammatory caspases can lead to chronic inflammation and the development of colitis-associated cancer.",
    "vicuna-7b_fact_raw": "1. Caspases-1 and -12 are considered inflammatory caspases that play a role in inflammation and cell death.\n2. Caspase-1 is involved in the processing and activation of the pro-inflammatory cytokines interleukin-1beta (IL-1beta) and IL-18.\n3. Mice lacking caspase-1 (Caspase-1(-/-) mice) exhibit defects in mucosal tissue repair and have an adverse reaction to dextran sulfate sodium administration.\n4. Caspase-12 is involved in the activation of the inflammasome, which is associated with the inflammasome adaptor protein ASC and the pro-inflammatory cytokines IL-1beta and IL-18.\n5. Caspase-12(-/-) mice are resistant to acute colitis and display enhanced repair yet are more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS.",
    "vicuna-7b_fact": [
      "Caspases-1 and -12 are considered inflammatory caspases that play a role in inflammation and cell death.",
      "Caspase-1 is involved in the processing and activation of the pro-inflammatory cytokines interleukin-1beta (IL-1beta) and IL-18.",
      "Mice lacking caspase-1 (Caspase-1(-/-) mice) exhibit defects in mucosal tissue repair and have an adverse reaction to dextran sulfate sodium administration.",
      "Caspase-12 is involved in the activation of the inflammasome, which is associated with the inflammasome adaptor protein ASC and the pro-inflammatory cytokines IL-1beta and IL-18.",
      "Caspase-12(-/-) mice are resistant to acute colitis and display enhanced repair yet are more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Caspase-1 and caspase-12 are indeed considered inflammatory caspases. Caspase-1 is well-known for its role in inflammation, while caspase-12 has been discussed in the context of modulating inflammation, albeit often considered an atypical inflammatory caspase because in humans it is largely non-functional due to a mutation in most populations.\n\n2. TRUE: Caspase-1 is indeed involved in the processing and activation of the pro-inflammatory cytokines interleukin-1beta (IL-1beta) and IL-18, which is a fundamental aspect of the inflammatory response.\n\n3. UNKNOWN: While caspase-1 knockout mice have been studied in various contexts, the statement regarding mucosal tissue repair and response to dextran sulfate sodium may depend on specific experimental findings not provided here. Without the specific context or findings, the response to this statement cannot be determined.\n\n4. FALSE [correction]: Caspase-12 is generally considered to be an inhibitor of the inflammatory response, and in humans, it is typically nonfunctional due to a frameshift mutation. Its role in inflammasome activation is not established and is more commonly associated with a negative regulation of the inflammasome. Caspase-1 and others like caspase-4/5 (in humans) or caspase-11 (in mice) are involved in inflammasome activation.\n\n5. UNKNOWN: The statement about the effects on caspase-12 knockout mice in relation to acute colitis, repair, and susceptibility to colorectal cancer induced by azoxymethane (AOM) + dextran sulfate sodium (DSS) would require specific experimental outcomes to verify. Without targeted research data or a publication to reference, the veracity of these claims is not ascertainable.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "vicuna-7b_response": "Yes, there is a link between Aurora B kinase and the polycomb protein ring1B.\nAccording to the information provided, Aurora C-SV, a novel splicing variant of Aurora C, was found to be expressed at the highest level in human testis. The in vitro kinase assay showed that Aurora C-SV phosphorylated MBP, and its T179A mutant lost the kinase activity. During cell mitosis, Aurora C-SV-EGFP associated with chromosomes in prophase and metaphase, and then transferred to the central spindle midzone and the cortex where the contract ring formed during the transition from anaphase to telophase. It then remained in the midbody during cytokinesis.\nFurthermore, the authors speculated that Aurora C-SV might also contribute to the regulation of chromosome segregation and cytokinesis. This suggests that Aurora C-SV may play a role in the regulation of cell division, which is a key function of Aurora B kinase.\nAurora B kinase is a key regulator of cell division, and it has been shown to play a role in the regulation of chromosome segregation and cytokinesis. The polycomb protein ring1B is also involved in the regulation of cell division, and it has been shown to play a role in the regulation of chromosome segregation and cytokinesis. Therefore, it is likely that there is a link between Aurora B kinase and the polycomb protein ring1B.",
    "vicuna-7b_fact_raw": "1. Aurora C-SV is a novel splicing variant of Aurora C that is expressed at the highest level in human testis.\n2. Aurora C-SV phosphorylated MBP in vitro, and the T179A mutant of Aurora C-SV lost kinase activity.\n3. During cell mitosis, Aurora C-SV-EGFP associated with chromosomes in prophase and metaphase before transferring to the central spindle midzone and the cortex during the transition from anaphase to telophase.\n4. Aurora B kinase is a key regulator of cell division and is known to regulate chromosome segregation and cytokinesis.\n5. The polycomb protein ring1B is involved in the regulation of cell division and chromosome segregation and cytokinesis.",
    "vicuna-7b_fact": [
      "Aurora C-SV is a novel splicing variant of Aurora C that is expressed at the highest level in human testis.",
      "Aurora C-SV phosphorylated MBP in vitro, and the T179A mutant of Aurora C-SV lost kinase activity.",
      "During cell mitosis, Aurora C-SV-EGFP associated with chromosomes in prophase and metaphase before transferring to the central spindle midzone and the cortex during the transition from anaphase to telophase.",
      "Aurora B kinase is a key regulator of cell division and is known to regulate chromosome segregation and cytokinesis.",
      "The polycomb protein ring1B is involved in the regulation of cell division and chromosome segregation and cytokinesis."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE (with clarification [correction]): The polycomb protein RING1B is involved in epigenetic regulation including those related to chromatin structure and gene expression which can affect processes such as cell division. However, its direct role in chromosome segregation and cytokinesis is not as well-established as that of Aurora B kinase.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "vicuna-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are overlapping alternative donor sites and acceptor sites. These sites are supported by a protein, by a full-length mRNA, or by expressed sequence tags (ESTs) from at least two independent clone libraries. Overlapping alternative donor sites are the most abundant and introduce a frameshift in the protein-coding region. They lead to major differences in the protein sequence and structure or generate nonsense-mediated decay-inducing mRNA isoforms. Overlapping alternative acceptor sites, on the other hand, mainly lead to microvariations in protein sequences.",
    "vicuna-7b_fact_raw": "1. The most frequent non-canonical sequence motifs at the donor splice sites in vertebrates are overlapping alternative donor sites.\n2. The most frequent non-canonical sequence motifs at the acceptor splice sites in vertebrates are overlapping alternative acceptor sites.\n3. These non-canonical splice sites are supported by protein, full-length mRNA, or expressed sequence tags (ESTs) from at least two independent clone libraries.\n4. Overlapping alternative donor sites can introduce a frameshift in the protein-coding region.\n5. Overlapping alternative acceptor sites typically lead to microvariations in protein sequences.",
    "vicuna-7b_fact": [
      "The most frequent non-canonical sequence motifs at the donor splice sites in vertebrates are overlapping alternative donor sites.",
      "The most frequent non-canonical sequence motifs at the acceptor splice sites in vertebrates are overlapping alternative acceptor sites.",
      "These non-canonical splice sites are supported by protein, full-length mRNA, or expressed sequence tags (ESTs) from at least two independent clone libraries.",
      "Overlapping alternative donor sites can introduce a frameshift in the protein-coding region.",
      "Overlapping alternative acceptor sites typically lead to microvariations in protein sequences."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The most frequent non-canonical sequence motifs at the donor splice sites in vertebrates are indeed overlapping alternative donor sites, as these allow for variation in splicing, potentially leading to different mRNA and protein isoforms.\n2. UNKNOWN: While overlapping alternative acceptor sites might occur, the statement about their frequency being the most frequent non-canonical sequence motif is not a well-established fact and would require specific evidence to support it, which is not provided.\n3. UNKNOWN: The statement that these non-canonical splice sites are supported by evidence from at least two independent clone libraries seems plausible given that experimental validation of splice sites often involves such evidence. However, without specific data or references, the truth of this statement cannot be determined.\n4. TRUE: Overlapping alternative donor sites can indeed lead to frameshifts in the resulting protein if they alter the reading frame of the encoding mRNA.\n5. TRUE: Overlapping alternative acceptor sites can lead to microvariations in protein sequences, as different splice acceptor sites can result in the inclusion or exclusion of small sequences of amino acids.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "vicuna-7b_response": "The event that results in the acetylation of S6K1 is growth factor stimulation. This is indicated by the statement \"we have recently shown that S6K1 is also targeted by lysine acetylation\" and \"using acetyl-specific K516 antibodies, we show that acetylation of endogenous S6K1 at this site is potently induced upon growth factor stimulation.\" Additionally, the statement \"experiments using inhibitors of S6K1 activation and exposure of cells to various stresses indicate that S6K1 acetylation can occur in the absence of phosphorylation and vice versa\" further supports this conclusion.",
    "vicuna-7b_fact_raw": "1. The acetylation of S6K1 is induced by growth factor stimulation.\n2. S6K1 can be acetylated at lysine 516, as shown using acetyl-specific K516 antibodies.\n3. Experiments suggest that S6K1 acetylation can occur independently of phosphorylation.",
    "vicuna-7b_fact": [
      "The acetylation of S6K1 is induced by growth factor stimulation.",
      "S6K1 can be acetylated at lysine 516, as shown using acetyl-specific K516 antibodies.",
      "Experiments suggest that S6K1 acetylation can occur independently of phosphorylation."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nGiven that the statements are very specific and pertain to molecular biology research, without specific evidence or published research findings to confirm or refute them, their veracity can't be determined. Statements 2 and 3 are beyond common knowledge and would require specific domain knowledge or research evidence to confirm.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "vicuna-7b_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene provides instructions for making a protein called the alpha subunit of the voltage-gated calcium channel, which is responsible for regulating the flow of calcium ions into cells. The mutations in the CACNA1A gene that cause EA6 result in reduced calcium channel function, which can lead to episodic ataxia symptoms.\nThe symptoms of EA6 typically begin in childhood or adolescence, but can also occur later in life. The episodes of ataxia, or difficulty with coordination and balance, can be triggered by a variety of factors, including stress, heat, exercise, or certain medications. The episodes can last from a few minutes to several hours and may be accompanied by other symptoms such as vertigo, nausea, and vomiting.\nThe diagnosis of EA6 is typically made through a combination of clinical examination, genetic testing, and electrophysiological studies. Treatment for EA6 typically involves medications to manage symptoms and prevent episodes, as well as lifestyle modifications to reduce triggers. In some cases, surgery may be considered to implant a device that can help regulate the flow of calcium ions into the brain.",
    "vicuna-7b_fact_raw": "1. Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene is responsible for making the alpha subunit of the voltage-gated calcium channel.\n3. Mutations in the CACNA1A gene that cause EA6 result in reduced calcium channel function.\n4. Symptoms of episodic ataxia type 6 can be triggered by stress, heat, exercise, or certain medications.\n5. Treatment options for episodic ataxia type 6 may include medications, lifestyle modifications, and potentially surgery to implant a device for calcium ion flow regulation.",
    "vicuna-7b_fact": [
      "Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene is responsible for making the alpha subunit of the voltage-gated calcium channel.",
      "Mutations in the CACNA1A gene that cause EA6 result in reduced calcium channel function.",
      "Symptoms of episodic ataxia type 6 can be triggered by stress, heat, exercise, or certain medications.",
      "Treatment options for episodic ataxia type 6 may include medications, lifestyle modifications, and potentially surgery to implant a device for calcium ion flow regulation."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Treatment options for forms of episodic ataxia, including type 6, typically involve medications and lifestyle modifications; however, there is no standard surgical treatment involving the implantation of a device for calcium ion flow regulation. Surgery is generally not a treatment option for episodic ataxia.",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "vicuna-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are a type of enzyme that adds a methyl group to a chromophore, which is a molecule that contains a chromophore. Chromomethylases are found in many organisms, including animals. The study you provided on Bactrocera dorsalis identified 12 Cht-related genes and 6 CDA genes, which are both types of enzymes involved in chitin metabolism. These genes were found to have different structures and expression patterns in B. dorsalis, providing important information for the development of new pest control strategies based on these vital enzymes.",
    "vicuna-7b_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to a chromophore.\n2. Chromomethylases are present in many organisms, including animals.\n3. The study on Bactrocera dorsalis identified 12 Cht-related genes.\n4. The study on Bactrocera dorsalis identified 6 CDA genes.\n5. The genes identified in Bactrocera dorsalis have different structures and expression patterns.",
    "vicuna-7b_fact": [
      "Chromomethylases are enzymes that add a methyl group to a chromophore.",
      "Chromomethylases are present in many organisms, including animals.",
      "The study on Bactrocera dorsalis identified 12 Cht-related genes.",
      "The study on Bactrocera dorsalis identified 6 CDA genes.",
      "The genes identified in Bactrocera dorsalis have different structures and expression patterns."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that methylate DNA, not a chromophore.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or definitive scientific references, it is not possible to accurately verify the details about the study on Bactrocera dorsalis and the number of Cht-related genes or CDA genes identified, as well as statements about their structures and expression patterns.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "vicuna-7b_response": "TFBSTools is an R/Bioconductor package for the analysis and manipulation of transcription factor binding sites (TFBSs) and their associated transcription factor profile matrices. The package provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments including whole genomes, and querying the JASPAR database. It also allows for advanced statistical analysis, data visualization, and data integration. The package is implemented in R and available under GPL-2 license from the Bioconductor website. The package can be contacted at [ge.tan09@imperial.ac.uk](mailto:ge.tan09@imperial.ac.uk). Supplementary data are available at Bioinformatics online.",
    "vicuna-7b_fact_raw": "1. TFBSTools is an R/Bioconductor package used for the analysis of transcription factor binding sites (TFBSs).\n2. The package provides functions for handling TFBS profile matrices and scanning sequences and alignments.\n3. TFBSTools allows querying the JASPAR database.\n4. The package includes features for statistical analysis, data visualization, and data integration.\n5. TFBSTools is available under the GPL-2 license from the Bioconductor website.",
    "vicuna-7b_fact": [
      "TFBSTools is an R/Bioconductor package used for the analysis of transcription factor binding sites (TFBSs).",
      "The package provides functions for handling TFBS profile matrices and scanning sequences and alignments.",
      "TFBSTools allows querying the JASPAR database.",
      "The package includes features for statistical analysis, data visualization, and data integration.",
      "TFBSTools is available under the GPL-2 license from the Bioconductor website."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "vicuna-7b_response": "Based on the information provided, here is a list of clinical trials for the prevention of sarcopenia:\n1. The Sarcopenia in Older People (SOAP) study, which is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n2. The Sarcopenia in the Elderly: Prevention and Management (SEPAM) study, which is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n3. The Sarcopenia in Older People (SOAP) study, which is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n4. The Sarcopenia in the Elderly: Prevention and Management (SEPAM) study, which is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n5. The Sarcopenia in Older People (SOAP) study, which is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n6. The Sarcopenia in the Elderly: Prevention and Management (SEPAM) study, which is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n7. The Sarcopenia in Older People (SOAP) study, which is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplement",
    "vicuna-7b_fact_raw": "1. The Sarcopenia in Older People (SOAP) study is a multicenter, randomized, double-blind, placebo-controlled trial.\n2. The SOAP study is designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n3. The Sarcopenia in the Elderly: Prevention and Management (SEPAM) study is a randomized, double-blind, placebo-controlled trial.\n4. The SEPAM study is designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.\n5. Both the SOAP and SEPAM trials have similar methodologies and objectives regarding the prevention of sarcopenia in older adults.",
    "vicuna-7b_fact": [
      "The Sarcopenia in Older People (SOAP) study is a multicenter, randomized, double-blind, placebo-controlled trial.",
      "The SOAP study is designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.",
      "The Sarcopenia in the Elderly: Prevention and Management (SEPAM) study is a randomized, double-blind, placebo-controlled trial.",
      "The SEPAM study is designed to evaluate the efficacy and safety of a combination of resistance exercise and protein supplementation in preventing sarcopenia in older adults.",
      "Both the SOAP and SEPAM trials have similar methodologies and objectives regarding the prevention of sarcopenia in older adults."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific details about the Sarcopenia in Older People (SOAP) study or the Sarcopenia in the Elderly: Prevention and Management (SEPAM) study available in the provided context, I cannot accurately verify the accuracy of the statements. Additional information would be needed to confirm if these descriptions of the studies, their objectives, and methodologies are accurate.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "vicuna-7b_response": "The database of molecular recognition features in membrane proteins is called mpMoRFsDB. It was created to collect, organize, and store all membrane proteins that contain molecular recognition features (MoRFs), which are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition on binding to their partners. MoRFs are involved in protein-protein interactions and may function as the initial step in molecular recognition.\nThe mpMoRFsDB database contains information on MoRFs in transmembrane and peripheral membrane proteins. The position of transmembrane protein MoRFs was determined in relation to a protein's topology. All information was stored in a publicly available mySQL database with a user-friendly web interface. A Jmol applet is integrated for visualization of the structures.\nThe mpMoRFsDB database provides valuable information related to disorder-based protein-protein interactions in membrane proteins. It can be accessed at the following URL: <http://bioinformatics.biol.uoa.gr/mpMoRFsDB>.",
    "vicuna-7b_fact_raw": "1. The database for molecular recognition features in membrane proteins is known as mpMoRFsDB.\n2. MpMoRFsDB was created to collect and store information on membrane proteins with molecular recognition features (MoRFs).\n3. MoRFs are small, intrinsically disordered regions that undergo a disorder-to-order transition upon binding to a partner.\n4. The database includes information on MoRFs in both transmembrane and peripheral membrane proteins.\n5. MpMoRFsDB is publicly available and features a user-friendly web interface and a Jmol applet for structure visualization.",
    "vicuna-7b_fact": [
      "The database for molecular recognition features in membrane proteins is known as mpMoRFsDB.",
      "MpMoRFsDB was created to collect and store information on membrane proteins with molecular recognition features (MoRFs).",
      "MoRFs are small, intrinsically disordered regions that undergo a disorder-to-order transition upon binding to a partner.",
      "The database includes information on MoRFs in both transmembrane and peripheral membrane proteins.",
      "MpMoRFsDB is publicly available and features a user-friendly web interface and a Jmol applet for structure visualization."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The database for molecular recognition features in membrane proteins is known as MoRFsDB, not mpMoRFsDB.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "vicuna-7b_response": "Yes, rivaroxaban is metabolized in the kidneys. The drug is cleared by the cytochrome P450 (CYP) 3A4/5, 2J2 pathways, and excreted via the kidneys. The metabolism of rivaroxaban is primarily mediated by the CYP3A4 enzyme, which is primarily expressed in the liver and the kidneys. The kidneys play an important role in the elimination of rivaroxaban from the body. Therefore, any impairment of kidney function can affect the elimination of rivaroxaban and may lead to accumulation of the drug, resulting in an increased risk of adverse effects.",
    "vicuna-7b_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. Rivaroxaban is cleared by the cytochrome P450 (CYP) 3A4/5, 2J2 pathways.\n3. The CYP3A4 enzyme is primarily responsible for the metabolism of rivaroxaban.\n4. The CYP3A4 enzyme is expressed in the liver as well as in the kidneys.\n5. Impairment of kidney function can affect the elimination of rivaroxaban from the body.",
    "vicuna-7b_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "Rivaroxaban is cleared by the cytochrome P450 (CYP) 3A4/5, 2J2 pathways.",
      "The CYP3A4 enzyme is primarily responsible for the metabolism of rivaroxaban.",
      "The CYP3A4 enzyme is expressed in the liver as well as in the kidneys.",
      "Impairment of kidney function can affect the elimination of rivaroxaban from the body."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver, not in the kidneys. The kidneys are mainly responsible for the excretion of the drug and its metabolites.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "vicuna-7b_response": "Based on the information provided, TRalpha2 is regulated by amiodarone (AM) and dronedarone (Dron) in the heart. Specifically, both drugs decrease the expression of TRalpha1 and TRbeta1, and increase the expression of TRalpha2 in different parts of the heart. The changes in TR expression are accompanied by similar effects on T3-dependent gene expression, which are reminiscent of foetal reprogramming. These findings suggest that AM and Dron may have similar effects on heart rate by decreasing the expression of TR isoforms and T3-dependent genes, and that AM may have a more profound effect on foetal reprogramming in the left ventricle.",
    "vicuna-7b_fact_raw": "1. Amiodarone (AM) and dronedarone (Dron) regulate the TRalpha2 gene in the heart.\n2. Both AM and Dron decrease the expression of TRalpha1 and TRbeta1 genes.\n3. AM and Dron increase the expression of TRalpha2 in different parts of the heart.\n4. The changes in TR gene expression are accompanied by effects on T3-dependent gene expression.\n5. Amiodarone (AM) may have a more profound effect on foetal reprogramming in the left ventricle.",
    "vicuna-7b_fact": [
      "Amiodarone (AM) and dronedarone (Dron) regulate the TRalpha2 gene in the heart.",
      "Both AM and Dron decrease the expression of TRalpha1 and TRbeta1 genes.",
      "AM and Dron increase the expression of TRalpha2 in different parts of the heart.",
      "The changes in TR gene expression are accompanied by effects on T3-dependent gene expression.",
      "Amiodarone (AM) may have a more profound effect on foetal reprogramming in the left ventricle."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a reference to the passage from which these statements are derived, it is impossible to verify the accuracy of the statements regarding the regulation of TR genes (TRalpha1, TRalpha2, TRbeta1) by Amiodarone (AM) and Dronedarone (Dron), as well as their impact on T3-dependent gene expression or any differential effects on foetal reprogramming in the left ventricle. These are highly specific statements that would require access to empirical studies or detailed scientific information to confirm or refute.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "vicuna-7b_response": "Here is a list of available biomedical question answering systems:\n1. Our biomedical question answering system, which is described in Document-0.\n2. The Biomedical Question Answering System (BioQAS) developed by the Stanford University. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n3. The Biomedical Text Analysis and Question Answering System (BioTaQAS) developed by the University of California, San Diego. BioTaQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n4. The Biomedical Question Answering System (BioQAS) developed by the University of California, Los Angeles. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n5. The Biomedical Question Answering System (BioQAS) developed by the University of Pennsylvania. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n6. The Biomedical Question Answering System (BioQAS) developed by the University of Washington. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n7. The Biomedical Question Answering System (BioQAS) developed by the University of Texas, Houston. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n8. The Biomedical Question Answering System (BioQAS) developed by the University of Michigan. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n9. The Biomedical Question Answering System (BioQAS) developed by the University of California, Irvine. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\n10. The Biomedical Question Answering System (BioQAS) developed by the University of California, San Francisco. BioQAS uses a combination of rule-based and machine learning approaches to answer biomedical questions.\nNote: This list is not exhaustive and there may be other biomedical question answering systems available.",
    "vicuna-7b_fact_raw": "1. Stanford University developed a Biomedical Question Answering System called BioQAS.\n2. The University of California, San Diego developed the Biomedical Text Analysis and Question Answering System (BioTaQAS).\n3. The University of Pennsylvania has a Biomedical Question Answering System named BioQAS.\n4. The University of Washington created a Biomedical Question Answering System, also referred to as BioQAS.\n5. The University of Texas, Houston has developed a Biomedical Question Answering System known as BioQAS.",
    "vicuna-7b_fact": [
      "Stanford University developed a Biomedical Question Answering System called BioQAS.",
      "The University of California, San Diego developed the Biomedical Text Analysis and Question Answering System (BioTaQAS).",
      "The University of Pennsylvania has a Biomedical Question Answering System named BioQAS.",
      "The University of Washington created a Biomedical Question Answering System, also referred to as BioQAS.",
      "The University of Texas, Houston has developed a Biomedical Question Answering System known as BioQAS."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the specific names and developers of the Biomedical Question Answering System (BioQAS) are not widely recognized facts, and without additional context or information on these systems, it is not possible to determine the veracity of the statements. The development of such system might be specific to a particular research group or institution and not commonly known unless one has access to the latest information in the field of biomedical informatics.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "vicuna-7b_response": "The transcription factor that activates the betalain pathway is unknown. The information provided suggests that a biased agonist, (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), can selectively activate the beta-arrestin pathway of the type 1 parathyroid hormone (PTH-PTH-related protein receptor (PTH1R)) and induce anabolic bone formation in mice. However, the information does not mention the specific transcription factor that is activated by this pathway.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "vicuna-7b_response": "There are several technologies that can be used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. One such technology is TiO2 bead-based enrichment, which is used in the strategy described in Document-0. This method involves the initial enrichment of phosphopeptides using TiO2 beads, followed by sequential elution using IMAC (imine-modified affinity chromatography) and HILIC (hydrophilic interaction liquid chromatography) to separate multi- and mono-phosphorylated peptides. The advantages of this strategy include high specificity, reduced sample preparation workload, and low adsorptive losses. Other technologies that can be used for phosphoproteome enrichment include metal-chelate affinity chromatography, magnetic bead-based enrichment, and immunoaffinity-based enrichment. The choice of enrichment method will depend on the specific research question and the characteristics of the sample being analyzed.",
    "vicuna-7b_fact_raw": "1. Titanium dioxide (TiO2) bead-based enrichment is a technology used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. TiO2 bead-based enrichment involves an initial enrichment step using TiO2 beads.\n3. The strategy involving TiO2 bead-based enrichment includes sequential elution using IMAC (imine-modified affinity chromatography) and HILIC (hydrophilic interaction liquid chromatography).\n4. Metal-chelate affinity chromatography is a technology that can be used for phosphoproteome enrichment.\n5. Magnetic bead-based enrichment and immunoaffinity-based enrichment are technologies used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.",
    "vicuna-7b_fact": [
      "Titanium dioxide (TiO2) bead-based enrichment is a technology used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.",
      "TiO2 bead-based enrichment involves an initial enrichment step using TiO2 beads.",
      "The strategy involving TiO2 bead-based enrichment includes sequential elution using IMAC (imine-modified affinity chromatography) and HILIC (hydrophilic interaction liquid chromatography).",
      "Metal-chelate affinity chromatography is a technology that can be used for phosphoproteome enrichment.",
      "Magnetic bead-based enrichment and immunoaffinity-based enrichment are technologies used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Titanium dioxide (TiO2) bead-based enrichment is indeed a technology used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. TRUE: TiO2 bead-based enrichment does involve an initial enrichment step using TiO2 beads, which bind to phosphorylated peptides due to their affinity for the phosphate groups.\n3. FALSE [correction]: Sequential elution involving TiO2 bead-based enrichment typically involves acidic solutions with different pH or composition for eluting the phosphopeptides. IMAC (Immobilized Metal Affinity Chromatography, not imine-modified) and HILIC (Hydrophilic Interaction Liquid Chromatography) are different techniques that can also be used for phosphopeptide enrichment but are not typically part of a TiO2 sequential elution strategy.\n4. TRUE: Metal-chelate affinity chromatography, specifically Immobilized Metal Affinity Chromatography (IMAC), is a technology that can be used for the enrichment of the phosphoproteome by targeting phosphorylated peptides.\n5. TRUE: Both magnetic bead-based enrichment and immunoaffinity-based enrichment are other techniques employed for the selective enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. These methods utilize the magnetic properties of beads or antibodies specific to phosphopeptides, respectively.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "vicuna-7b_response": "The disorder described in the information is likely X-linked intellectual disability with spastic paraplegia and palmo-plantar hyperkeratosis, also known as Fitzsimmons-Victor syndrome or Palmini classification.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "vicuna-7b_response": "Based on the information provided, it is not clear if viruses are involved in the etiology of human subacute thyroiditis. The information mentions the isolation of viruses from patients with subacute thyroiditis de Quervain, but does not provide any evidence that these viruses are causally related to the disease.\nDocument-0 describes the characteristics of the isolated viruses, but does not provide any information on their role in human health disorders. Additionally, the fact that the isolated viruses remain unclassified so far suggests that their identity and function are still unknown.\nTherefore, it is not possible to provide a detailed answer to the question based on the information provided. Further research is needed to determine if viruses are involved in the etiology of human subacute thyroiditis.",
    "vicuna-7b_fact_raw": "1. Viruses have been isolated from patients with subacute thyroiditis de Quervain.\n2. There is no evidence provided that these isolated viruses are causally related to subacute thyroiditis.\n3. The isolated viruses remain unclassified.\n4. The role of the isolated viruses in human health disorders is not detailed.\n5. Further research is necessary to determine if viruses are involved in the etiology of human subacute thyroiditis.",
    "vicuna-7b_fact": [
      "Viruses have been isolated from patients with subacute thyroiditis de Quervain.",
      "There is no evidence provided that these isolated viruses are causally related to subacute thyroiditis.",
      "The isolated viruses remain unclassified.",
      "The role of the isolated viruses in human health disorders is not detailed.",
      "Further research is necessary to determine if viruses are involved in the etiology of human subacute thyroiditis."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "vicuna-7b_response": "Based on the information provided, it appears that STAT3 is involved in the regulation of autophagy through its interaction with the eIF2 kinase 2 (EIF2AK2) also known as protein kinase R (PKR). STAT3 inhibitors were found to potently stimulate autophagic flux, and genetic inhibition of STAT3 stimulated autophagy in vitro and in vivo. On the other hand, overexpression of STAT3 variants, including nonphosphorylatable and extranuclear STAT3, inhibited starvation-induced autophagy. The SH2 domain of STAT3 was found to interact with the catalytic domain of EIF2AK2, leading to the activation of PKR and consequent eIF2 hyperphosphorylation. Additionally, PKR depletion inhibited autophagy, suggesting that STAT3-PKR interactions play a crucial role in the regulation of autophagy. These findings suggest that STAT3 and PKR are interacting partners that regulate autophagy through the disruption of inhibitory STAT3-PKR interactions, leading to PKR-dependent eIF2 phosphorylation and facilitating autophagy induction.",
    "vicuna-7b_fact_raw": "1. STAT3 is involved in the regulation of autophagy through its interaction with EIF2AK2, also known as protein kinase R (PKR).\n2. Inhibitors of STAT3 stimulated autophagic flux.\n3. Genetic inhibition of STAT3 stimulated autophagy both in vitro and in vivo.\n4. Overexpression of nonphosphorylatable and extranuclear STAT3 variants inhibited starvation-induced autophagy.\n5. The SH2 domain of STAT3 interacts with the catalytic domain of EIF2AK2, which leads to the activation of PKR and eIF2 hyperphosphorylation.",
    "vicuna-7b_fact": [
      "STAT3 is involved in the regulation of autophagy through its interaction with EIF2AK2, also known as protein kinase R (PKR).",
      "Inhibitors of STAT3 stimulated autophagic flux.",
      "Genetic inhibition of STAT3 stimulated autophagy both in vitro and in vivo.",
      "Overexpression of nonphosphorylatable and extranuclear STAT3 variants inhibited starvation-induced autophagy.",
      "The SH2 domain of STAT3 interacts with the catalytic domain of EIF2AK2, which leads to the activation of PKR and eIF2 hyperphosphorylation."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: STAT3 can be involved in the regulation of autophagy. It has interactions with various proteins including EIF2AK2, and while this specific interaction is not widely confirmed in the literature, it is plausible as both are involved in cellular stress response pathways.\n2. TRUE: Inhibitors of STAT3 have been reported to stimulate autophagic flux. This is in line with the understanding that STAT3 can negatively regulate autophagy, and its inhibition can relieve this suppression.\n3. TRUE: Genetic inhibition of STAT3 has been shown in scientific studies to stimulate autophagy both in cell culture (in vitro) and animal models (in vivo).\n4. TRUE: The overexpression of certain forms of STAT3, such as nonphosphorylatable or mutants that are localized outside the nucleus, can inhibit autophagy. This could be because these forms of STAT3 might not carry out the normal regulatory functions that phosphorylatable and nuclear-localized STAT3 would have.\n5. UNKNOWN: The specific interaction between the SH2 domain of STAT3 and the catalytic domain of EIF2AK2 leading to PKR activation and eIF2 hyperphosphorylation is a detailed molecular mechanism. Without more context or a source, this information cannot be confirmed as true or false, so the truth value of this statement remains unknown.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "vicuna-7b_response": "Theatre is a web-based computing system designed for genomic analysis, particularly in the field of regulation of gene expression. It provides an interface to commonly used sequence analysis tools and biological sequence databases to determine or predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences. The information is displayed in a user-friendly manner, allowing for easy understanding and revealing patterns that might not have been noticed otherwise. In addition to web-based output, Theatre can produce publication-quality color hardcopies showing predicted features in aligned genomic sequences.\nA case study using the p53 promoter region of four mammalian species and two fish species is described. The study revealed differences in the p53 promoter region of the four mammals and the predicted region for the two fish species. Theatre can be accessed at <http://www.hgmp.mrc.ac.uk/Registered/Webapp/theatre/>.",
    "vicuna-7b_fact_raw": "1. Theatre is a web-based computing system used for genomic analysis.\n2. The primary focus of Theatre is on the regulation of gene expression.\n3. Theatre includes an interface to sequence analysis tools and biological sequence databases.\n4. Theatre can predict positions of coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.\n5. Theatre can produce publication-quality color hardcopies of aligned genomic sequences.",
    "vicuna-7b_fact": [
      "Theatre is a web-based computing system used for genomic analysis.",
      "The primary focus of Theatre is on the regulation of gene expression.",
      "Theatre includes an interface to sequence analysis tools and biological sequence databases.",
      "Theatre can predict positions of coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.",
      "Theatre can produce publication-quality color hardcopies of aligned genomic sequences."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The sentence may be referring to Galaxy, which is a web-based platform for computational biomedical research, including genomic analysis.\n2. UNKNOWN: Without more context or information on a system actually named \"Theatre,\" it's unclear whether it focuses on the regulation of gene expression or not.\n3. UNKNOWN: As above, without more context or information on the system referred to here, it's impossible to confirm the interface capabilities of \"Theatre.\"\n4. UNKNOWN: Again, without more context or information, it's not possible to verify whether \"Theatre\" has these predictive capabilities.\n5. UNKNOWN: There is no information available to confirm or deny whether \"Theatre\" can produce publication-quality color hardcopies of aligned genomic sequences.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "vicuna-7b_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on several factors, including the length of the sequences, the number of mismatches, and the gap penalty parameters.\nIn general, the Smith-Waterman algorithm has a time complexity of O(N^2), where N is the length of the sequences. This means that the algorithm becomes increasingly slower as the length of the sequences increases.\nHowever, the execution time of the algorithm can be improved by optimizing various parameters, such as the gap penalty, the search range, and the alignment matrix. The paper you provided describes a GPU-accelerated implementation of the S-W algorithm that achieves a performance of 21.4 GCUPS, which is 1.13 times better than the state-of-the-art implementation on an NVIDIA GTX 275 graphics card.\nTherefore, the execution time of the Smith-Waterman algorithm for the alignment of two sequences can vary depending on the specific implementation and the parameters used. However, in general, the algorithm has a time complexity of O(N^2) and can be optimized for better performance.",
    "vicuna-7b_fact_raw": "1. The Smith-Waterman algorithm has a time complexity of O(N^2) for the alignment of two sequences.\n2. The execution time of the Smith-Waterman algorithm increases with the length of the sequences.\n3. The time complexity considers factors such as the number of mismatches and the gap penalty parameters.\n4. The execution time of the Smith-Waterman algorithm can be improved through optimization of certain parameters.\n5. A GPU-accelerated implementation of the Smith-Waterman algorithm achieved a performance of 21.4 GCUPS on an NVIDIA GTX 275 graphics card.",
    "vicuna-7b_fact": [
      "The Smith-Waterman algorithm has a time complexity of O(N^2) for the alignment of two sequences.",
      "The execution time of the Smith-Waterman algorithm increases with the length of the sequences.",
      "The time complexity considers factors such as the number of mismatches and the gap penalty parameters.",
      "The execution time of the Smith-Waterman algorithm can be improved through optimization of certain parameters.",
      "A GPU-accelerated implementation of the Smith-Waterman algorithm achieved a performance of 21.4 GCUPS on an NVIDIA GTX 275 graphics card."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The Smith-Waterman algorithm, which uses dynamic programming, has a quadratic time complexity, O(N^2), for aligning two sequences of length N.\n2. TRUE: As the length of the sequences increases, the execution time of the Smith-Waterman algorithm also increases, given its quadratic time complexity with respect to sequence length.\n3. FALSE [correction]: The time complexity of the Smith-Waterman algorithm, being O(N^2), does not consider factors such as the number of mismatches or the gap penalty parameters. Time complexity is a theoretical measure of the number of operations required for the algorithm, and in the case of the Smith-Waterman algorithm, is primarily affected by the length of the sequences being aligned.\n4. TRUE: The execution time of the Smith-Waterman algorithm can be improved by optimizing parameters such as the substitution matrix, gap penalties, and by capitalizing on parallelism and other computational techniques.\n5. UNKNOWN: Without the specific reference to the performance results of a GPU-accelerated implementation of the Smith-Waterman algorithm, it is not possible to verify the accuracy of the performance claim. Performance can vary based on implementation and hardware specifications.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "vicuna-7b_response": "FLVCR1 is a member of the SLC22 protein family, which is a member of the SLC (Solute carriers) superfamily of polyspecific membrane transporters responsible for uptake of a wide range of organic anions and cations, including numerous endo- and xenobiotics. The SLC22 family is composed of 20 zebrafish genes, which are organized in the same functional subgroups as human SLC22 members. The tissue expression profiles of slc22 transcripts were analyzed using qRT-PCR determinations in nine zebrafish tissues, including liver, kidney, intestine, gills, brain, skeletal muscle, eye, heart, and gonads. The study revealed high expression of oct1 in kidney, especially in females, followed by oat3 and oat2c in females, oat2e in males and orctl4 in females. oct1 was also dominant in male liver. oat2d showed the highest expression in intestine with less noticeable gender differences. All slc22 genes showed low expression in gills, and moderate expression in heart and skeletal muscle. Dominant genes in brain were oat1 in females and oct1 in males, while the highest gender differences were determined in gonads, with dominant expression of almost all slc22 genes in testes and the highest expression of oat2a.",
    "vicuna-7b_fact_raw": "1. FLVCR1 is a member of the SLC22 protein family.\n2. The SLC22 family is composed of 20 zebrafish genes.\n3. Human SLC22 members are organized in the same functional subgroups as zebrafish SLC22 members.\n4. Tissue expression profiles of slc22 transcripts in zebrafish were analyzed using qRT-PCR in nine different tissues.\n5. In zebrafish, oct1 shows high expression in the kidney, especially in females.",
    "vicuna-7b_fact": [
      "FLVCR1 is a member of the SLC22 protein family.",
      "The SLC22 family is composed of 20 zebrafish genes.",
      "Human SLC22 members are organized in the same functional subgroups as zebrafish SLC22 members.",
      "Tissue expression profiles of slc22 transcripts in zebrafish were analyzed using qRT-PCR in nine different tissues.",
      "In zebrafish, oct1 shows high expression in the kidney, especially in females."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC22 protein family. Instead, it is a member of the major facilitator superfamily.\n2. UNKNOWN: The exact number of SLC22 genes in zebrafish is not specified, and without specific literature, it's not possible to confirm the number of zebrafish genes in the SLC22 family.\n3. UNKNOWN: The organization of SLC22 family members in humans compared to zebrafish in terms of functional subgroups requires specific literature or scientific data for confirmation.\n4. TRUE: This statement sounds like a specific scientific observation that could be part of a study's methodology, and such an analysis is commonly used to study gene expression.\n5. UNKNOWN: Without specific literature or scientific research data related to the expression of oct1 in zebrafish, it is not possible to confirm the high expression in the kidney, especially in females.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "vicuna-7b_response": "GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach are:\n1. Other transcription factors: GATA-1 has been shown to interact with several other transcription factors, such as Oct-1, AP-1, and NF-E2, to regulate gene expression.\n2. Chromatin remodeling cofactors: GATA-1 complexes have been characterized to include proteins involved in chromatin remodeling, such as BRM, BAP-1, and ISWI.\n3. Coactivators: GATA-1 complexes also include proteins that enhance transcriptional activation, such as p300, CBP, and PCAF.\n4. Corepressors: GATA-1 complexes also include proteins that repress transcriptional activation, such as HDAC1, HDAC2, and SMRT.\nThese interactions have been identified by mass spectrometry analysis of the purified GATA-1 complexes using the BirA-mediated biotinylation tagging approach described in Document-0.",
    "vicuna-7b_fact_raw": "1. GATA-1 interacts with several other transcription factors, which include Oct-1, AP-1, and NF-E2.\n2. BRM, BAP-1, and ISWI are proteins involved in chromatin remodeling that have been shown to interact with GATA-1.\n3. GATA-1 complexes include coactivator proteins such as p300, CBP, and PCAF.\n4. HDAC1, HDAC2, and SMRT are corepressor proteins that interact with GATA-1 complexes.\n5. The BirA-mediated biotinylation tagging approach was utilized to identify the interacting partners of GATA-1.",
    "vicuna-7b_fact": [
      "GATA-1 interacts with several other transcription factors, which include Oct-1, AP-1, and NF-E2.",
      "BRM, BAP-1, and ISWI are proteins involved in chromatin remodeling that have been shown to interact with GATA-1.",
      "GATA-1 complexes include coactivator proteins such as p300, CBP, and PCAF.",
      "HDAC1, HDAC2, and SMRT are corepressor proteins that interact with GATA-1 complexes.",
      "The BirA-mediated biotinylation tagging approach was utilized to identify the interacting partners of GATA-1."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: GATA-1 does interact with several other transcription factors, and these can include Oct-1, AP-1, and NF-E2.\n2. TRUE: BRM, BAP-1 (actually the related BAF complex component), and ISWI (also associated with chromatin remodeling complexes) have been known to interact with various transcription factors, and it's plausible that they would interact with GATA-1.\n3. TRUE: GATA-1 is known to interact with coactivator proteins such as p300, CBP, and PCAF which help in the facilitation of transcription.\n4. TRUE: HDAC1, HDAC2, and SMRT are corepressor proteins, and these types of proteins can interact with GATA-1 complexes to repress transcription.\n5. UNKNOWN: While the BirA-mediated biotinylation tagging approach is a method used to identify protein interactions, without specific context or citation, it is not possible to confirm its usage for identifying interacting partners of GATA-1.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "vicuna-7b_response": "Based on the information provided, it appears that TAF10 interacts with the GATA1 transcription factor, and this interaction is important for proper differentiation of erythroid cells. Specifically, ablating TAF10 in erythroid cells in vivo resulted in a differentiation block and deregulation of GATA1 target genes, including Gata1 itself. Additionally, analysis of TFIID and SAGA complexes in mouse and human cells showed that their global integrity is maintained during erythroid cell differentiation and development, and that TAF10 interacts directly with GATA1 and is enriched on the GATA1 locus in human fetal erythroid cells. These findings suggest that TAF10 and GATA1 have a functional cross talk during development and differentiation.",
    "vicuna-7b_fact_raw": "1. TAF10 interacts with the GATA1 transcription factor.\n2. The interaction between TAF10 and GATA1 is crucial for the proper differentiation of erythroid cells.\n3. Ablation of TAF10 in erythroid cells in vivo leads to a differentiation block.\n4. Deregulation of GATA1 target genes occurs when TAF10 is ablated in erythroid cells.\n5. TAF10 is directly enriched on the GATA1 locus in human fetal erythroid cells.",
    "vicuna-7b_fact": [
      "TAF10 interacts with the GATA1 transcription factor.",
      "The interaction between TAF10 and GATA1 is crucial for the proper differentiation of erythroid cells.",
      "Ablation of TAF10 in erythroid cells in vivo leads to a differentiation block.",
      "Deregulation of GATA1 target genes occurs when TAF10 is ablated in erythroid cells.",
      "TAF10 is directly enriched on the GATA1 locus in human fetal erythroid cells."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nNote: While there is evidence supporting the interactions between TAF10 and GATA1 transcription factor and their roles in erythroid cell differentiation, the specific enrichment of TAF10 on the GATA1 locus in human fetal erythroid cells is not a widely established fact and could require specific experimental evidence that is not mentioned here.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "vicuna-7b_response": "Yes, there are decision support systems for chronic pain management. A study was conducted to test whether computer-based decision support (CBDS) could enhance the ability of primary care physicians (PCPs) to manage chronic pain. The study used a decision support system to determine appropriate pain therapy and sent letters to the referring physicians outlining these recommendations. The study found that the use of a CBDS system may improve the ability of PCPs to manage chronic pain and may also facilitate screening of consults to optimize specialist utilization.",
    "vicuna-7b_fact_raw": "1. There exist decision support systems for chronic pain management.\n2. A study tested the efficacy of computer-based decision support (CBDS) in enhancing primary care physicians' management of chronic pain.\n3. A decision support system in the study recommended appropriate pain therapy.\n4. Letters were sent to referring physicians with therapy recommendations from the decision support system.\n5. The study indicated that the use of CBDS may improve the management of chronic pain by primary care physicians and help optimize specialist utilization.",
    "vicuna-7b_fact": [
      "There exist decision support systems for chronic pain management.",
      "A study tested the efficacy of computer-based decision support (CBDS) in enhancing primary care physicians' management of chronic pain.",
      "A decision support system in the study recommended appropriate pain therapy.",
      "Letters were sent to referring physicians with therapy recommendations from the decision support system.",
      "The study indicated that the use of CBDS may improve the management of chronic pain by primary care physicians and help optimize specialist utilization."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "vicuna-7b_response": "The subcellular localization of the protein angiogenin is in the perinuclear region at 30 min and then dispersed throughout the cytoplasm. In conditions favoring receptor-mediated endocytosis, internalization of iodinated angiogenin shows a first peak at 5 min and then further increases for up to 24 h. The half-life of the molecule is 12 hours, which contributes to its intracellular accumulation. In addition to the 14-kDa protein, a 8.7-kDa fragment is observed at 24 h, and three fragments with molecular mass of 10.5, 8.7, and 6.1 kDa are detected at 48 h. These data suggest that angiogenin is specifically internalized and processed by aortic smooth muscle cells.",
    "vicuna-7b_fact_raw": "1. The protein angiogenin initially localizes in the perinuclear region at 30 minutes.\n2. Angiogenin is then dispersed throughout the cytoplasm.\n3. Internalization of iodinated angiogenin has a first peak at 5 minutes and increases up to 24 hours.\n4. The half-life of angiogenin is 12 hours.\n5. A fragment of angiogenin with a molecular mass of 8.7-kDa is detected at 24 hours.",
    "vicuna-7b_fact": [
      "The protein angiogenin initially localizes in the perinuclear region at 30 minutes.",
      "Angiogenin is then dispersed throughout the cytoplasm.",
      "Internalization of iodinated angiogenin has a first peak at 5 minutes and increases up to 24 hours.",
      "The half-life of angiogenin is 12 hours.",
      "A fragment of angiogenin with a molecular mass of 8.7-kDa is detected at 24 hours."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided refer to specific biochemical properties and behaviors of the protein angiogenin. Without a specific scientific study or source to refer to that provides this information, it's not possible to verify the accuracy of these statements. They require specialized knowledge in biochemistry and access to the relevant scientific research.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "vicuna-7b_response": "Ranolazine is a drug that has been shown to have anti-ischemic and antidiabetic effects. It has been studied in diabetic mellitus (DM) rats following myocardial infarction (MI) to determine its effect on cardiac function. The study found that Ranolazine improved the recovery of function in both nondiabetic and diabetic postinfarcted hearts, with the effect being greater in the diabetic group. The drug increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted hearts without changing the activation of mitogen-activated protein kinases (MAPKs). In diabetic hearts, Ranolazine resulted in a significant increase in the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban and increased levels of phosphorylated calcium-regulated adenosine monophosphate-activated protein kinase (AMPK). The drug also increased insulin and lowered glucose levels in serum in diabetic animals. The study's findings suggest that Ranolazine's beneficial effect on cardiac function after MI is greater in DM rats and is associated with activation of Akt/mTOR and AMPK. These results provide a plausible explanation for the results of the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) trial, which showed a greater antianginal effect of Ranolazine in patients with coronary artery disease and diabetes.",
    "vicuna-7b_fact_raw": "1. Ranolazine has anti-ischemic and antidiabetic effects.\n2. The study indicated that Ranolazine improved the recovery of function in both nondiabetic and diabetic postinfarcted hearts.\n3. Ranolazine increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in infarcted hearts.\n4. In diabetic hearts, Ranolazine significantly increased the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban and levels of phosphorylated AMPK.\n5. Ranolazine increased insulin and lowered glucose levels in serum in diabetic animals.",
    "vicuna-7b_fact": [
      "Ranolazine has anti-ischemic and antidiabetic effects.",
      "The study indicated that Ranolazine improved the recovery of function in both nondiabetic and diabetic postinfarcted hearts.",
      "Ranolazine increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in infarcted hearts.",
      "In diabetic hearts, Ranolazine significantly increased the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban and levels of phosphorylated AMPK.",
      "Ranolazine increased insulin and lowered glucose levels in serum in diabetic animals."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Ranolazine is known to have anti-ischemic effects due to its action on myocardial cells and has been reported to exhibit antidiabetic effects as well.\n2. TRUE: Based on the provided statement, it's specified that the study found Ranolazine improved the recovery of function in both nondiabetic and diabetic postinfarcted hearts, which is consistent with known effects of the drug on heart function after myocardial infarction.\n3. TRUE: If the statement indicates that the study found increases in levels of phosphorylated Akt and mTOR in infarcted hearts after treatment with Ranolazine, this is considered true as these are intracellular signaling proteins that could be affected by pharmacological agents.\n4. TRUE: This statement describes specific biochemical effects of Ranolazine in diabetic hearts, which seems consistent with the known molecular actions of the drug reported in scientific studies on heart muscle cells.\n5. UNKNOWN: While Ranolazine is known to have antidiabetic effects, the specific effects on serum insulin and glucose levels can vary, and without specific study data, we cannot confirm or refute this statement. It would be necessary to refer to the particular study to determine the truthfulness of this statement.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "vicuna-7b_response": "Based on the information provided in Document-0, it appears that the regulation of Vsr endonuclease is not dependent on the growth phase of bacteria. The document states that overexpression of Vsr does not have a regulatory role in stationary-phase mutation and that the effects of Vsr overproduction are likely to be artifactual. Therefore, it can be concluded that the regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
    "vicuna-7b_fact_raw": "1. The regulation of Vsr endonuclease is reported to be independent of the bacterial growth phase.\n2. Overexpression of Vsr endonuclease does not have a regulatory role in stationary-phase mutation according to Document-0.\n3. Effects of Vsr endonuclease overproduction are considered likely to be artifactual.",
    "vicuna-7b_fact": [
      "The regulation of Vsr endonuclease is reported to be independent of the bacterial growth phase.",
      "Overexpression of Vsr endonuclease does not have a regulatory role in stationary-phase mutation according to Document-0.",
      "Effects of Vsr endonuclease overproduction are considered likely to be artifactual."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout access to the actual content of \"Document-0\" or additional specific information regarding the regulation and effects of Vsr endonuclease, it is not possible to verify the accuracy of these statements.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "vicuna-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. One such method is the transFold algorithm, which uses pairwise interstrand residue statistical potentials derived from globular proteins to predict the supersecondary structure of transmembrane beta-barrel proteins. The algorithm employs a generalized hidden Markov model to describe potential beta-barrel supersecondary structures and then computes the minimum free energy beta-barrel structure by dynamic programming. This approach differs from traditional machine learning methods and does not require a training phase on known TMB structures. The transFold algorithm has been shown to outperform previous programs for predicting TMBs on smaller proteins and to match their performance for recognizing longer proteins. A web server running transFold is available and outputs contact predictions and locations for sequences predicted to form TMBs.",
    "vicuna-7b_fact_raw": "1. The transFold algorithm is used to predict the supersecondary structure of transmembrane beta-barrel proteins.\n2. transFold uses pairwise interstrand residue statistical potentials derived from globular proteins.\n3. A generalized hidden Markov model is employed by transFold to describe potential beta-barrel supersecondary structures.\n4. The transFold algorithm computes the minimum free energy beta-barrel structure through dynamic programming.\n5. transFold does not require a training phase on known transmembrane beta-barrel (TMB) structures.",
    "vicuna-7b_fact": [
      "The transFold algorithm is used to predict the supersecondary structure of transmembrane beta-barrel proteins.",
      "transFold uses pairwise interstrand residue statistical potentials derived from globular proteins.",
      "A generalized hidden Markov model is employed by transFold to describe potential beta-barrel supersecondary structures.",
      "The transFold algorithm computes the minimum free energy beta-barrel structure through dynamic programming.",
      "transFold does not require a training phase on known transmembrane beta-barrel (TMB) structures."
    ],
    "vicuna-7b_judge_raw": "1. TRUE \n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: transFold does require a training phase on known transmembrane beta-barrel (TMB) structures in order to develop the statistical potentials and model parameters it uses for prediction.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "vicuna-7b_response": "Galassi classification is used for bipolar affective disorder. It is a classification system that is used to measure the period prevalence of bipolar affective disorder based on treatment with lithium. The classification is named after its creator, Dr. Galassi. The paper describes three measures of the period prevalence of bipolar affective disorder, two of which are of the \"unobtrusive\" type. The paper also states that the use of lithium has been demonstrated beyond doubt for the treatment of bipolar affective disorder, and that the occurrence of mania in this disorder enables this aspect of the condition to be used as a marker.",
    "vicuna-7b_fact_raw": "1. The Galassi classification is used for bipolar affective disorder.\n2. The Galassi classification is a system used to measure the period prevalence of bipolar affective disorder.\n3. The Galassi classification system is based on treatment with lithium.\n4. The creator of the Galassi classification is Dr. Galassi.\n5. Lithium treatment has been demonstrated beyond doubt for the treatment of bipolar affective disorder.",
    "vicuna-7b_fact": [
      "The Galassi classification is used for bipolar affective disorder.",
      "The Galassi classification is a system used to measure the period prevalence of bipolar affective disorder.",
      "The Galassi classification system is based on treatment with lithium.",
      "The creator of the Galassi classification is Dr. Galassi.",
      "Lithium treatment has been demonstrated beyond doubt for the treatment of bipolar affective disorder."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is used to categorize the different types of cranial fractures.\n2. FALSE [correction]: The Galassi classification is not a system used to measure the period prevalence of bipolar affective disorder; rather, it's used in the context of otolaryngology to describe temporal bone fractures.\n3. FALSE [correction]: The Galassi classification system is not based on treatment with lithium; it is related to the classification of temporal bone fractures.\n4. UNKNOWN (I do not have information about the creator of the Galassi classification named Dr. Galassi)\n5. TRUE (Lithium treatment is a well-established therapy for the treatment of bipolar affective disorder.)",
    "vicuna-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "vicuna-7b_response": "Shapiro Syndrome is a rare genetic disorder characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum. It is defined by fewer than 100 reported cases and only a few cases without a complete agenesis of corpus callosum. The onset of symptoms is usually before the age of one year. The condition is often misdiagnosed as epilepsy due to the similarity of symptoms. The condition is caused by mutations in the SHANK3 gene, which plays a role in the development of the corpus callosum. The triad of symptoms is not always present and can vary from case to case. Treatment options include anti-epileptic drugs and therapy to manage symptoms.",
    "vicuna-7b_fact_raw": "1. Shapiro Syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. There have been fewer than 100 reported cases of Shapiro Syndrome.\n3. The onset of symptoms in Shapiro Syndrome usually occurs before the age of one year.\n4. Shapiro Syndrome is often misdiagnosed as epilepsy.\n5. Mutations in the SHANK3 gene are a cause of Shapiro Syndrome.",
    "vicuna-7b_fact": [
      "Shapiro Syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum.",
      "There have been fewer than 100 reported cases of Shapiro Syndrome.",
      "The onset of symptoms in Shapiro Syndrome usually occurs before the age of one year.",
      "Shapiro Syndrome is often misdiagnosed as epilepsy.",
      "Mutations in the SHANK3 gene are a cause of Shapiro Syndrome."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The onset of symptoms in Shapiro Syndrome typically occurs after the age of one year.\n4. TRUE\n5. FALSE [correction]: Shapiro Syndrome is not associated with mutations in the SHANK3 gene; instead, it is a rare neurologic condition without a well-defined genetic cause.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "vicuna-7b_response": "BRAG1 mutations have been linked to Hirschsprung's disease. In the given information, a male infant was diagnosed with congenital central hypoventilation syndrome (CCHS) and Hirschsprung's disease, and further testing revealed a mutation in the BRAF oncogene. The report describes a novel association between these mutations and the shared qualities of tumorigenesis between BRAF and PHOX2B. However, it is important to note that the report does not specifically mention BRAG1.",
    "vicuna-7b_fact_raw": "1. Mutations within BRAG1 have been linked to Hirschsprung's disease.\n2. A male infant was diagnosed with both congenital central hypoventilation syndrome (CCHS) and Hirschsprung's disease.\n3. Further testing on this infant revealed a mutation in the BRAF oncogene.\n4. There is an identified novel association between mutations and shared qualities of tumorigenesis between BRAF and PHOX2B.",
    "vicuna-7b_fact": [
      "Mutations within BRAG1 have been linked to Hirschsprung's disease.",
      "A male infant was diagnosed with both congenital central hypoventilation syndrome (CCHS) and Hirschsprung's disease.",
      "Further testing on this infant revealed a mutation in the BRAF oncogene.",
      "There is an identified novel association between mutations and shared qualities of tumorigenesis between BRAF and PHOX2B."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Mutations within the gene RET are more commonly associated with Hirschsprung's disease.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "vicuna-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "vicuna-7b_response": "The main inhibitor of protein phosphatase 1 (PP1) is protein phosphatase inhibitor-1 (PPI-1). PPI-1 is a major inhibitor of PP1 and regulates signal transduction in many eukaryotic cellular processes. PPI-1 has a large Stokes radius and is heat stable, suggesting that it lacks extensive secondary structures. The unfolded structure of PPI-1 may enable it to interact with many proteins or ligands during stress conditions. In addition to its role as an inhibitor of PP1, PPI-1 has been shown to act as a protective molecule, inhibiting protein aggregation and guarding E. coli cells against various stresses. Therefore, PPI-1 has a physiological function as both an inhibitor of protein serine/threonine phosphatases and a protective molecule.",
    "vicuna-7b_fact_raw": "1. Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PPI-1 regulates signal transduction in many eukaryotic cellular processes.\n3. PPI-1 has a large Stokes radius and is heat stable.\n4. The unfolded structure of PPI-1 allows it to interact with many proteins or ligands during stress conditions.\n5. PPI-1 acts as a protective molecule, inhibiting protein aggregation and protecting E. coli cells against various stresses.",
    "vicuna-7b_fact": [
      "Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PPI-1 regulates signal transduction in many eukaryotic cellular processes.",
      "PPI-1 has a large Stokes radius and is heat stable.",
      "The unfolded structure of PPI-1 allows it to interact with many proteins or ligands during stress conditions.",
      "PPI-1 acts as a protective molecule, inhibiting protein aggregation and protecting E. coli cells against various stresses."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Protein phosphatase inhibitor-1 (PPI-1), also known as Inhibitor-1, is indeed a potent and specific inhibitor of protein phosphatase 1 (PP1).\n2. TRUE: PPI-1 does regulate signal transduction in a variety of eukaryotic cellular processes, primarily through its inhibitory effect on PP1.\n3. UNKNOWN: Without specific biochemical data, the statement regarding the Stokes radius and heat stability of PPI-1 cannot be verified. The specific physical properties can differ among proteins and their inhibitor types.\n4. UNKNOWN: The statement about the unfolded structure of PPI-1 interacting with many proteins or ligands during stress conditions is not verifiable without specific scientific references. The conformational flexibility of proteins under stress can indeed facilitate interactions with various molecules, but this is a generalization and may not specifically apply to PPI-1.\n5. FALSE [correction]: The statement provided makes a claim about the role of PPI-1 in Escherichia coli (E. coli) cells, but there is no evidence suggesting that PPI-1 directly inhibits protein aggregation or protects E. coli cells against various stresses. This statement might be confusing PPI-1 with molecular chaperones or other stress response proteins known in prokaryotes and eukaryotes. It's important to note that PPI-1 is a regulatory protein primarily studied in the context of eukaryotic cells; its functional role in bacteria like E. coli is either not established or is misunderstood in this statement.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "vicuna-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a mechanism that occurs in the gram-positive bacterium Bacillus subtilis. This type of mutagenesis is subject to regulation involving at least two of the genes that are involved in the regulation of post-exponential phase prokaryotic differentiation, i.e., comA and comK. The results suggest that a small subpopulation of the culture is involved in adaptive mutagenesis and that this subpopulation is hypermutable. The existence of such a hypermutable subpopulation raises important considerations with respect to evolution, the development of specific mutations, the nature of bacterial populations, and the level of communication among bacteria in an ecological niche.",
    "vicuna-7b_fact_raw": "1. Adaptive mutagenesis occurs in the gram-positive bacterium Bacillus subtilis.\n2. Stationary-phase mutagenesis is also known as adaptive mutagenesis.\n3. The regulation of adaptive mutagenesis in Bacillus subtilis involves at least the comA and comK genes.\n4. A small subpopulation of the culture undergoes adaptive mutagenesis.\n5. The subpopulation involved in adaptive mutagenesis is considered hypermutable.",
    "vicuna-7b_fact": [
      "Adaptive mutagenesis occurs in the gram-positive bacterium Bacillus subtilis.",
      "Stationary-phase mutagenesis is also known as adaptive mutagenesis.",
      "The regulation of adaptive mutagenesis in Bacillus subtilis involves at least the comA and comK genes.",
      "A small subpopulation of the culture undergoes adaptive mutagenesis.",
      "The subpopulation involved in adaptive mutagenesis is considered hypermutable."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "vicuna-7b_response": "Erucism is a skin condition caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens). The gum leaf skeletoniser is a recently established pest in the Auckland region of New Zealand, and its venom-containing spines can cause adverse reactions in humans, including a stinging sensation, itching, and the formation of wheals. These symptoms are similar to those of contact dermatitis, and exposure to U. lugens should be considered by medical practitioners in the differential diagnosis of this condition in the Auckland region.",
    "vicuna-7b_fact_raw": "1. Erucism is a skin condition caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).\n2. The gum leaf skeletoniser is a pest in the Auckland region of New Zealand.\n3. Human exposure to the spines of Uraba lugens can cause a stinging sensation, itching, and the formation of wheals.\n4. Symptoms of erucism are similar to those of contact dermatitis.\n5. Medical practitioners in the Auckland region are advised to consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis.",
    "vicuna-7b_fact": [
      "Erucism is a skin condition caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).",
      "The gum leaf skeletoniser is a pest in the Auckland region of New Zealand.",
      "Human exposure to the spines of Uraba lugens can cause a stinging sensation, itching, and the formation of wheals.",
      "Symptoms of erucism are similar to those of contact dermatitis.",
      "Medical practitioners in the Auckland region are advised to consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nErucism is indeed caused by contact with certain caterpillars or their hairs/spines, and Uraba lugens, known as the gum leaf skeletoniser, has been documented to cause these reactions. These caterpillars are considered pests in various regions, including Auckland, New Zealand. The symptoms described (stinging, itching, wheals) are consistent with the reactions to caterpillar spines, and such symptoms do resemble those of contact dermatitis. In areas where the organism is common, it would be prudent for medical practitioners to consider it in their differential diagnosis when similar skin conditions are observed.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "vicuna-7b_response": "Hydrochlorothiazide is a diuretic medication that is used to treat hypertension, or high blood pressure. It belongs to class IV of the Biopharmaceutics Classification System, which indicates that it is a drug that is absorbed in the small intestine and is highly lipid soluble.\nThe drug was evaluated through quality control, thermal characterization tests, and pharmaceutical formulation compatibility studies. The results of these studies showed that the generic drug, Lab 2, was not a pharmaceutical equivalent of hydrochlorothiazide. The compounded drugs, Lab 5 and Lab 6, also produced unsatisfactory results, but it is not clear why this is the case.\nIn a compatibility study, lactose and mannitol were found to be incompatible with hydrochlorothiazide, which may explain why the generic pharmaceutical product was not equivalent. It is important to note that there is no requirement for dissolution and dissolution profile testing for the commercialization of these products.\nIn summary, hydrochlorothiazide is a diuretic medication that is used to treat hypertension. It is a highly lipid soluble drug that is absorbed in the small intestine and belongs to class IV of the Biopharmaceutics Classification System. The drug was evaluated through quality control, thermal characterization tests, and pharmaceutical formulation compatibility studies, which showed that the generic drug, Lab 2, was not a pharmaceutical equivalent. The compounded drugs, Lab 5 and Lab 6, also produced unsatisfactory results, but the reason for this is not clear. It is important to note that there is no requirement for dissolution and dissolution profile testing for the commercialization of these products.",
    "vicuna-7b_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension, or high blood pressure.\n2. It is classified as a class IV drug according to the Biopharmaceutics Classification System.\n3. Hydrochlorothiazide is a highly lipid soluble drug that is absorbed in the small intestine.\n4. Lactose and mannitol were found to be incompatible with hydrochlorothiazide in a compatibility study.\n5. There is no requirement for dissolution and dissolution profile testing for the commercialization of hydrochlorothiazide products.",
    "vicuna-7b_fact": [
      "Hydrochlorothiazide is used to treat hypertension, or high blood pressure.",
      "It is classified as a class IV drug according to the Biopharmaceutics Classification System.",
      "Hydrochlorothiazide is a highly lipid soluble drug that is absorbed in the small intestine.",
      "Lactose and mannitol were found to be incompatible with hydrochlorothiazide in a compatibility study.",
      "There is no requirement for dissolution and dissolution profile testing for the commercialization of hydrochlorothiazide products."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hydrochlorothiazide is classified as a class I drug according to the Biopharmaceutics Classification System, which means it has high solubility and high permeability.\n3. FALSE [correction]: Hydrochlorothiazide is not highly lipid soluble; it is actually relatively hydrophilic, which affects its absorption characteristics.\n4. UNKNOWN: Without specific details from the compatibility study, it is not possible to verify the compatibility of hydrochlorothiazide with lactose and mannitol.\n5. FALSE [correction]: There are requirements for dissolution testing for the commercialization of hydrochlorothiazide products, as these tests ensure the drug's quality and bioavailability.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "vicuna-7b_response": "Yes, silicone has been used in the treatment of incontinence. In the given document, transurethral submucosal injection therapy of polydimethylsiloxane (PDS) was used to treat incontinence after radical prostatectomy (RP) in six patients. The patients suffered from severe post-operative incontinence with a mean duration of incontinence after RP of 28 months. The material used, PDS, has a mean particle size of 188 microns and provides stability at the injection site. The results showed that five out of the six patients were dry after the injection therapy, one patient improved significantly but still required two pads during the day but was continent during the night, and three patients required a second injection. The side-effects of therapy were minimal. In conclusion, the authors state that because of PDS's excellent biocompatibility, few side-effects or complications, transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after RP.",
    "vicuna-7b_fact_raw": "1. Silicone has been used in the treatment of incontinence.\n2. Transurethral submucosal injection therapy of polydimethylsiloxane (PDS) was used to treat incontinence in six patients who had undergone radical prostatectomy.\n3. The mean duration of incontinence after radical prostatectomy in the patients was 28 months.\n4. Five out of the six patients treated with the PDS injection therapy were dry after the treatment.\n5. Polydimethylsiloxane (PDS) used in the injection therapy has a mean particle size of 188 microns.",
    "vicuna-7b_fact": [
      "Silicone has been used in the treatment of incontinence.",
      "Transurethral submucosal injection therapy of polydimethylsiloxane (PDS) was used to treat incontinence in six patients who had undergone radical prostatectomy.",
      "The mean duration of incontinence after radical prostatectomy in the patients was 28 months.",
      "Five out of the six patients treated with the PDS injection therapy were dry after the treatment.",
      "Polydimethylsiloxane (PDS) used in the injection therapy has a mean particle size of 188 microns."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific medical passage or study results that these statements are derived from, it's not possible to categorically confirm the details regarding treatment specifics, patient outcomes, or the properties of the substances used. Information on such topics typically requires access to specialized medical literature or clinical study reports.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "vicuna-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of interest in the medical field. According to the information provided in Document-0, there is a statistically significant increase in the incidence of aneurysmal subarachnoid hemorrhage (SAH) during the phase of new moon. In contrast, no seasonal variation in the incidence of SAH was observed. The study suggests that the lunar cycle may affect the incidence of intracranial aneurysm rupture. However, further research is needed to confirm these findings and to better understand the potential mechanisms behind this association.",
    "vicuna-7b_fact_raw": "1. There is a statistically significant increase in the incidence of aneurysmal subarachnoid hemorrhage (SAH) during the new moon phase.\n2. No seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage (SAH) was found.\n3. A study suggests that the lunar cycle may affect the incidence of intracranial aneurysm rupture.\n4. There is a need for further research to confirm the findings regarding the lunar cycle's effect on intracranial aneurysm rupture.\n5. Understanding the potential mechanisms behind the association between the lunar cycle and intracranial aneurysm rupture requires more study.",
    "vicuna-7b_fact": [
      "There is a statistically significant increase in the incidence of aneurysmal subarachnoid hemorrhage (SAH) during the new moon phase.",
      "No seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage (SAH) was found.",
      "A study suggests that the lunar cycle may affect the incidence of intracranial aneurysm rupture.",
      "There is a need for further research to confirm the findings regarding the lunar cycle's effect on intracranial aneurysm rupture.",
      "Understanding the potential mechanisms behind the association between the lunar cycle and intracranial aneurysm rupture requires more study."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE (Assuming that there is indeed a study suggesting this, but without specific context, it is difficult to verify the specific findings of the study.)\n4. TRUE (This statement is generic and typically true for many studies in the medical field, as further research is often needed to confirm initial findings.)\n5. TRUE (This statement is a reasonable and common scientific position following observations from studies that suggest a potential association, indicating the need for more study to understand mechanisms.)",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "vicuna-7b_response": "Based on the information provided, it appears that the HuR protein plays a role in regulating the splicing process. The report states that HuR modulates mRNA splicing, trafficking, translation, and stability, and that it serves as a model of RNA-protein interactions. The report also mentions that the cryogenic RNA immunoprecipitation technique was used to analyze HuR-interacting RNAs, and that hundreds of non-coding RNAs, including natural antisense transcripts from stress responsive loci, were identified as interacting with HuR. The report also suggests that HuR may play a role in the regulation of protein degradation, which could be related to its role in the splicing process.",
    "vicuna-7b_fact_raw": "1. The HuR protein modulates mRNA splicing, trafficking, translation, and stability.\n2. HuR serves as a model of RNA-protein interactions.\n3. The cryogenic RNA immunoprecipitation technique was used to analyze HuR-interacting RNAs.\n4. Hundreds of non-coding RNAs, including natural antisense transcripts from stress responsive loci, interact with HuR.\n5. HuR may play a role in the regulation of protein degradation.",
    "vicuna-7b_fact": [
      "The HuR protein modulates mRNA splicing, trafficking, translation, and stability.",
      "HuR serves as a model of RNA-protein interactions.",
      "The cryogenic RNA immunoprecipitation technique was used to analyze HuR-interacting RNAs.",
      "Hundreds of non-coding RNAs, including natural antisense transcripts from stress responsive loci, interact with HuR.",
      "HuR may play a role in the regulation of protein degradation."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: HuR may play a role in the regulation of mRNA degradation, not directly in the regulation of protein degradation. HuR generally regulates the fate of the mRNAs by influencing their stability and translation, which indirectly affects protein synthesis.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "vicuna-7b_response": "The prothymosin alpha c-terminal peptide is a nuclear protein that is highly acidic and lacks an amino-terminal signal peptide. It is present in sealed nuclei obtained by treating cells with cytochalasin B and enucleating them centrifugally. The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, has been identified as part of the nuclear targeting signal, whereas the basic cluster of amino acids situated within the thymosin alpha 1 sequence at the amino terminus failed to effect nuclear transport. The prothymosin alpha c-terminal peptide is not a precursor for thymosin alpha 1, but it is a nuclear protein.",
    "vicuna-7b_fact_raw": "1. The prothymosin alpha c-terminal peptide is a nuclear protein.\n2. The prothymosin alpha c-terminal peptide is highly acidic.\n3. The protein lacks an amino-terminal signal peptide.\n4. The basic cluster of amino acids at the carboxyl terminus, TKKQKT, is part of the nuclear targeting signal of the prothymosin alpha.\n5. Prothymosin alpha c-terminal peptide is not a precursor for thymosin alpha 1.",
    "vicuna-7b_fact": [
      "The prothymosin alpha c-terminal peptide is a nuclear protein.",
      "The prothymosin alpha c-terminal peptide is highly acidic.",
      "The protein lacks an amino-terminal signal peptide.",
      "The basic cluster of amino acids at the carboxyl terminus, TKKQKT, is part of the nuclear targeting signal of the prothymosin alpha.",
      "Prothymosin alpha c-terminal peptide is not a precursor for thymosin alpha 1."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Prothymosin alpha is a nuclear protein, and thus its c-terminal peptide would typically be associated with nuclear functions.\n2. TRUE: Prothymosin alpha is known to be a highly acidic protein.\n3. TRUE: Prothymosin alpha does not have a classical amino-terminal signal peptide as it is not secreted but instead is localized in the nucleus.\n4. TRUE: Basic clusters of amino acids are often involved in nuclear localization signals (NLS), and the sequence provided is indicative of such a role.\n5. FALSE [correction]: Prothymosin alpha is indeed a precursor for thymosin alpha 1.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "vicuna-7b_response": "The (47)LQVVR(51) peptide plays a pivotal role in human cystatin C (HCC) fibrillization. HCC is a low molecular weight member of the cystatin family (type 2) and consists of 120 amino acids. Normally, it is an inhibitor of cysteine proteases, but in pathological conditions, it forms amyloid fibrils in brain arteries of young adults. The (47)LQVVR(51) peptide was located within the HCC sequence using AmylPred, an 'aggregation-prone' peptide prediction algorithm developed in the lab. This peptide was synthesized and self-assembled into amyloid-like fibrils in vitro, as electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies reveal. Thus, the (47)LQVVR(51) peptide seems to have an important role in HCC fibrillization.",
    "vicuna-7b_fact_raw": "1. The peptide (47)LQVVR(51) plays a pivotal role in human cystatin C (HCC) fibrillization.\n2. Human cystatin C consists of 120 amino acids.\n3. Normally, human cystatin C acts as an inhibitor of cysteine proteases.\n4. The (47)LQVVR(51) peptide within human cystatin C was located using the AmylPred prediction algorithm.\n5. The synthesized (47)LQVVR(51) peptide can self-assemble into amyloid-like fibrils in vitro, confirmed by electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining.",
    "vicuna-7b_fact": [
      "The peptide (47)LQVVR(51) plays a pivotal role in human cystatin C (HCC) fibrillization.",
      "Human cystatin C consists of 120 amino acids.",
      "Normally, human cystatin C acts as an inhibitor of cysteine proteases.",
      "The (47)LQVVR(51) peptide within human cystatin C was located using the AmylPred prediction algorithm.",
      "The synthesized (47)LQVVR(51) peptide can self-assemble into amyloid-like fibrils in vitro, confirmed by electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe answers provided for statements 1, 2, 3, and 5 are based on common scientific knowledge about human cystatin C and its properties related to amyloid fibril formation. Statement 4 is specific and would require access to the actual scientific study or data that employed the AmylPred prediction algorithm to confirm its validity; hence, the response \"UNKNOWN\".",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "vicuna-7b_response": "Based on the information provided, it appears that the concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). The study investigated the cytoprotective pathways involving intracellular hypoxia and the activation of the hypoxia-inducible factor (HIF) pathway, which is linked with radioresistance. The study found that by 30 minutes following amifostine administration, the hemoglobin oxygen saturation and pO2 levels had increased in the peripheral blood while glucose levels had reduced, providing evidence that normal tissue metabolism switches to glycolytic pathways. Additionally, incubation of cell lines with amifostine resulted in HIF1 induction, and in Wistar rats administration of amifostine resulted in increased HIF1 accumulation in normal tissues. Therefore, it can be concluded that intracellular hypoxia and upregulation of HIF1 represents an additional, normal tissue-specific, amifostine cytoprotective pathway.",
    "vicuna-7b_fact_raw": "1. The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. A study found that hemoglobin oxygen saturation and pO2 levels increase in the peripheral blood 30 minutes following amifostine administration.\n3. The same study observed a reduction in glucose levels after amifostine administration.\n4. Incubation of cell lines with amifostine resulted in HIF1 induction.\n5. Administration of amifostine in Wistar rats resulted in increased HIF1 accumulation in normal tissues.",
    "vicuna-7b_fact": [
      "The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "A study found that hemoglobin oxygen saturation and pO2 levels increase in the peripheral blood 30 minutes following amifostine administration.",
      "The same study observed a reduction in glucose levels after amifostine administration.",
      "Incubation of cell lines with amifostine resulted in HIF1 induction.",
      "Administration of amifostine in Wistar rats resulted in increased HIF1 accumulation in normal tissues."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Amifostine is known to have cytoprotective effects, and one of its mechanisms is the stabilization and accumulation of the transcription factor HIF-1 which is consistent with an increase in concentration.\n2. TRUE: Hemoglobin oxygen saturation and pO2 levels in the peripheral blood can increase after the administration of amifostine due to its potential to improve oxygenation in tissues.\n3. UNKNOWN: Without specific data from the study mentioned, it's unclear if glucose levels were affected by amifostine administration.\n4. TRUE: It is plausible that the incubation of cell lines with amifostine could result in the induction of HIF1 as this transcription factor responds to various stress signals and pharmacological agents, including cytoprotective drugs like amifostine.\n5. TRUE: This statement is consistent with what's known about amifostine and the effects it can have in inducing HIF1, including in animal models such as Wistar rats.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "vicuna-7b_response": "PR-Set7 is a histone methyltransferase that deposits histone H4 lysine 20 methylation, a mark of constitutive and facultative heterochromatin. This mark is essential for the process of mitosis and is highly stable, even in the absence of PR-Set7 protein. PR-Set7 functions in silencing general gene expression and is involved in the suppression of position effect variegation. In PR-Set7 larval leg and eye discs, the number of cells is lower than normal and the DNA content in these cells is significantly increased. These data suggest that PR-Set7-dependent methylation is essential for the process of mitosis.",
    "vicuna-7b_fact_raw": "1. PR-Set7 is a histone methyltransferase.\n2. PR-Set7 deposits histone H4 lysine 20 methylation.\n3. Histone H4 lysine 20 methylation is associated with both constitutive and facultative heterochromatin.\n4. This histone mark is essential for the process of mitosis.\n5. PR-Set7 is involved in the suppression of position effect variegation.",
    "vicuna-7b_fact": [
      "PR-Set7 is a histone methyltransferase.",
      "PR-Set7 deposits histone H4 lysine 20 methylation.",
      "Histone H4 lysine 20 methylation is associated with both constitutive and facultative heterochromatin.",
      "This histone mark is essential for the process of mitosis.",
      "PR-Set7 is involved in the suppression of position effect variegation."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Histone H4 lysine 20 methylation is associated with the regulation of cell cycle progression and DNA damage response rather than being essential for the process of mitosis.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "vicuna-7b_response": "Hepcidin 1-25 is a small protein that contains four disulfide bridges. These disulfide bridges have a particular connectivity that is difficult to reproduce and could induce a bias in quantification. Hepcidin 1-25 is involved in iron-related disorders and anemia, in an inflammatory context, and its clinical relevance in neurodegenerative disorders is under investigation. It is also an emerging biomarker. Recent inter-laboratory studies showed a need for standardization of hepcidin assay and the need to produce certified reference materials.",
    "vicuna-7b_fact_raw": "1. The protein hepcidin contains four disulfide bridges.\n2. Hepcidin 1-25 is involved in iron-related disorders and anemia, often in an inflammatory context.\n3. The clinical relevance of hepcidin 1-25 in neurodegenerative disorders is being investigated.\n4. Hepcidin 1-25 is considered an emerging biomarker.\n5. There is a recognized need for standardization of hepcidin assay and the production of certified reference materials, as shown by recent inter-laboratory studies.",
    "vicuna-7b_fact": [
      "The protein hepcidin contains four disulfide bridges.",
      "Hepcidin 1-25 is involved in iron-related disorders and anemia, often in an inflammatory context.",
      "The clinical relevance of hepcidin 1-25 in neurodegenerative disorders is being investigated.",
      "Hepcidin 1-25 is considered an emerging biomarker.",
      "There is a recognized need for standardization of hepcidin assay and the production of certified reference materials, as shown by recent inter-laboratory studies."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nHepcidin is a key regulator of iron metabolism, and statements 2 through 5 are consistent with current research on its role in iron-related disorders, its potential as a biomarker, and the need for assay standardization. The first statement requires specific biochemical knowledge, but generally, the structure of hepcidin does indeed include multiple disulfide bridges, which is crucial for its biological function, so unless the exact number in the statement is incorrect, it would be considered true.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "vicuna-7b_response": "The localization of the protein encoded by the gene DNAJC11 is not mentioned in the provided information. However, based on the information provided about the gene DNAJC12, it can be inferred that the protein encoded by DNAJC11 may also have a similar localization to DNAJC12.\nThe information provided about DNAJC12 shows that it is a J domain-containing protein that is expressed in human LNCaP prostate cancer cells. Immunofluorescence studies showed that a recombinant DNAJC12 protein is diffusely distributed in the cytoplasm. To identify substrates of DNAJC12, an immunoaffinity-mass spectrometry approach was used, which identified several nucleotide-binding proteins as potential DNAJC12-binding proteins, including Hsc70, a cognate Hsp70 chaperone, and BiP, the ER chaperone. Immunoprecipitation experiments confirmed that the endogenous DNAJC12 and Hsc70 proteins interact in LNCaP cells.\nBased on these findings, it can be inferred that the protein encoded by DNAJC11 may also interact with Hsc70 or BiP, as both proteins are known to interact with DNAJC12. However, further experimental evidence is needed to confirm this hypothesis.",
    "vicuna-7b_fact_raw": "1. DNAJC12 is a J domain-containing protein expressed in human LNCaP prostate cancer cells.\n2. A recombinant DNAJC12 protein is distributed diffusely in the cytoplasm as shown by immunofluorescence studies.\n3. An immunoaffinity-mass spectrometry approach identified nucleotide-binding proteins as potential DNAJC12-binding proteins.\n4. Hsc70, a cognate Hsp70 chaperone, and BiP, the ER chaperone, were among the identified potential DNAJC12-binding proteins.\n5. Immunoprecipitation experiments confirmed an interaction between the endogenous DNAJC12 and Hsc70 proteins in LNCaP cells.",
    "vicuna-7b_fact": [
      "DNAJC12 is a J domain-containing protein expressed in human LNCaP prostate cancer cells.",
      "A recombinant DNAJC12 protein is distributed diffusely in the cytoplasm as shown by immunofluorescence studies.",
      "An immunoaffinity-mass spectrometry approach identified nucleotide-binding proteins as potential DNAJC12-binding proteins.",
      "Hsc70, a cognate Hsp70 chaperone, and BiP, the ER chaperone, were among the identified potential DNAJC12-binding proteins.",
      "Immunoprecipitation experiments confirmed an interaction between the endogenous DNAJC12 and Hsc70 proteins in LNCaP cells."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nFor statements 2 and 3, there is not enough detailed information provided to ascertain their veracity without access to specific scientific studies or literature that confirm these findings. Hence, these are marked as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "vicuna-7b_response": "Yes, it is known that ultraconserved elements (UCEs) are depleted among copy number variants (CNVs). UCEs are segments of DNA that are highly conserved across different species and are typically found in the same location on the genome in all individuals. However, CNVs, which are duplications or deletions of segments of the genome, can disrupt the presence of UCEs. Studies have shown that depletion of UCEs is a characteristic of recent large-scale human CNV datasets, even for newly formed de novo CNVs, which have passed through meiosis at most once. In contrast, CNVs arising specifically in cancer cells are not typically depleted for UCEs and can even become significantly enriched. This observation suggests that somatic CNVs that are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, the lack of depletion for UCEs in cancer CNVs may reflect the diseased state. It is also known that CNVs of induced pluripotent stem (iPS) cells can become depleted of UCEs over time, suggesting that depletion may be established through selection against UCE-disrupting CNVs without the requirement for meiotic divisions.",
    "vicuna-7b_fact_raw": "1. Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).\n2. UCEs are highly conserved segments of DNA across different species.\n3. CNVs, which are duplications or deletions of segments of the genome, can disrupt the presence of UCEs.\n4. Studies indicate that recent large-scale human CNV datasets are typically characterized by the depletion of UCEs.\n5. CNVs arising specifically in cancer cells are not typically depleted for UCEs and can become significantly enriched.",
    "vicuna-7b_fact": [
      "Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).",
      "UCEs are highly conserved segments of DNA across different species.",
      "CNVs, which are duplications or deletions of segments of the genome, can disrupt the presence of UCEs.",
      "Studies indicate that recent large-scale human CNV datasets are typically characterized by the depletion of UCEs.",
      "CNVs arising specifically in cancer cells are not typically depleted for UCEs and can become significantly enriched."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: CNVs arising specifically in cancer cells are typically depleted for UCEs, maintaining the trend that UCEs are generally conserved and not prone to duplication or deletion, even in cancer genomes.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "vicuna-7b_response": "The substrate of the Haspin kinase during mitosis is histone H3.",
    "vicuna-7b_fact_raw": "1. Histone H3 is the substrate of the Haspin kinase during mitosis.",
    "vicuna-7b_fact": [
      "Histone H3 is the substrate of the Haspin kinase during mitosis."
    ],
    "vicuna-7b_judge_raw": "1. TRUE",
    "vicuna-7b_judge": [
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "vicuna-7b_response": "The mechanism of viroid replication is through a rolling circle mechanism that is exclusively RNA dependent. The study identified a universal initiation site for each of the PLMVd polarities, shared by a wide repertoire of viroid variants. An in vitro selection procedure was developed, leading to the identification of a highly conserved CAGACG box, which is reminiscent of the sequence found in the vicinity of the PLMVd initiation sites. The conserved sequence contributes to delineating the initiation site and provides an explanation for the presence of a specific universal initiation site on the PLMVd molecule.",
    "vicuna-7b_fact_raw": "1. Viroid replication occurs through a rolling circle mechanism that is exclusively RNA dependent.\n2. A universal initiation site for each of the PLMVd polarities is shared by a wide variety of viroid variants.\n3. An in vitro selection procedure has been developed to identify specific sequences in viroids.\n4. A highly conserved CAGACG box has been identified as part of the viroid replication process.\n5. The conserved CAGACG box is found in the vicinity of the PLMVd initiation sites.",
    "vicuna-7b_fact": [
      "Viroid replication occurs through a rolling circle mechanism that is exclusively RNA dependent.",
      "A universal initiation site for each of the PLMVd polarities is shared by a wide variety of viroid variants.",
      "An in vitro selection procedure has been developed to identify specific sequences in viroids.",
      "A highly conserved CAGACG box has been identified as part of the viroid replication process.",
      "The conserved CAGACG box is found in the vicinity of the PLMVd initiation sites."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Viroid replication is known to involve a rolling circle mechanism and is RNA dependent, as they are composed of RNA and do not encode proteins.\n2. UNKNOWN: The specificity of a 'universal initiation site' for the polarities of Peach latent mosaic viroid (PLMVd) may require detailed virology knowledge and sequence analysis to confirm.\n3. TRUE: In vitro selection procedures, such as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), have been developed and can be used to identify specific sequences in nucleic acids, including viroids.\n4. TRUE: Conserved sequences can play a role in the replication of viroids, and while it is common to have conserved motifs such as this, it is difficult to confirm the presence of a specific \"CAGACG box\" without more context.\n5. UNKNOWN: Without specific contextual information confirming the presence and location of the conserved CAGACG box in relation to PLMVd initiation sites, it is not possible to verify this statement.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "vicuna-7b_response": "Based on the information provided, fibronectin is a potential serum biomarker for Duchenne muscular dystrophy (DMD). The study used a bottom-up proteomics approach to identify candidate biomarkers in serum samples from control subjects and DMD patients. Fibronectin was chosen for follow-up based on differences in peptide spectral counts and sequence coverage observed between the DMD and control groups. The study found that fibronectin levels were significantly increased in DMD patients compared to age-matched controls. Additionally, the study observed a progressive elevation in fibronectin levels in longitudinal samples from DMD patients followed up for 6 months to 4 years. Therefore, the study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
    "vicuna-7b_fact_raw": "1. Fibronectin is identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. A study using a bottom-up proteomics approach discerned differences in fibronectin between serum samples of control subjects and DMD patients.\n3. Fibronectin levels were found to be significantly increased in DMD patients compared to age-matched controls.\n4. There was a progressive elevation in fibronectin levels in longitudinal samples from DMD patients over a period of 6 months to 4 years observed in the study.\n5. The study suggests that serum fibronectin levels may serve as a biomarker to monitor disease progression in DMD patients.",
    "vicuna-7b_fact": [
      "Fibronectin is identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "A study using a bottom-up proteomics approach discerned differences in fibronectin between serum samples of control subjects and DMD patients.",
      "Fibronectin levels were found to be significantly increased in DMD patients compared to age-matched controls.",
      "There was a progressive elevation in fibronectin levels in longitudinal samples from DMD patients over a period of 6 months to 4 years observed in the study.",
      "The study suggests that serum fibronectin levels may serve as a biomarker to monitor disease progression in DMD patients."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: Without the specific context or publication details, I have assumed that the statements are drawn from a study that has been conducted and has produced these results. If the study findings are as described in the statements, then the responses would be accurate. However, if the actual study contradicts these findings, the statements would be incorrect.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "vicuna-7b_response": "DeepBlue Epigenomic Data Server contains data from four major epigenome projects: ENCODE, ROADMAP, BLUEPRINT, and DEEP. It provides a comprehensive programmatic interface for finding, selecting, filtering, summarizing, and downloading region sets, making it easier to analyze epigenomic data. DeepBlue also comes with a user manual, examples, and a well-documented API, which can be accessed via the XML-RPC protocol supported by many programming languages. The API can be used to retrieve data, and the optional web interface is available for non-programmers to use. DeepBlue can be accessed at <http://deepblue.mpi-inf.mpg.de>.",
    "vicuna-7b_fact_raw": "1. The DeepBlue Epigenomic Data Server contains data from the ENCODE project.\n2. The DeepBlue Epigenomic Data Server contains data from the ROADMAP project.\n3. The DeepBlue Epigenomic Data Server contains data from the BLUEPRINT project.\n4. The DeepBlue Epigenomic Data Server contains data from the DEEP project.\n5. The DeepBlue Epigenomic Data Server can be accessed via the XML-RPC protocol.",
    "vicuna-7b_fact": [
      "The DeepBlue Epigenomic Data Server contains data from the ENCODE project.",
      "The DeepBlue Epigenomic Data Server contains data from the ROADMAP project.",
      "The DeepBlue Epigenomic Data Server contains data from the BLUEPRINT project.",
      "The DeepBlue Epigenomic Data Server contains data from the DEEP project.",
      "The DeepBlue Epigenomic Data Server can be accessed via the XML-RPC protocol."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - The DeepBlue Epigenomic Data Server does contain data from the ENCODE project as part of its collection of epigenomic data.\n2. TRUE - The DeepBlue Epigenomic Data Server includes data from the ROADMAP Epigenomics Project, which is a collection of human epigenomic data intended to provide insights into epigenetic changes that occur during development.\n3. TRUE - The DeepBlue Epigenomic Data Server also contains data from the BLUEPRINT project, a large-scale research project that aims to study the epigenomes of different cell types of the blood system.\n4. TRUE - The DeepBlue Epigenomic Data Server includes data from the DEEP (Deutsches Epigenom Programm) project, which is part of the International Human Epigenome Consortium (IHEC).\n5. TRUE - The DeepBlue Epigenomic Data Server can indeed be accessed via the XML-RPC protocol, allowing programmatic access to its data and functionalities.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "vicuna-7b_response": "The tool that employs self organizing maps for analyzing synonymous codon usage is the \"Correspondence Analysis of Codon Usage Data\" available through the Pole Bioinformatique Lyonnais (PBIL) Web server at <http://pbil.univ-lyon1.fr/datasets/charif04/>. This tool is a user-friendly implementation of within-group correspondence analysis, which is a method used to analyze synonymous codon usage variability. The tool is distributed under a GPL licence and has a demo available to reproduce the figures in the present application note. The tool is contacted through the PBIL website at <http://pbil.univ-lyon1.fr/members/lobry>.",
    "vicuna-7b_fact_raw": "1. The tool \"Correspondence Analysis of Codon Usage Data\" is used for analyzing synonymous codon usage.\n2. The tool is accessible through the Pole Bioinformatique Lyonnais (PBIL) Web server.\n3. The PBIL Web server can be found at http://pbil.univ-lyon1.fr/datasets/charif04/.\n4. Within-group correspondence analysis is the method utilized by the tool to analyze synonymous codon usage variability.\n5. The tool is distributed under a GPL licence.",
    "vicuna-7b_fact": [
      "The tool \"Correspondence Analysis of Codon Usage Data\" is used for analyzing synonymous codon usage.",
      "The tool is accessible through the Pole Bioinformatique Lyonnais (PBIL) Web server.",
      "The PBIL Web server can be found at http://pbil.univ-lyon1.fr/datasets/charif04/.",
      "Within-group correspondence analysis is the method utilized by the tool to analyze synonymous codon usage variability.",
      "The tool is distributed under a GPL licence."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The PBIL Web server can be found at various URLs depending on the specific resources, but the one provided does not appear to be a correct link to the PBIL Web server or related to codon usage analysis tools directly.\n4. UNKNOWN (The specific method used by the tool isn't provided in the statements, and without additional information, this cannot be confirmed or denied.)\n5. UNKNOWN (The licensing of the tool isn't provided in the statements, and without additional information, it is not possible to confirm the correct license.)",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "vicuna-7b_response": "MINDY-1 is a protein that is homologous to the Indy (I'm Not Dead, Yet) gene in Drosophila melanogaster and Caenorhabditis elegans. These genes have been shown to prolong life span and augment mitochondrial biogenesis in a manner similar to caloric restriction in these organisms. However, the cellular mechanism by which Indy does this is unknown.\nIn mammals, the homolog of Indy is called SLC13A5, and it has been shown to play a role in regulating energy metabolism. In a study conducted on knockout mouse models of SLC13A5, it was found that deletion of the gene reduced the hepatocellular ATP/ADP ratio, activated hepatic AMPK, induced PGC-1, inhibited ACC-2, and reduced SREBP-1c levels. This signaling network promoted hepatic mitochondrial biogenesis, lipid oxidation, and energy expenditure and attenuated hepatic de novo lipogenesis.\nThese findings suggest that SLC13A5 plays a crucial role in regulating mammalian energy metabolism and that its deletion protects mice from the adiposity and insulin resistance that evolve with high-fat feeding and aging. The study also suggests that SLC13A5 might be a therapeutic target for the treatment of obesity and type 2 diabetes.",
    "vicuna-7b_fact_raw": "1. MINDY-1 is homologous to the Indy gene in Drosophila melanogaster and Caenorhabditis elegans.\n2. Indy genes in Drosophila melanogaster and Caenorhabditis elegans have been shown to prolong life span and augment mitochondrial biogenesis.\n3. The mammalian homolog of Indy is called SLC13A5.\n4. Deletion of SLC13A5 in knockout mouse models reduced the hepatocellular ATP/ADP ratio, activated AMPK, induced PGC-1, inhibited ACC-2, and reduced SREBP-1c levels.\n5. The deletion of SLC13A5 protects mice from adiposity and insulin resistance induced by high-fat feeding and aging.",
    "vicuna-7b_fact": [
      "MINDY-1 is homologous to the Indy gene in Drosophila melanogaster and Caenorhabditis elegans.",
      "Indy genes in Drosophila melanogaster and Caenorhabditis elegans have been shown to prolong life span and augment mitochondrial biogenesis.",
      "The mammalian homolog of Indy is called SLC13A5.",
      "Deletion of SLC13A5 in knockout mouse models reduced the hepatocellular ATP/ADP ratio, activated AMPK, induced PGC-1, inhibited ACC-2, and reduced SREBP-1c levels.",
      "The deletion of SLC13A5 protects mice from adiposity and insulin resistance induced by high-fat feeding and aging."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - MINDY-1 is indeed homologous to the Indy gene in both Drosophila melanogaster and Caenorhabditis elegans, sharing similar functions related to metabolism and longevity.\n2. TRUE - Studies have shown that the Indy gene in Drosophila melanogaster and Caenorhabditis elegans can prolong lifespan and are involved in mitochondrial biogenesis as well as various metabolic processes.\n3. TRUE - SLC13A5 is recognized as the mammalian homolog of the Indy gene.\n4. TRUE - Deletion of SLC13A5 in knockout mouse models has been reported to produce metabolic changes such as reduced hepatic ATP/ADP ratio, activation of AMPK, induction of PGC-1, inhibition of ACC-2, and reduction of SREBP-1c levels.\n5. TRUE - Research indicates that the deletion of SLC13A5 can protect mice from diet-induced obesity (adiposity) and insulin resistance, which are typically associated with high-fat diets and aging.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "vicuna-7b_response": "The software package available for the analysis of conserved genomic loci is Mega. Mega is a powerful software package that contains many sophisticated methods and tools for phylogenomics and phylomedicine. The latest version of Mega, which is optimized for use on 64-bit computing systems, allows researchers to analyze larger datasets and explore and analyze tens of thousands of sequences. The new version also includes an advanced wizard for building timetrees and a new functionality to automatically predict gene duplication events in gene family trees. Mega is available in two interfaces: graphical and command line, and is available for free from [www.megasoftware.net](http://www.megasoftware.net) free of charge.",
    "vicuna-7b_fact_raw": "1. Mega is a software package designed for the analysis of conserved genomic loci.\n2. Mega includes tools for phylogenomics and phylomedicine.\n3. The latest version of Mega is optimized for 64-bit computing systems, which supports the analysis of larger datasets.\n4. Mega provides an advanced wizard for building timetrees and a new functionality for predicting gene duplication events in gene family trees.\n5. Mega is available in both graphical and command line interfaces and can be downloaded free of charge from www.megasoftware.net.",
    "vicuna-7b_fact": [
      "Mega is a software package designed for the analysis of conserved genomic loci.",
      "Mega includes tools for phylogenomics and phylomedicine.",
      "The latest version of Mega is optimized for 64-bit computing systems, which supports the analysis of larger datasets.",
      "Mega provides an advanced wizard for building timetrees and a new functionality for predicting gene duplication events in gene family trees.",
      "Mega is available in both graphical and command line interfaces and can be downloaded free of charge from www.megasoftware.net."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: MEGA (Molecular Evolutionary Genetics Analysis) is software designed for analyzing gene sequences, not specifically conserved genomic loci.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "vicuna-7b_response": "Based on the information provided, three diseases associated with the PIEZO2 gene are:\n1. Dominant distal arthrogryposis 3 (DA3), which is caused by heterozygous gain-of-function missense mutations mainly localized at the C terminus of PIEZO2.\n2. Distal arthrogryposis 5 (DA5), which is also caused by heterozygous gain-of-function missense mutations mainly localized at the C terminus of PIEZO2.\n3. Marden-Walker syndrome (MWKS), which is caused by heterozygous gain-of-function missense mutations mainly localized at the C terminus of PIEZO2.\nAll of these diseases are characterized by arthrogryposis, muscular atrophy, scoliosis, and mild distal sensory involvement. However, they differ in their mode of inheritance and the specific type of mutation that causes the disease.",
    "vicuna-7b_fact_raw": "1. Dominant distal arthrogryposis 3 (DA3) is associated with the PIEZO2 gene.\n2. Distal arthrogryposis 5 (DA5) is associated with the PIEZO2 gene.\n3. Marden-Walker syndrome (MWKS) is associated with the PIEZO2 gene.",
    "vicuna-7b_fact": [
      "Dominant distal arthrogryposis 3 (DA3) is associated with the PIEZO2 gene.",
      "Distal arthrogryposis 5 (DA5) is associated with the PIEZO2 gene.",
      "Marden-Walker syndrome (MWKS) is associated with the PIEZO2 gene."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Distal arthrogryposis 5 (DA5) is not associated with the PIEZO2 gene, but with other genes such as ECEL1 or MYH3.\n3. FALSE [correction]: Marden-Walker syndrome (MWKS) is typically associated with the PIEZO2 gene.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "vicuna-7b_response": "ERAP1-ERAP2 dimerization promotes the production of final epitopes presented by MHC class I molecules. The formation of heterodimers by ERAP1 and ERAP2 facilitates the trimming of epitope precursor peptides, and stabilized ERAP1-ERAP2 heterodimers produce several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. Physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. Thus, by bringing the two enzymes in proximity and by producing allosteric effects on ERAP1, dimerization of ERAP1/2 creates complexes with superior peptide-trimming efficacy. These complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.",
    "vicuna-7b_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the production of final epitopes presented by MHC class I molecules.\n2. The formation of ERAP1-ERAP2 heterodimers facilitates the trimming of epitope precursor peptides.\n3. ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than when the two enzymes are unable to dimerize.\n4. The physical interaction with ERAP2 changes the basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity.\n5. Dimerization of ERAP1/2 results in complexes with greater peptide-trimming efficacy, which can enhance antigen presentation by cells that express both enzymes.",
    "vicuna-7b_fact": [
      "ERAP1-ERAP2 dimerization promotes the production of final epitopes presented by MHC class I molecules.",
      "The formation of ERAP1-ERAP2 heterodimers facilitates the trimming of epitope precursor peptides.",
      "ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than when the two enzymes are unable to dimerize.",
      "The physical interaction with ERAP2 changes the basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity.",
      "Dimerization of ERAP1/2 results in complexes with greater peptide-trimming efficacy, which can enhance antigen presentation by cells that express both enzymes."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The statement correctly describes the role of ERAP1-ERAP2 dimerization in the production of peptides that will be presented by MHC class I molecules.\n2. TRUE: ERAP1 and ERAP2 form heterodimers, which are involved in the trimming of epitope precursor peptides for presentation by MHC class I molecules.\n3. TRUE: Research indicates that ERAP1-ERAP2 heterodimers can be more effective in producing mature epitopes than when the enzymes are functioning independently.\n4. TRUE: Studies suggest that the interaction between ERAP1 and ERAP2 can alter the enzymatic properties of ERAP1, which may include changes in substrate affinity.\n5. TRUE: Dimerization of ERAP1 and ERAP2 is believed to lead to increased peptide-trimming efficacy, thereby enhancing their role in antigen processing and presentation by cells containing both enzymes.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "vicuna-7b_response": "R-spondin 1 and noggin are two proteins that play a role in the development and maintenance of the gallbladder. R-spondin 1 is a protein that is expressed in the developing gallbladder and is involved in the differentiation of the epithelial cells that line the gallbladder. Noggin, on the other hand, is a protein that is expressed in the developing embryo and is involved in the inhibition of bone morphogenetic protein (BMP) signaling. BMP signaling is involved in the development of the gallbladder and its associated structures.\nIn non-damaged gallbladders, R-spondin 1 and noggin are thought to play a role in the development and maintenance of the gallbladder by regulating the differentiation and function of the epithelial cells that line the gallbladder. It is thought that R-spondin 1 may be involved in the differentiation of the epithelial cells and noggin may be involved in the inhibition of BMP signaling.\nIn summary, R-spondin 1 and noggin are two proteins that play a role in the development and maintenance of the gallbladder. In non-damaged gallbladders, they are thought to be involved in the differentiation and function of the epithelial cells that line the gallbladder.",
    "vicuna-7b_fact_raw": "1. R-spondin 1 is a protein that is expressed in the developing gallbladder.\n2. R-spondin 1 is involved in the differentiation of epithelial cells that line the gallbladder.\n3. Noggin is a protein that is expressed in the developing embryo.\n4. Noggin is involved in the inhibition of bone morphogenetic protein (BMP) signaling.\n5. BMP signaling is involved in the development of the gallbladder and its associated structures.",
    "vicuna-7b_fact": [
      "R-spondin 1 is a protein that is expressed in the developing gallbladder.",
      "R-spondin 1 is involved in the differentiation of epithelial cells that line the gallbladder.",
      "Noggin is a protein that is expressed in the developing embryo.",
      "Noggin is involved in the inhibition of bone morphogenetic protein (BMP) signaling.",
      "BMP signaling is involved in the development of the gallbladder and its associated structures."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BMP signaling is primarily known for its role in bone and cartilage development, not specifically in the development of the gallbladder and its associated structures.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "vicuna-7b_response": "The information provided in Document-0 suggests that the heterodimeric cytochrome b558 in the neutrophil oxidase complex is responsible for the presumed NADPH dehydrogenase function in bovine neutrophils. The photoaffinity probe used was [4-[N-(4-azido-2-nitrophenyl)[3H]amino]butyryl]NADPH ([3H]azido-NADPH), and the antibodies used were directed against the C-terminal regions of the two subunits of cytochrome b558. The results of the study showed that azido-NADPH behaved as a competitive inhibitor of NADPH oxidase with a Ki of 6 microM, and bound to high-affinity specific binding sites with a Kd of 5-6 microM. This indicates that the oxidase has a higher affinity for the photoprobe than for the substrate NADPH. The study also showed that the enzymatic deglycosylation of photolabeled neutrophil membranes shifted the masses of both the photolabeled band and the immunoreactive beta subunit from 80-100 to 55-65 kDa, indicating that the beta subunit is glycosylated. Based on this information, it can be concluded that NADPH oxidase 5 requires the beta subunit for function.",
    "vicuna-7b_fact_raw": "1. The heterodimeric cytochrome b558 in the neutrophil oxidase complex is responsible for NADPH dehydrogenase function in bovine neutrophils.\n2. [3H]azido-NADPH is a competitive inhibitor of NADPH oxidase with a Ki of 6 microM.\n3. Azido-NADPH binds to specific binding sites with a Kd of 5-6 microM.\n4. The enzymatic deglycosylation of photolabeled neutrophil membranes shifts the mass of the immunoreactive beta subunit from 80-100 kDa to 55-65 kDa.\n5. The beta subunit of the neutrophil oxidase complex is glycosylated.",
    "vicuna-7b_fact": [
      "The heterodimeric cytochrome b558 in the neutrophil oxidase complex is responsible for NADPH dehydrogenase function in bovine neutrophils.",
      "[3H]azido-NADPH is a competitive inhibitor of NADPH oxidase with a Ki of 6 microM.",
      "Azido-NADPH binds to specific binding sites with a Kd of 5-6 microM.",
      "The enzymatic deglycosylation of photolabeled neutrophil membranes shifts the mass of the immunoreactive beta subunit from 80-100 kDa to 55-65 kDa.",
      "The beta subunit of the neutrophil oxidase complex is glycosylated."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The heterodimeric cytochrome b558 is indeed a part of the neutrophil oxidase complex, often referred to as NADPH oxidase, and is essential for its function. It is made up of a large gp91^phox (also known as NOX2) and a smaller p22^phox subunit.\n\n2. UNKNOWN: Without the specific context or reference, it is difficult to confirm the Ki value for [3H]azido-NADPH as a competitive inhibitor of NADPH oxidase. The specificity of inhibitors can also depend on the experimental conditions and the isoform of the enzyme under study.\n\n3. UNKNOWN: Similar to the Ki value mentioned above, the Kd value for binding interactions can vary depending on experimental design and conditions. Without additional information, it's not possible to verify the provided Kd of 5-6 microM for azido-NADPH binding to specific sites.\n\n4. UNKNOWN: The statement provides specific information about the apparent molecular weight shift of a protein upon deglycosylation. While it's true that enzymatic deglycosylation can lead to a shift in the apparent molecular weight of glycoproteins due to the removal of sugar moieties, the exact mass shift for the immunoreactive beta subunit would require experimental data for confirmation.\n\n5. TRUE: The beta subunit of the neutrophil oxidase complex (often referred to as the p22^phox subunit) is known to be glycosylated. The glycosylation is important for the stability and function of the complex.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "vicuna-7b_response": "Hepcidin is a hormone that regulates iron metabolism in the body. It is encoded as a prepropeptide that contains a targeting signal sequence and a pro region with a consensus furin cleavage site. The cleavage of prohepcidin by furin results in the production of the mature form of hepcidin, which is bioactive and regulates iron absorption and storage. In this study, the authors found that furin is responsible for processing hepcidin in human hepatoma cells and primary human hepatocytes. They also found that the processing of hepcidin is not regulated by iron-transferrin or the HIF pathway. Therefore, the connection between furin and hepcidin is that furin is responsible for the posttranslational processing of hepcidin, which is necessary for its bioactivity.",
    "vicuna-7b_fact_raw": "1. Hepcidin is a hormone that regulates iron metabolism in the body.\n2. The prepropeptide form of hepcidin contains a consensus furin cleavage site.\n3. The cleavage of prohepcidin by furin produces the bioactive mature form of hepcidin.\n4. Furin is responsible for processing hepcidin in human hepatoma cells and primary human hepatocytes.\n5. The processing of hepcidin by furin is not regulated by iron-transferrin or the HIF pathway.",
    "vicuna-7b_fact": [
      "Hepcidin is a hormone that regulates iron metabolism in the body.",
      "The prepropeptide form of hepcidin contains a consensus furin cleavage site.",
      "The cleavage of prohepcidin by furin produces the bioactive mature form of hepcidin.",
      "Furin is responsible for processing hepcidin in human hepatoma cells and primary human hepatocytes.",
      "The processing of hepcidin by furin is not regulated by iron-transferrin or the HIF pathway."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The processing of hepcidin by furin can be regulated by iron-transferrin and/or signals from the HIF pathway.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "vicuna-7b_response": "The largest metabolic gene cluster in yeast is the GAL cluster. The GAL cluster is composed of genes that encode enzymes involved in the biosynthesis of galactose, a simple sugar that is an important carbon source for yeast. The GAL cluster is located on chromosome XII of the yeast genome and contains 20 genes, including GAL1, GAL10, and GAL7. The GAL cluster is the largest metabolic gene cluster in yeast and is an example of a metabolic gene cluster that is coordinately expressed and physically clustered.",
    "vicuna-7b_fact_raw": "1. The GAL cluster is the largest metabolic gene cluster in yeast.\n2. The GAL cluster includes genes that encode enzymes for the biosynthesis of galactose.\n3. Galactose is an important carbon source for yeast.\n4. The GAL cluster is located on chromosome XII of the yeast genome.\n5. The GAL cluster contains 20 genes including GAL1, GAL10, and GAL7.",
    "vicuna-7b_fact": [
      "The GAL cluster is the largest metabolic gene cluster in yeast.",
      "The GAL cluster includes genes that encode enzymes for the biosynthesis of galactose.",
      "Galactose is an important carbon source for yeast.",
      "The GAL cluster is located on chromosome XII of the yeast genome.",
      "The GAL cluster contains 20 genes including GAL1, GAL10, and GAL7."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The GAL cluster does not contain 20 genes. In Saccharomyces cerevisiae, for example, the core GAL cluster contains fewer genes, including GAL1, GAL10, and GAL7 among others, but not as many as 20.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "vicuna-7b_response": "The lncRNA LIMT (LncRNA Inhibiting Metastasis) has been found to play a role in the progression of aggressive subtypes of breast cancer, such as the basal-like subtype. LIMT is a highly conserved lncRNA that is depleted in basal-like and HER2-positive tumors and has been shown to predict poor patient prognosis. The role of LIMT in cancer progression is thought to be related to its ability to inhibit extracellular matrix invasion of mammary cells and to suppress tumor metastasis. Additionally, LIMT is downregulated by EGF, which enhances histone deacetylation at the promoter. The study suggests that lncRNAs, such as LIMT, may be novel drivers of cancer progression and serve as prognostic biomarkers.",
    "vicuna-7b_fact_raw": "1. LIMT (LncRNA Inhibiting Metastasis) is associated with the progression of aggressive subtypes of breast cancer.\n2. LIMT is depleted in basal-like and HER2-positive breast cancer tumors.\n3. LIMT lncRNA can predict poor patient prognosis.\n4. The role of LIMT includes inhibiting extracellular matrix invasion of mammary cells and suppressing tumor metastasis.\n5. LIMT is downregulated by EGF which leads to enhanced histone deacetylation at its promoter.",
    "vicuna-7b_fact": [
      "LIMT (LncRNA Inhibiting Metastasis) is associated with the progression of aggressive subtypes of breast cancer.",
      "LIMT is depleted in basal-like and HER2-positive breast cancer tumors.",
      "LIMT lncRNA can predict poor patient prognosis.",
      "The role of LIMT includes inhibiting extracellular matrix invasion of mammary cells and suppressing tumor metastasis.",
      "LIMT is downregulated by EGF which leads to enhanced histone deacetylation at its promoter."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: LIMT is upregulated by EGF leading to enhanced histone acetylation at its promoter, which increases its expression and contributes to the suppression of tumor metastasis.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "vicuna-7b_response": "The R/Bioconductor package used for performing SNP enrichment analysis is GATK (Genome Analysis Toolkit). GATK is a widely used tool for genome-wide association studies (GWAS) and whole-genome sequencing (WGS) data analysis. It provides a suite of tools for variant discovery, including SNP and indel calling, and can perform enrichment analysis for specific variants of interest. GATK is implemented in the R language and is available as a Bioconductor package for Linux, Windows, and MacOS from the Bioconductor website.",
    "vicuna-7b_fact_raw": "1. GATK (Genome Analysis Toolkit) is an R/Bioconductor package used for performing SNP enrichment analysis.\n2. GATK is used for genome-wide association studies (GWAS) and whole-genome sequencing (WGS) data analysis.\n3. GATK includes tools for variant discovery, such as SNP and indel calling.\n4. The Genome Analysis Toolkit is implemented in the R programming language.\n5. GATK is available as a Bioconductor package for Linux, Windows, and MacOS.",
    "vicuna-7b_fact": [
      "GATK (Genome Analysis Toolkit) is an R/Bioconductor package used for performing SNP enrichment analysis.",
      "GATK is used for genome-wide association studies (GWAS) and whole-genome sequencing (WGS) data analysis.",
      "GATK includes tools for variant discovery, such as SNP and indel calling.",
      "The Genome Analysis Toolkit is implemented in the R programming language.",
      "GATK is available as a Bioconductor package for Linux, Windows, and MacOS."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: GATK (Genome Analysis Toolkit) is not an R/Bioconductor package. It is a software package developed at the Broad Institute to analyze high-throughput sequencing data.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Genome Analysis Toolkit is implemented in Java, not the R programming language.\n5. FALSE [correction]: GATK is not available as a Bioconductor package. Bioconductor is an R project and GATK is a standalone toolkit; it is available for use on Linux, macOS, and Windows, but not as a package within the Bioconductor framework.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "vicuna-7b_response": "Based on the information provided in Document-0, the key players in radial glial specification to ependymal cells after stroke are:\n1. Adult ependymal cells: Adult ependymal cells are postmitotic and highly differentiated cells that can undergo cell division and transformation into radial glial cells after stroke.\n2. Radial glial cells: Radial glial cells are neurogenic precursors that can divide and support neuron migration after stroke.\n3. Subventricular zone (SVZ): The SVZ is a region that contains neural progenitors that can give rise to new neurons and support their migration towards the ischemic boundary region. After stroke, radial glial cells derived from the SVZ can support the migration of new neurons to the affected region.\nIn summary, after stroke, adult ependymal cells can divide and transform into radial glial cells, which can function as neural progenitor cells to generate new neurons and act as scaffolds to support neuroblast migration towards the ischemic boundary region. The SVZ is a region that contains neural progenitors that can give rise to new neurons and support their migration towards the affected region.",
    "vicuna-7b_fact_raw": "1. Adult ependymal cells can undergo cell division and transform into radial glial cells after stroke.\n2. Radial glial cells are neurogenic precursors that can support neuron migration after stroke.\n3. The subventricular zone contains neural progenitors that can produce new neurons following a stroke.\n4. Radial glial cells originated from the subventricular zone can support the migration of new neurons to the ischemic boundary region after a stroke.\n5. After stroke, radial glial cells function as neural progenitor cells to generate new neurons.",
    "vicuna-7b_fact": [
      "Adult ependymal cells can undergo cell division and transform into radial glial cells after stroke.",
      "Radial glial cells are neurogenic precursors that can support neuron migration after stroke.",
      "The subventricular zone contains neural progenitors that can produce new neurons following a stroke.",
      "Radial glial cells originated from the subventricular zone can support the migration of new neurons to the ischemic boundary region after a stroke.",
      "After stroke, radial glial cells function as neural progenitor cells to generate new neurons."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: After stroke, radial glial-like cells function as neural progenitor cells to support the migration and integration of new neurons, but they do not directly generate new neurons; this is typically the role of neural stem/progenitor cells, which can be found in regions such as the subventricular zone.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "vicuna-7b_response": "Triple-negative breast cancer is a type of breast cancer that does not express the proteins estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). These proteins are typically found in other types of breast cancer, such as ER-positive breast cancer and HER2-positive breast cancer. Triple-negative breast cancer is characterized by the absence of these receptors, which makes it more aggressive and difficult to treat.\nTo differentiate triple-negative breast cancer from other types of breast cancer, a computer-aided diagnosis (CAD) system can be used. The CAD system uses DCE magnetic resonance (MR) images to capture and quantify certain features of the breast lesions. In a study, the CAD system was used to classify breast lesions into five categories: triple-negative breast cancer, ER-positive breast cancer, HER2-positive breast cancer, and benign fibroadenoma lesions. The study included 65 women with 76 breast lesions, and the lesions were classified as Breast Imaging Reporting and Data System category 4 or higher.\nThe study found that the CAD system was able to accurately differentiate triple-negative breast cancer from other types of breast cancer with an Az score of 0.73 for triple-negative cancer versus all non-triple-negative lesions, 0.74 for triple-negative cancer versus ER- and HER2-positive cancer, 0.77 for triple-negative versus ER-positive cancer, 0.74 for triple-negative versus HER2-positive cancer, and 0.97 for triple-negative cancer versus fibroadenoma. This suggests that triple-negative breast cancer has certain characteristic features on DCE MR images that can be captured and quantified with CAD, enabling good discrimination of triple-negative cancers from non-triple-negative cancers, as well as between triple-negative cancers and benign fibroadenomas.",
    "vicuna-7b_fact_raw": "1. Triple-negative breast cancer does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2).\n2. Triple-negative breast cancer is considered more aggressive and more difficult to treat than other types of breast cancer.\n3. A computer-aided diagnosis (CAD) system can use DCE magnetic resonance (MR) images to classify breast lesions into categories such as triple-negative, ER-positive, and HER2-positive breast cancer, as well as benign fibroadenoma.\n4. The study mentioned included 65 women with 76 breast lesions classified as Breast Imaging Reporting and Data System category 4 or higher.\n5. The CAD system differentiated triple-negative breast cancer from other lesions with an Az score of 0.73 versus all non-triple-negative lesions, and 0.97 versus fibroadenoma.",
    "vicuna-7b_fact": [
      "Triple-negative breast cancer does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2).",
      "Triple-negative breast cancer is considered more aggressive and more difficult to treat than other types of breast cancer.",
      "A computer-aided diagnosis (CAD) system can use DCE magnetic resonance (MR) images to classify breast lesions into categories such as triple-negative, ER-positive, and HER2-positive breast cancer, as well as benign fibroadenoma.",
      "The study mentioned included 65 women with 76 breast lesions classified as Breast Imaging Reporting and Data System category 4 or higher.",
      "The CAD system differentiated triple-negative breast cancer from other lesions with an Az score of 0.73 versus all non-triple-negative lesions, and 0.97 versus fibroadenoma."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile statements 1 and 2 are established facts about triple-negative breast cancer, the details in statements 3, 4, and 5 relating to specific research findings, study parameters, or performance metrics of a CAD system are not verifiable without the context of the specific study being referenced. These details cannot be confirmed as true or false without additional information.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "vicuna-7b_response": "TOPAZ1 is a unit intended for cleaning of immunological plates. It is a device that is designed to remove impurities and unwanted substances from the surface of immunological plates, which are used in various medical and scientific applications. The unit is composed of several components, including a cleaning device, a discharge block, a cleaning solution vessel, and a wasted liquid collector. The technical parameters of the unit are stated in Document-0, which provides detailed information about its design and functionality.",
    "vicuna-7b_fact_raw": "1. TOPAZ1 is a unit intended for cleaning immunological plates.\n2. It is designed to remove impurities and unwanted substances from the surface of immunological plates.\n3. The unit includes components such as a cleaning device, discharge block, cleaning solution vessel, and wasted liquid collector.\n4. Detailed information about the design and functionality of TOPAZ1 can be found in Document-0.",
    "vicuna-7b_fact": [
      "TOPAZ1 is a unit intended for cleaning immunological plates.",
      "It is designed to remove impurities and unwanted substances from the surface of immunological plates.",
      "The unit includes components such as a cleaning device, discharge block, cleaning solution vessel, and wasted liquid collector.",
      "Detailed information about the design and functionality of TOPAZ1 can be found in Document-0."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout having access to specific information regarding the product \"TOPAZ1,\" it is impossible to determine the truthfulness of statements 1, 2, and 3. Similarly, without having Document-0 or knowing its contents, the truthfulness of statement 4 cannot be ascertained.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "vicuna-7b_response": "The gene that controls the expression of GATA-1 isoforms is FOG-1. FOG-1 physically interacts with GATA-1 to augment or inhibit its activity. The mechanisms by which FOG-1 regulates GATA-1 function are unknown. By using an assay that is based on the phenotypic rescue of a GATA-1-null erythroid cell line, the authors found that a conditional form of GATA-1 (GATA-1-ER) strongly induced histone acetylation at the beta-major globin promoter in vivo, consistent with previous results. In contrast, GATA-1 bearing a point mutation that impairs FOG-1 binding [GATA-1(V205M)-ER] failed to induce high levels of histone acetylation at this site. However, at DNase I-hypersensitive site (HS)3 of the beta-globin locus control region, GATA-1-induced histone acetylation was FOG-1-independent. Because the V205M mutation does not disrupt GATA-1 binding to DNA templates in vitro, the authors were surprised to find that in vivo GATA-1(V205M)-ER fails to bind the beta-globin promoter. However, at HS3, DNA binding by GATA-1 was FOG-1-independent, thus correlating histone acetylation with GATA-1 occupancy. Examination of additional GATA-1-dependent regulatory elements showed that the interaction with FOG-1 is required for GATA-1 occupancy at select sites, such as HS2, but is dispensable at others, including the FOG-1-independent GATA-1 target gene EKLF. Remarkably, at the GATA-2 gene, which is repressed by GATA-1, interaction with FOG-1 was dispensable for GATA-1 occupancy and was required for transcriptional inhibition and histone deacetylation. These results indicate that FOG-1 employs distinct mechanisms when cooperating with GATA-1 during transcriptional activation and repression.",
    "vicuna-7b_fact_raw": "1. FOG-1 gene controls the expression of GATA-1 isoforms.\n2. FOG-1 physically interacts with GATA-1 to augment or inhibit its activity.\n3. A point mutation in GATA-1 (specifically V205M) impairs its ability to bind with FOG-1.\n4. The V205M mutation in GATA-1 leads to a failure to induce high levels of histone acetylation at the beta-major globin promoter in vivo.\n5. FOG-1 is required for GATA-1 occupancy at select sites, but dispensable at others.",
    "vicuna-7b_fact": [
      "FOG-1 gene controls the expression of GATA-1 isoforms.",
      "FOG-1 physically interacts with GATA-1 to augment or inhibit its activity.",
      "A point mutation in GATA-1 (specifically V205M) impairs its ability to bind with FOG-1.",
      "The V205M mutation in GATA-1 leads to a failure to induce high levels of histone acetylation at the beta-major globin promoter in vivo.",
      "FOG-1 is required for GATA-1 occupancy at select sites, but dispensable at others."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The FOG-1 gene, also known as ZFPM1, interacts with GATA-1 and influences the expression of GATA-1 isoforms.\n2. TRUE: FOG-1 (Friend of GATA-1) is a cofactor that physically interacts with GATA-1, influencing its transcriptional activity.\n3. TRUE: Point mutations in GATA-1, including V205M, have been reported to impair its ability to interact with cofactors like FOG-1.\n4. UNKNOWN: Without specific evidence from a study or scientific reference, it's impossible to determine the exact effects of the V205M mutation in GATA-1 on histone acetylation at the beta-major globin promoter in vivo.\n5. TRUE: FOG-1 is required for GATA-1 binding at some genomic sites, indicating a differential requirement for FOG-1's assistance in GATA-1's occupancy and function.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "vicuna-7b_response": "MIRA-seq is a system developed by integrating the Minimum Basic Data Set into the patient administration system and hospital information system at the University Hospital Freiburg. It provides physicians with access to basic medical data of all patients treated in all medical departments and separate buildings since 1986. MIRA-seq is mainly used in cases of readmission and for scientific and managerial purposes. The system has 610 online PCs and dialog terminals, and offers privacy-controlled access to the central patient data bases of over 450,000 patients. MIRA-seq has become one of the best-accepted EDP systems for physicians, nurses, and administrators due to its many standard functions and special extensions for different clinical departments.",
    "vicuna-7b_fact_raw": "1. MIRA-seq integrates the Minimum Basic Data Set into the patient administration and hospital information system at the University Hospital Freiburg.\n2. MIRA-seq provides access to basic medical data of patients treated since 1986 in all medical departments and separate buildings at the University Hospital Freiburg.\n3. The system is used for readmissions, as well as scientific and managerial purposes.\n4. MIRA-seq has 610 online PCs and dialog terminals.\n5. The central patient databases that MIRA-seq provides access to contain data of over 450,000 patients.",
    "vicuna-7b_fact": [
      "MIRA-seq integrates the Minimum Basic Data Set into the patient administration and hospital information system at the University Hospital Freiburg.",
      "MIRA-seq provides access to basic medical data of patients treated since 1986 in all medical departments and separate buildings at the University Hospital Freiburg.",
      "The system is used for readmissions, as well as scientific and managerial purposes.",
      "MIRA-seq has 610 online PCs and dialog terminals.",
      "The central patient databases that MIRA-seq provides access to contain data of over 450,000 patients."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without a specific passage about MIRA-seq, and with no widely known information about the system to reference, the veracity of most statements related to the University Hospital Freiburg's patient administration and hospital information system cannot be confirmed. However, the general use of such systems for readmissions, scientific, and managerial purposes is consistent with typical usage, hence statement 3 is rated as true.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "vicuna-7b_response": "ARCALYST is a medication that is used to treat chronic autoimmune thyroiditis (also known as Hashimoto's thyroiditis). It is a biologic disease-modifying antirheumatic drug (DMARD) that works by inhibiting the activity of interleukin-6 (IL-6), a protein that plays a role in the immune system. ARCALYST is given as an injection under the skin (subcutaneous injection) and is usually administered once a month. The medication can help reduce the symptoms of chronic autoimmune thyroiditis, such as pain, stiffness, and swelling in the joints. It can also help improve the overall function of the joints. However, it is important to note that ARCALYST is not a cure for chronic autoimmune thyroiditis and may not work for everyone. It is important to talk to your doctor about the risks and benefits of using ARCALYST to treat your condition.",
    "vicuna-7b_fact_raw": "1. ARCALYST is used to treat chronic autoimmune thyroiditis, also known as Hashimoto's thyroiditis.\n2. ARCALYST is classified as a biologic disease-modifying antirheumatic drug (DMARD).\n3. ARCALYST works by inhibiting the activity of interleukin-6 (IL-6).\n4. ARCALYST is administered through a subcutaneous injection.\n5. ARCALYST is usually given once a month.",
    "vicuna-7b_fact": [
      "ARCALYST is used to treat chronic autoimmune thyroiditis, also known as Hashimoto's thyroiditis.",
      "ARCALYST is classified as a biologic disease-modifying antirheumatic drug (DMARD).",
      "ARCALYST works by inhibiting the activity of interleukin-6 (IL-6).",
      "ARCALYST is administered through a subcutaneous injection.",
      "ARCALYST is usually given once a month."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: ARCALYST (rilonacept) is not used to treat chronic autoimmune thyroiditis, also known as Hashimoto's thyroiditis; it is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) and other conditions like Familial Mediterranean Fever (FMF).\n2. TRUE\n3. FALSE [correction]: ARCALYST works by inhibiting the activity of interleukin-1 (IL-1), not interleukin-6 (IL-6).\n4. TRUE\n5. FALSE [correction]: ARCALYST is usually administered once weekly, rather than once a month.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "vicuna-7b_response": "Robertsonian translocations are chromosomal rearrangements that involve the acrocentric chromosomes, which are the most common type of translocation in humans. These translocations are formed by the fusion of two acrocentric chromosomes, resulting in a structurally abnormal chromosome. The most common type of Robertsonian translocation is the translocation between the short (p) arm of one acrocentric chromosome and the long (q) arm of another acrocentric chromosome. This type of translocation is called rob(p;q).\nIn the case of a non-mosaic de novo Robertsonian translocation 21q;21q, the two 21q arms of the rearranged chromosome have different parental origins. The genotypes of the family with this translocation indicate that one 21q arm is paternal and the other maternal. This suggests that the formation of the rob(21q;21q) occurs in the zygote or in the first few postzygotic mitotic divisions.\nIt is important to note that Robertsonian translocations can occur in both somatic cells and gametes, and they can be inherited in an autosomal or X-linked manner. The inheritance of Robertsonian translocations can affect the expression of genes on the affected chromosomes, and can also lead to genetic disorders such as Down syndrome.",
    "vicuna-7b_fact_raw": "1. Robertsonian translocations involve acrocentric chromosomes.\n2. These translocations result from the fusion of two acrocentric chromosomes.\n3. The translocation between the short (p) arm of one acrocentric chromosome and the long (q) arm of another is common and is called rob(p;q).\n4. In a non-mosaic de novo Robertsonian translocation 21q;21q, one 21q arm comes from the father, and the other comes from the mother.\n5. Robertsonian translocations can lead to genetic disorders such as Down syndrome.",
    "vicuna-7b_fact": [
      "Robertsonian translocations involve acrocentric chromosomes.",
      "These translocations result from the fusion of two acrocentric chromosomes.",
      "The translocation between the short (p) arm of one acrocentric chromosome and the long (q) arm of another is common and is called rob(p;q).",
      "In a non-mosaic de novo Robertsonian translocation 21q;21q, one 21q arm comes from the father, and the other comes from the mother.",
      "Robertsonian translocations can lead to genetic disorders such as Down syndrome."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The common Robertsonian translocation is between the long (q) arms of two acrocentric chromosomes, with the short (p) arms usually being lost. The designation \"rob\" indicates a Robertsonian translocation but does not specify the arms as \"p;q\".\n4. TRUE  This is a simplified explanation. In a Robertsonian translocation involving chromosome 21, such as the one described, both long arms of chromosome 21 (21q) could indeed come from different parents, leading to a child with three copies of 21q (one from the normal chromosome and two from the translocation), which is a karyotypic cause of Down syndrome.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "vicuna-7b_response": "The R package that could be used for the identification of pediatric brain tumors is \"R-IN-PHANT.\" This package is specifically designed for the analysis of in vivo proton magnetic resonance spectroscopy (MRS) data and has been used in studies to differentiate between normal brain, benign and malignant tumors as well as discriminating the three main groups of pediatric brain tumors namely pilocytic astrocytoma, ependymoma and medulloblastoma. The package allows for the analysis of spectra obtained from proton MRS for N-acetylaspartate (NAA), choline containing-compounds (Cho), creatine and phosphocreatine (Cr) and lactate (Lac) and the calculation of the Cho/NAA ratio which is the most useful parameter for differentiating between normal brain, benign and malignant tumors as well as discriminating the three main groups of pediatric brain tumors.",
    "vicuna-7b_fact_raw": "1. The R package \"R-IN-PHANT\" can be used for the identification of pediatric brain tumors.\n2. \"R-IN-PHANT\" is designed for the analysis of in vivo proton magnetic resonance spectroscopy (MRS) data.\n3. The package has been utilized in studies to differentiate between normal brain, benign and malignant tumors.\n4. It is used to discriminate between the three main groups of pediatric brain tumors: pilocytic astrocytoma, ependymoma, and medulloblastoma.\n5. The package allows for the calculation of the Cho/NAA ratio, a parameter helpful in differentiating between normal brain, benign and malignant tumors, and for discriminating among the main pediatric brain tumor groups.",
    "vicuna-7b_fact": [
      "The R package \"R-IN-PHANT\" can be used for the identification of pediatric brain tumors.",
      "\"R-IN-PHANT\" is designed for the analysis of in vivo proton magnetic resonance spectroscopy (MRS) data.",
      "The package has been utilized in studies to differentiate between normal brain, benign and malignant tumors.",
      "It is used to discriminate between the three main groups of pediatric brain tumors: pilocytic astrocytoma, ependymoma, and medulloblastoma.",
      "The package allows for the calculation of the Cho/NAA ratio, a parameter helpful in differentiating between normal brain, benign and malignant tumors, and for discriminating among the main pediatric brain tumor groups."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the context of the statements, all provide a description that is plausible for a specialized R package designed for medical data analysis in the field of pediatric brain tumors. However, unless the specific features and applications of the \"R-IN-PHANT\" package are verified against its official documentation or published studies, it is not possible to fact-check these statements with absolute certainty. They are assumed to be true based on the context provided.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "vicuna-7b_response": "Yes, NEMO is a zinc finger protein. The zinc finger motif in the regulatory C-terminal half of NEMO forms a specific complex with ubiquitin, and this interaction is essential for NF-kappaB signaling. The NEMO zinc finger-ubiquitin interaction is a bona fide ubiquitin-binding domain of the ubiquitin-binding zinc finger type.",
    "vicuna-7b_fact_raw": "1. NEMO is a zinc finger protein.\n2. The zinc finger motif is located in the regulatory C-terminal half of NEMO.\n3. The NEMO zinc finger motif forms a complex with ubiquitin.\n4. The interaction between NEMO zinc finger motif and ubiquitin is essential for NF-kappaB signaling.\n5. The NEMO zinc finger-ubiquitin interaction is classified as a ubiquitin-binding zinc finger type domain.",
    "vicuna-7b_fact": [
      "NEMO is a zinc finger protein.",
      "The zinc finger motif is located in the regulatory C-terminal half of NEMO.",
      "The NEMO zinc finger motif forms a complex with ubiquitin.",
      "The interaction between NEMO zinc finger motif and ubiquitin is essential for NF-kappaB signaling.",
      "The NEMO zinc finger-ubiquitin interaction is classified as a ubiquitin-binding zinc finger type domain."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The NEMO zinc finger-ubiquitin interaction is not classified as a ubiquitin-binding zinc finger (UBZ) type domain but as a novel type of ubiquitin-binding domain (UBD) known as the NEMO Ubiquitin-binding Motif (NUB).",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "vicuna-7b_response": "TFIIS is a transcription factor that stimulates RNA cleavage by RNA polymerase II and promotes the resolution of backtracking events. It acts in the chromatin context, but its contribution to the chromatin landscape has not yet been investigated. Co-transcriptional chromatin alterations include subtle changes in nucleosome positioning, which are elusive to detect. The most popular method to map nucleosomes involves intensive chromatin digestion by micrococcal nuclease (MNase), but this method misses any MNase-sensitive nucleosomes caused by transcription. In contrast, partial digestion approaches preserve such nucleosomes, but introduce noise due to MNase sequence preferences.\nTo investigate the contribution of TFIIS to the chromatin landscape, the authors developed a refined nucleosome-mapping method in Saccharomyces cerevisiae. The method is based on partial MNase digestion and a sequence-bias correction derived from naked DNA cleavage. The refined method efficiently mapped nucleosomes in promoter regions rich in MNase-sensitive structures and in gene bodies, particularly in those genes whose core promoters contain a canonical TATA element.\nThe authors analyzed the global nucleosomal changes caused by lack of TFIIS using this improved method. They detected a general increase in nucleosomal fuzziness and more restricted changes in nucleosome occupancy, which concentrated in some gene categories. The TATA-containing genes were preferentially associated with decreased occupancy in gene bodies, whereas the TATA-like genes did so with increased fuzziness. The detected chromatin alterations correlated with functional defects in nascent transcription, as revealed by genomic run-on experiments.\nIn conclusion, the combination of partial MNase digestion and naked DNA correction of the sequence bias is a precise nucleosomal mapping method that does not exclude MNase-sensitive nucleosomes. This method is useful for detecting subtle alterations in nucleosome positioning produced by lack of TFIIS. The analysis revealed that TFIIS generally contributed to nucleosome positioning in both gene promoters and bodies. The independent effect of lack of TFIIS on nucleosome occupancy and",
    "vicuna-7b_fact_raw": "1. TFIIS is a transcription factor that can stimulate RNA cleavage by RNA polymerase II.\n2. TFIIS promotes the resolution of RNA polymerase II backtracking events.\n3. The most popular method to map nucleosomes involves chromatin digestion by micrococcal nuclease (MNase).\n4. The authors developed a refined nucleosome-mapping method that corrects for MNase sequence bias.\n5. The study found that a lack of TFIIS generally increased nucleosomal fuzziness and altered nucleosome occupancy.",
    "vicuna-7b_fact": [
      "TFIIS is a transcription factor that can stimulate RNA cleavage by RNA polymerase II.",
      "TFIIS promotes the resolution of RNA polymerase II backtracking events.",
      "The most popular method to map nucleosomes involves chromatin digestion by micrococcal nuclease (MNase).",
      "The authors developed a refined nucleosome-mapping method that corrects for MNase sequence bias.",
      "The study found that a lack of TFIIS generally increased nucleosomal fuzziness and altered nucleosome occupancy."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding TFIIS, RNA polymerase II, and the general method to map nucleosomes (statements 1, 2, and 3) are scientifically accurate based on established knowledge. However, the information provided does not include enough context to verify the claims made in statements 4 and 5 about the authors developing a refined nucleosome-mapping method or the specific findings of a study. Therefore, without additional input, those statements must be classified as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "vicuna-7b_response": "Based on the information provided in Document-0, it appears that origins of replication that are located close to yeast centromeres tend to fire early in S phase. However, it is important to note that the information is based on studies in budding yeast and fission yeast, and the cis-acting sequences that affect replication timing may be different between the two species. Additionally, the study only identified a small number of origins that fire in very late S phase in fission yeast, and it is possible that there are other origins that fire late in S phase that were not identified in the study. Therefore, it is not possible to make a definitive statement about whether origins of replication close to yeast centromeres fire early or late without further research.",
    "vicuna-7b_fact_raw": "1. Origins of replication close to yeast centromeres tend to fire early in S phase according to the information in Document-0.\n2. The information about replication timing is based on studies in budding yeast and fission yeast.\n3. The cis-acting sequences that affect replication timing may differ between budding yeast and fission yeast.\n4. A small number of origins that fire in very late S phase were identified in fission yeast according to the study.\n5. It is acknowledged that there might be other origins that fire late in S phase that were not identified in the study.",
    "vicuna-7b_fact": [
      "Origins of replication close to yeast centromeres tend to fire early in S phase according to the information in Document-0.",
      "The information about replication timing is based on studies in budding yeast and fission yeast.",
      "The cis-acting sequences that affect replication timing may differ between budding yeast and fission yeast.",
      "A small number of origins that fire in very late S phase were identified in fission yeast according to the study.",
      "It is acknowledged that there might be other origins that fire late in S phase that were not identified in the study."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: A small number of origins that fire in very late S phase were identified in budding yeast according to the study.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "vicuna-7b_response": "Pure GA-sequences are a type of DNA sequence that is longer than 50 bases and consists exclusively of G's and A's. They are found ubiquitously along the chromosomes of various mammalian species, with a species-dependent density and reaching sizes of up to 1300 bases. They are unique individuals and contain several repeated short GA-containing motifs. Only a small number of poly-A-, poly-G-, poly-GA-, and poly-GAAA-sequences are found, combined <0.5%. The majority of pure GA-sequences are not coding for proteins and contain fewer point mutations than one would expect from the genome at large. The functions of pure GA-sequences are not known, but the article suggests that they may serve as genomic signposts to guide polymerases and transcription factors to their proper targets, and/or as spatial linkers to help generate the 3-dimensional organization of chromatin.",
    "vicuna-7b_fact_raw": "1. Pure GA-sequences consist exclusively of the nucleotides G (guanine) and A (adenine).\n2. These sequences are found ubiquitously along the chromosomes of various mammalian species.\n3. GA-sequences can reach sizes of up to 1300 bases.\n4. The majority of pure GA-sequences do not code for proteins.\n5. Pure GA-sequences contain fewer point mutations than expected from the genome at large.",
    "vicuna-7b_fact": [
      "Pure GA-sequences consist exclusively of the nucleotides G (guanine) and A (adenine).",
      "These sequences are found ubiquitously along the chromosomes of various mammalian species.",
      "GA-sequences can reach sizes of up to 1300 bases.",
      "The majority of pure GA-sequences do not code for proteins.",
      "Pure GA-sequences contain fewer point mutations than expected from the genome at large."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe nature and distribution of specific sequences such as GA-sequences can be complex and vary between species. Determining their ubiquity, size, and mutation rate without specific scientific data is difficult. Therefore, statements 2, 3, and 5 are marked as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "vicuna-7b_response": "Based on the information provided in Document-0, there are at least four family members of Groucho-related genes (GRG) in the mouse genome. The Groucho protein is involved in the Notch signalling pathway and interacts with Hairy-related transcription factors to regulate segmentation, neurogenesis, and sex determination. Grg4 is one of the murine Grg proteins and is expressed in proliferating epithelial tissues undergoing mesenchymal induction, overlapping with Grg3, Notch1, and Hes1 expression. It is also expressed in the central nervous system and somites, but in cells adjacent to Grg3-, Notch1-, and Hes1-expressing cells. This distinct pattern of expression suggests a role for Grg4 in later stages of cell differentiation than for the other mouse neurogenic gene homologues. Therefore, the answer to the question is that there are at least four Groucho-related genes (GRG) contained in the mouse genome.",
    "vicuna-7b_fact_raw": "1. There are at least four family members of Groucho-related genes (GRG) in the mouse genome.\n2. The Groucho protein is involved in the Notch signalling pathway.\n3. Groucho-related genes interact with Hairy-related transcription factors to regulate segmentation, neurogenesis, and sex determination.\n4. The murine Grg protein Grg4 is expressed in proliferating epithelial tissues undergoing mesenchymal induction.\n5. Grg4 is expressed in the central nervous system and somites.",
    "vicuna-7b_fact": [
      "There are at least four family members of Groucho-related genes (GRG) in the mouse genome.",
      "The Groucho protein is involved in the Notch signalling pathway.",
      "Groucho-related genes interact with Hairy-related transcription factors to regulate segmentation, neurogenesis, and sex determination.",
      "The murine Grg protein Grg4 is expressed in proliferating epithelial tissues undergoing mesenchymal induction.",
      "Grg4 is expressed in the central nervous system and somites."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The Groucho family (also known as TLE family) does contain multiple members. The exact number varies by species, but mice have at least four Groucho-related genes (GRG1, GRG2, GRG3, and GRG4/TLE4).\n2. TRUE: Groucho family proteins, which are known as transducin-like Enhancer of split (TLE) proteins in mammals, are indeed involved in several signaling pathways, including the Notch signaling pathway.\n3. TRUE: Groucho-related proteins interact with various transcription factors, including Hairy and Hairy-related factors, to regulate developmental processes such as segmentation, neurogenesis, and sex determination.\n4. UNKNOWN: The specific expression patterns of Grg4 (or TLE4) in proliferating epithelial tissues undergoing mesenchymal induction is not provided, so this statement can't be confirmed as true or false without additional context.\n5. TRUE: Grg4, like other Groucho/TLE family members, is known to be expressed in various tissues during development, including the central nervous system and somites.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "vicuna-7b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain (CTD) of the enzyme's largest subunit. The CTD of RNAP II is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro. Using a deletion analysis of glutathione S-transferase-CTD fusion proteins, it was found that heptads in the vicinity of 30 to 37 contribute modestly more than other sections, but no specific subsection of the CTD is necessary or sufficient for cleavage. The nonconsensus CTD heptads are together responsible for only 20% of the wild-type cleavage activity. Analysis of the all-consensus CTD series revealed that the remaining 80% of the CTD-dependent cleavage activity directly correlates with CTD length, with significant activity requiring approximately 26 or more repeats. These results suggest that the CTD of RNAP II plays a scaffolding role in the pre-mRNA cleavage reaction.",
    "vicuna-7b_fact_raw": "1. The C-terminal domain (CTD) of RNA polymerase II's largest subunit carries RNA cleavage activity.\n2. The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.\n3. Heptads in the vicinity of 30 to 37 of the CTD contribute modestly more to cleavage activity than other sections.\n4. Nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity.\n5. Approximately 26 or more repeats of the CTD are required for significant cleavage activity.",
    "vicuna-7b_fact": [
      "The C-terminal domain (CTD) of RNA polymerase II's largest subunit carries RNA cleavage activity.",
      "The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.",
      "Heptads in the vicinity of 30 to 37 of the CTD contribute modestly more to cleavage activity than other sections.",
      "Nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity.",
      "Approximately 26 or more repeats of the CTD are required for significant cleavage activity."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The C-terminal domain (CTD) of RNA polymerase II's largest subunit does not carry RNA cleavage activity. It is involved in the processing of the pre-mRNA, but the cleavage activity for polyadenylation is carried out by other proteins in the complex.\n2. FALSE [correction]: The CTD is involved in the regulation of pre-mRNA polyadenylation, but it does not directly perform the cleavage reaction in vitro. The cleavage reaction is performed by the cleavage and polyadenylation specificity factor (CPSF) and other proteins within the pre-mRNA 3' end processing complex.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe role of the CTD in RNA polymerase II is complex and involves multiple processes related to RNA synthesis and processing. However, direct cleavage activity is not one of its functions; it rather serves as a platform for the assembly of various proteins that regulate transcription and RNA processing. Without more specific context or references, it is not possible to accurately assess the statements regarding the heptad repeats and their contribution to cleavage activity.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "vicuna-7b_response": "Based on the information provided, it appears that Ohdo syndrome is a genetic disorder characterized by a range of malformations, including blepharophimosis (a condition where the eyelids are abnormally small), ptosis (drooping of the eyelids), dental hypoplasia (underdeveloped teeth), hearing impairment, and intellectual disability. The disorder is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the gene (one from each parent) to develop the disorder.\nThe information also suggests that there is variability in the severity of the symptoms of Ohdo syndrome, with some individuals having mild symptoms and others having more severe symptoms. The severe phenotype of the disorder is characterized by distinctive facial features, and all cases with this severe phenotype have been found to be sporadic, meaning that they occur randomly and are not inherited from a parent.\nFurthermore, the information indicates that the disorder is caused by a genetic mutation, but the specific gene or mutation responsible for Ohdo syndrome has not been identified. Subtelomeric FISH studies, which are a type of genetic testing, were performed on the two cases reported in the article, but no abnormalities were found.\nIn summary, the genetic basis of Ohdo syndrome is not yet fully understood, but it is believed to be caused by a mutation in a specific gene or genes. The disorder is inherited in an autosomal recessive pattern, and the severity of the symptoms can vary. The diagnosis of Ohdo syndrome is currently based on clinical criteria, and further research is needed to identify the specific gene(s) responsible for the disorder.",
    "vicuna-7b_fact_raw": "1. Ohdo syndrome is a genetic disorder with symptoms that may include blepharophimosis, ptosis, dental hypoplasia, hearing impairment, and intellectual disability.\n2. Ohdo syndrome is inherited in an autosomal recessive pattern.\n3. There is variability in the severity of the symptoms of Ohdo syndrome.\n4. The severe phenotype of Ohdo syndrome characterized by distinctive facial features has been found to be sporadic.\n5. The specific gene or mutation responsible for Ohdo syndrome has not been identified, despite research such as subtelomeric FISH studies.",
    "vicuna-7b_fact": [
      "Ohdo syndrome is a genetic disorder with symptoms that may include blepharophimosis, ptosis, dental hypoplasia, hearing impairment, and intellectual disability.",
      "Ohdo syndrome is inherited in an autosomal recessive pattern.",
      "There is variability in the severity of the symptoms of Ohdo syndrome.",
      "The severe phenotype of Ohdo syndrome characterized by distinctive facial features has been found to be sporadic.",
      "The specific gene or mutation responsible for Ohdo syndrome has not been identified, despite research such as subtelomeric FISH studies."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ohdo syndrome can be inherited in an autosomal dominant pattern, particularly in the form named Say-Barber-Biesecker-Young-Simpson variant.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in several genes have been identified in individuals with Ohdo syndrome, such as KAT6B and MED12, although not all causal genes may have been found yet.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "vicuna-7b_response": "CTDquerier is a R/Bioconductor package that has been developed for the analysis of psychiatric disease genes. The package provides tools for performing enrichment analysis at the gene-pathway level, allowing researchers to develop novel hypotheses about the etiology of human diseases. CTDquerier also allows users to easily download data from the Comparative Toxicogenomics DatabaseTM (CTD) and integrate it into R/Bioconductor analysis pipelines. The package contains functions for visualizing CTD data and performing enrichment analyses, and it is illustrated with a real data analysis of asthma-related genes. CTDquerier is available through Bioconductor and its development version can be accessed through <https://github.com/isglobal-brge/CTDquerier>.",
    "vicuna-7b_fact_raw": "1. CTDquerier is a R/Bioconductor package for the analysis of psychiatric disease genes.\n2. The package includes tools for enrichment analysis at the gene-pathway level.\n3. CTDquerier enables users to download data from the Comparative Toxicogenomics DatabaseTM (CTD).\n4. The package can be integrated into R/Bioconductor analysis pipelines.\n5. CTDquerier allows for visualization and enrichment analysis of CTD data.",
    "vicuna-7b_fact": [
      "CTDquerier is a R/Bioconductor package for the analysis of psychiatric disease genes.",
      "The package includes tools for enrichment analysis at the gene-pathway level.",
      "CTDquerier enables users to download data from the Comparative Toxicogenomics DatabaseTM (CTD).",
      "The package can be integrated into R/Bioconductor analysis pipelines.",
      "CTDquerier allows for visualization and enrichment analysis of CTD data."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "vicuna-7b_response": "The swirl sign is a radiological finding seen on noncontrast CT scan in patients of head trauma who develop extradural hematoma. It is composed of two components: the hyperacute component, which represents ongoing active intracranial bleed, and the acute component, which comprises surrounding hyperattenuated clotted blood. The swirl sign is relatively uncommon and its importance lies in its ability to identify expanding extradural hematoma with ongoing active bleed, which warrants aggressive surgical management. The clinical implication of the swirl sign is that it suggests ongoing active bleeding and a potentially life-threatening situation. Two clinical scenarios have been described in the provided document to emphasize the importance of early identification and aggressive surgical management of the swirl sign.",
    "vicuna-7b_fact_raw": "1. The swirl sign is a radiological finding observed on noncontrast CT scans.\n2. It is associated with patients who have experienced head trauma and developed extradural hematoma.\n3. The swirl sign consists of a hyperacute component representing active intracranial bleeding.\n4. The swirl sign also includes an acute component that comprises surrounding hyperattenuated clotted blood.\n5. The presence of the swirl sign suggests that there is ongoing active bleeding and indicates a potentially life-threatening condition that requires aggressive surgical management.",
    "vicuna-7b_fact": [
      "The swirl sign is a radiological finding observed on noncontrast CT scans.",
      "It is associated with patients who have experienced head trauma and developed extradural hematoma.",
      "The swirl sign consists of a hyperacute component representing active intracranial bleeding.",
      "The swirl sign also includes an acute component that comprises surrounding hyperattenuated clotted blood.",
      "The presence of the swirl sign suggests that there is ongoing active bleeding and indicates a potentially life-threatening condition that requires aggressive surgical management."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "vicuna-7b_response": "ROF1 expression in Arabidopsis is induced by heat stress and is developmentally regulated. ROF1 is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family. In this study, it was found that ROF1 binds to heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions. Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2. HsfA2 interacts with HSP90.1 but not with ROF1. Nuclear localization of ROF1 was not detected in Arabidopsis HSP90.1 and HsfA2 knockout mutants. The rof1 knockout plants exhibited collapse when 24-48 h passed between acclimation at 37 degrees C and exposure to 45 degrees C. Transgenic ROF1 over-expressors showed better survival in response to exposure to 45 degrees C than wild-type plants did. In rof1 knockout mutants, the level of expression of small HSPs regulated by HsfA2 was dramatically reduced after exposure to 37 degrees C and recovery for 24-48 h, and correlates well with the mutant phenotype. The study suggests a role for ROF1 in prolongation of thermotolerance by sustaining the levels of small HSPs that are essential for survival at high temperatures.",
    "vicuna-7b_fact_raw": "1. ROF1 expression in Arabidopsis is induced by heat stress.\n2. ROF1 is a member of the FKBP (FK506 binding protein) family.\n3. ROF1 binds to heat shock proteins HSP90.1 in Arabidopsis.\n4. The nuclear localization of the ROF1-HSP90.1 complex is induced by heat stress and is dependent on the presence of the transcription factor HsfA2.\n5. Transgenic Arabidopsis plants overexpressing ROF1 showed better survival when exposed to 45 degrees C compared to wild-type plants.",
    "vicuna-7b_fact": [
      "ROF1 expression in Arabidopsis is induced by heat stress.",
      "ROF1 is a member of the FKBP (FK506 binding protein) family.",
      "ROF1 binds to heat shock proteins HSP90.1 in Arabidopsis.",
      "The nuclear localization of the ROF1-HSP90.1 complex is induced by heat stress and is dependent on the presence of the transcription factor HsfA2.",
      "Transgenic Arabidopsis plants overexpressing ROF1 showed better survival when exposed to 45 degrees C compared to wild-type plants."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: It has been reported in scientific literature that ROF1 (also known as AtFKBP62) expression in Arabidopsis is induced by heat stress.\n2. TRUE: ROF1 is indeed a member of the FKBP (FK506 binding protein) family.\n3. TRUE: ROF1 has been reported to interact with heat shock protein HSP90.1 in Arabidopsis thaliana.\n4. UNKNOWN: While it is established that heat stress can induce the nuclear localization of certain proteins and that it often involves transcription factors like HsfA2, the specific interaction and dependency of ROF1-HSP90.1 complex on HsfA2 for its nuclear localization under heat stress requires specific empirical evidence for confirmation.\n5. TRUE: Studies have shown that overexpressing particular genes like ROF1 in Arabidopsis can confer increased thermotolerance, implying that transgenic plants overexpressing ROF1 may indeed show better survival at elevated temperatures like 45 degrees C compared to wild-type plants.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "vicuna-7b_response": "The most common cause of hereditary renal amyloidosis is a variant of the fibrinogen alpha-chain gene, specifically the arginine to leucine mutation (Arg554Leu) in the fibrinogen alpha-chain gene. This mutation was found to be the cause of amyloidosis in three members of a family through amino acid sequence analysis of amyloid fibril protein and direct genomic DNA sequencing and restriction fragment length polymorphism analysis. This is the first demonstration of hereditary amyloidosis associated with a variant fibrinogen alpha-chain. Variants of circulating fibrinogen may be the cause of a number of systemic amyloidoses with primarily renal involvement.",
    "vicuna-7b_fact_raw": "1. Hereditary renal amyloidosis is most commonly caused by a variant of the fibrinogen alpha-chain gene.\n2. The specific mutation associated with this condition is the arginine to leucine mutation (Arg554Leu) in the fibrinogen alpha-chain gene.\n3. Amino acid sequence analysis of amyloid fibril protein and direct genomic DNA sequencing along with restriction fragment length polymorphism analysis can identify this mutation.\n4. The described mutation in the fibrinogen alpha-chain is associated with amyloidosis that primarily affects the kidneys.\n5. This identification is marked as the first demonstration of hereditary amyloidosis associated with a variant fibrinogen alpha-chain.",
    "vicuna-7b_fact": [
      "Hereditary renal amyloidosis is most commonly caused by a variant of the fibrinogen alpha-chain gene.",
      "The specific mutation associated with this condition is the arginine to leucine mutation (Arg554Leu) in the fibrinogen alpha-chain gene.",
      "Amino acid sequence analysis of amyloid fibril protein and direct genomic DNA sequencing along with restriction fragment length polymorphism analysis can identify this mutation.",
      "The described mutation in the fibrinogen alpha-chain is associated with amyloidosis that primarily affects the kidneys.",
      "This identification is marked as the first demonstration of hereditary amyloidosis associated with a variant fibrinogen alpha-chain."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\nStatements 1-4 regarding hereditary renal amyloidosis and the specific mutation in the fibrinogen alpha-chain gene are consistent with known information about the disease and its genetic basis. However, without information on the historical context or additional details, it is not possible to accurately determine the truth of statement 5 regarding whether this was the first demonstration of hereditary amyloidosis associated with a variant fibrinogen alpha-chain.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "vicuna-7b_response": "Yes, the proteome of mice hippocampus has been analyzed. The use of proteomics technologies has enabled the simultaneous demonstration of the expression of hundreds of proteins, and the mouse hippocampus has been a major target of analysis in the search for molecular correlates to neuronal information storage. Although human and rat hippocampal samples have been successfully subjected to proteomic profiling, no elaborate analysis providing the fundamental experimental basis for protein-expression studies in the mouse hippocampus has been carried out as yet. To establish a comprehensive reference database of proteins expressed in the mouse hippocampus, a proteomic approach based on 2-DE coupled to MS (MALDI-TOF/TOF) has been chosen. 469 individual proteins, represented by 1156 spots displaying various functional states of the respective gene products, were identified. Proteomic profiling of the hippocampus, a brain region with a pivotal role for neuronal information processing and storage, may provide insight into the characteristics of proteins serving this highly sophisticated function.",
    "vicuna-7b_fact_raw": "1. Proteomics technologies have been used to analyze the expression of hundreds of proteins in the mouse hippocampus.\n2. The mouse hippocampus has been a subject of proteomic profiling in research related to neuronal information storage.\n3. Proteomic profiling of rat and human hippocampal samples has been successfully performed.\n4. A proteomic approach using 2-dimensional electrophoresis (2-DE) coupled with mass spectrometry (MALDI-TOF/TOF) has been used to establish a reference database of proteins expressed in the mouse hippocampus.\n5. A total of 469 individual proteins, represented by 1156 spots, have been identified in the mouse hippocampus through this proteomic approach.",
    "vicuna-7b_fact": [
      "Proteomics technologies have been used to analyze the expression of hundreds of proteins in the mouse hippocampus.",
      "The mouse hippocampus has been a subject of proteomic profiling in research related to neuronal information storage.",
      "Proteomic profiling of rat and human hippocampal samples has been successfully performed.",
      "A proteomic approach using 2-dimensional electrophoresis (2-DE) coupled with mass spectrometry (MALDI-TOF/TOF) has been used to establish a reference database of proteins expressed in the mouse hippocampus.",
      "A total of 469 individual proteins, represented by 1156 spots, have been identified in the mouse hippocampus through this proteomic approach."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - Proteomics technologies are indeed capable of and have been used to analyze the expression of hundreds or even thousands of proteins in various tissues, including the mouse hippocampus.\n\n2. TRUE - The mouse hippocampus is a common focus in proteomic profiling research, especially studies concerning neurological functions such as memory and learning, which can be related to neuronal information storage.\n\n3. TRUE - Proteomic profiling has been performed on samples from various species, including rats and humans, and the hippocampus is a region of interest in many such studies.\n\n4. TRUE - The approach using 2-dimensional electrophoresis (2-DE) coupled with mass spectrometry, such as Matrix-Assisted Laser Desorption/Ionization-Time of Flight/Time of Flight (MALDI-TOF/TOF), is a common and well-documented method for establishing protein expression profiles in tissues, including the mouse hippocampus.\n\n5. UNKNOWN - Without specific research citations, it's not possible to verify the precise number of individual proteins and spots identified in the mouse hippocampus through proteomic approaches.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "vicuna-7b_response": "Yes, mouse chromosomes are acrocentric. According to the information provided, the mouse karyotype is an all-acrocentric one, with all chromosomes being morphologically very similar. The only exception is chromosomes 19 and the sex chromosomes, which are acrocentric. The information also mentions the presence of a heterozygous reciprocal translocation between chromosomes 13 and 17 involved in two Rb chromosomes, which provides additional marker chromosomes.",
    "vicuna-7b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. The mouse karyotype is composed of chromosomes that are morphologically very similar.\n3. Chromosomes 19 and sex chromosomes in mice are acrocentric.\n4. There is a heterozygous reciprocal translocation between chromosomes 13 and 17 in mice.\n5. This translocation in mice involves two Rb chromosomes and provides additional marker chromosomes.",
    "vicuna-7b_fact": [
      "Mouse chromosomes are acrocentric.",
      "The mouse karyotype is composed of chromosomes that are morphologically very similar.",
      "Chromosomes 19 and sex chromosomes in mice are acrocentric.",
      "There is a heterozygous reciprocal translocation between chromosomes 13 and 17 in mice.",
      "This translocation in mice involves two Rb chromosomes and provides additional marker chromosomes."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Mouse chromosomes are indeed acrocentric, meaning that their centromeres are located very close to one end of the chromosome, creating a long arm and a very short (almost negligible) arm.\n2. TRUE: In mice, the chromosomes are morphologically very similar to one another, which makes it challenging to distinguish between them without specific staining techniques.\n3. TRUE: Chromosome 19, as well as the sex chromosomes in mice, are indeed acrocentric.\n4. UNKNOWN: The statement regarding a heterozygous reciprocal translocation between chromosomes 13 and 17 in mice cannot be confirmed as true or false without specific genetic information from a studied group of mice since translocations are not normally found in all individuals of a species.\n5. UNKNOWN: Similar to the above statement, confirmation regarding whether this translocation involves two Rb chromosomes (Robertsonian chromosomes) and provides additional marker chromosomes, would require specific genetic or scientific research information about the mice in question. Robertsonian translocations involve the fusion of whole long arms of two acrocentric chromosomes, but whether this is the case for the stated chromosomes in mice is not specified.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "vicuna-7b_response": "The siRNA based drug that is in clinical trials for the treatment of pancreatic cancer is pSsik-ras(GAT). This drug targets the mutant k-ras oncogene through specific siRNA and has been shown to significantly inhibit tumor growth in vitro and in vivo. The combination of pSsik-ras(GAT) with gemcitabine has also shown to have strong growth inhibition of orthotopic pancreatic tumors and prolonged survival rate in mice. These findings suggest that targeting mutant k-ras through specific siRNA might be an effective treatment for pancreatic cancer and could potentially potentiate the effects of conventional therapy.",
    "vicuna-7b_fact_raw": "1. The siRNA based drug pSsik-ras(GAT) is in clinical trials for the treatment of pancreatic cancer.\n2. pSsik-ras(GAT) targets the mutant k-ras oncogene.\n3. pSsik-ras(GAT) has been shown to significantly inhibit tumor growth in vitro and in vivo.\n4. Combining pSsik-ras(GAT) with gemcitabine has resulted in strong growth inhibition of orthotopic pancreatic tumors in mice.\n5. The combination of pSsik-ras(GAT) with gemcitabine prolonged survival rates in mice.",
    "vicuna-7b_fact": [
      "The siRNA based drug pSsik-ras(GAT) is in clinical trials for the treatment of pancreatic cancer.",
      "pSsik-ras(GAT) targets the mutant k-ras oncogene.",
      "pSsik-ras(GAT) has been shown to significantly inhibit tumor growth in vitro and in vivo.",
      "Combining pSsik-ras(GAT) with gemcitabine has resulted in strong growth inhibition of orthotopic pancreatic tumors in mice.",
      "The combination of pSsik-ras(GAT) with gemcitabine prolonged survival rates in mice."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements require specific and up-to-date knowledge about the drug pSsik-ras(GAT) and its clinical trials, which may not be available in the general knowledge database as of my last update in 2023. For accurate verification, contemporary clinical trial databases, scientific research papers, and the latest regulatory information regarding the drug need to be consulted.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "vicuna-7b_response": "The HPG pore refers to the pore structure of HPG-based granules, which are produced using a swellable hydrophilic material based on heterodisperse polysaccharides. The purpose of the study described in Document-0 was to investigate the release-controlling action of these granules in relation to their initial pore structure. The study found that the tablets had substantially different pore volumes and pore size distributions, and that the release of a water-soluble model compound from swollen matrices was not affected by total porosity or median pore diameter of the initial dry matrix. The study also found that HPG-based formulations containing either diclofenac sodium or propranolol HCl had a high intraparticulate porosity in the dry state, and that the in vitro release profiles from matrix tablets compacted from any of the formulations were similar to those obtained when the same materials were contained uncompacted in hard gelatin capsules.",
    "vicuna-7b_fact_raw": "1. The HPG pore refers to the pore structure of granules made from a hydrophilic material based on heterodisperse polysaccharides.\n2. The study referenced, Document-0, aimed to investigate the release-controlling action of HPG-based granules based on their initial pore structure.\n3. The study found variations in pore volume and pore size distribution among the tablets.\n4. Release of a water-soluble model compound from swollen HPG matrices was not affected by total porosity or median pore diameter of the initial dry matrix.\n5. HPG-based formulations with diclofenac sodium or propranolol HCl showed high intraparticulate porosity when dry and had similar in vitro release profiles in both compacted matrix tablets and uncompacted materials in hard gelatin capsules.",
    "vicuna-7b_fact": [
      "The HPG pore refers to the pore structure of granules made from a hydrophilic material based on heterodisperse polysaccharides.",
      "The study referenced, Document-0, aimed to investigate the release-controlling action of HPG-based granules based on their initial pore structure.",
      "The study found variations in pore volume and pore size distribution among the tablets.",
      "Release of a water-soluble model compound from swollen HPG matrices was not affected by total porosity or median pore diameter of the initial dry matrix.",
      "HPG-based formulations with diclofenac sodium or propranolol HCl showed high intraparticulate porosity when dry and had similar in vitro release profiles in both compacted matrix tablets and uncompacted materials in hard gelatin capsules."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Release of a water-soluble model compound from swollen HPG matrices was likely affected by total porosity or median pore diameter of the initial dry matrix, given the context suggests the study aimed to investigate release-controlling actions based on pore structure.\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "vicuna-7b_response": "The 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The main goal of the wiki is to track sequencing projects that have been proposed, are in progress, or have been completed. The wiki provides a way to link pages for species and strains to pages for people and organizations, using machine- and human-readable metadata that users can query to see the status of their favorite worm. The site is based on the same platform that runs Wikipedia, with semantic extensions that allow the underlying taxonomy and data storage models to be maintained and updated with ease compared with a conventional database-driven web site. The wiki also provides a way to track and share preliminary data if those data are not polished enough to be submitted to the official sequence repositories. The initiative has already fostered new international collaborations and attracted newcomers to the enthusiastic community of nematode genomicists.",
    "vicuna-7b_fact_raw": "1. The 959 Nematode Genomes initiative coordinates sequencing efforts of various labs to sequence 959 genomes across the phylum Nematoda.\n2. The initiative tracks sequencing projects that are proposed, in progress, or completed, through a community-curated semantic wiki.\n3. The semantic wiki links pages for species and strains to those of people and organizations, and includes machine- and human-readable metadata.\n4. The platform used by the initiative is similar to the one running Wikipedia, but with semantic extensions to facilitate taxonomy and data storage management.\n5. The 959 Nematode Genomes initiative provides a platform for sharing preliminary data that may not be suitable yet for submission to official sequence repositories.",
    "vicuna-7b_fact": [
      "The 959 Nematode Genomes initiative coordinates sequencing efforts of various labs to sequence 959 genomes across the phylum Nematoda.",
      "The initiative tracks sequencing projects that are proposed, in progress, or completed, through a community-curated semantic wiki.",
      "The semantic wiki links pages for species and strains to those of people and organizations, and includes machine- and human-readable metadata.",
      "The platform used by the initiative is similar to the one running Wikipedia, but with semantic extensions to facilitate taxonomy and data storage management.",
      "The 959 Nematode Genomes initiative provides a platform for sharing preliminary data that may not be suitable yet for submission to official sequence repositories."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe given statements seem consistent with the type of project that the 959 Nematode Genomes initiative would undertake. It is common for such initiatives to use wikis for coordination and sharing of information, and semantic wikis would be particularly useful in managing links between different types of pages and including metadata. The initiative could logically include a platform for preliminary data sharing, as this would support collaboration and acceleration of research before formal publication. However, without specific details or a direct source confirming each of these statements, it is assumed that they provide an accurate overview of such a scientific initiative based on common practices in the field.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "vicuna-7b_response": "The R package for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTmer. It was developed by a team of researchers and is based on counting pre-defined per-chromosome sets of unique k-mers from raw sequencing data, and applying linear regression model on the counts. The processing time of one sample is less than 10 CPU-minutes on a high-end workstation. NIPTmer has the potential to reduce significantly the time and complexity of NIPT post-sequencing analysis compared to mapping-based methods. The software package is freely available for non-commercial users at <http://bioinfo.ut.ee/NIPTMer/>.",
    "vicuna-7b_fact_raw": "1. The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTmer.\n2. NIPTmer uses a method based on counting pre-defined per-chromosome sets of unique k-mers from raw sequencing data.\n3. The software applies a linear regression model on the counts in its analysis.\n4. The processing time of one NIPT sample using NIPTmer is less than 10 CPU-minutes on a high-end workstation.\n5. NIPTmer is available for free for non-commercial users at the website http://bioinfo.ut.ee/NIPTMer/.",
    "vicuna-7b_fact": [
      "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTmer.",
      "NIPTmer uses a method based on counting pre-defined per-chromosome sets of unique k-mers from raw sequencing data.",
      "The software applies a linear regression model on the counts in its analysis.",
      "The processing time of one NIPT sample using NIPTmer is less than 10 CPU-minutes on a high-end workstation.",
      "NIPTmer is available for free for non-commercial users at the website http://bioinfo.ut.ee/NIPTMer/."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "vicuna-7b_response": "Achenbach's syndrome is a rare clinical condition characterized by the formation of blood clots (haematomas) on the volar (palm) surface of the fingers, which are often accompanied by burning pain and swelling. The condition is named after Dr. Achenbach, who first described it in 1966. The exact cause of Achenbach's syndrome is not known, but it is thought to be related to trauma or injury to the fingers, as well as certain medical conditions such as blood clotting disorders.\nThe symptoms of Achenbach's syndrome typically begin suddenly and are severe, making it difficult for the affected person to use their fingers. The haematomas are usually small, but they can grow over time and become more painful. In some cases, the haematomas can cause permanent damage to the fingers if they are not treated promptly.\nTreatment for Achenbach's syndrome typically involves rest and immobilization of the affected fingers to prevent further bleeding and swelling. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) may also be prescribed to help reduce pain and inflammation. In severe cases, surgery may be necessary to remove the haematomas and promote healing.\nIt is important to note that Achenbach's syndrome is a rare condition, and its exact prevalence is not known. However, it is more common in individuals who have a history of blood clotting disorders or who have sustained trauma or injury to their fingers. If you are experiencing symptoms of Achenbach's syndrome, it is important to seek medical attention promptly to receive proper diagnosis and treatment.",
    "vicuna-7b_fact_raw": "1. Achenbach's syndrome is characterized by the formation of blood clots (haematomas) on the palm surface of the fingers.\n2. Dr. Achenbach first described Achenbach's syndrome in 1966.\n3. The cause of Achenbach's syndrome is not fully understood but is thought to be related to finger trauma or blood clotting disorders.\n4. Treatment for Achenbach's syndrome can include rest, immobilization of the fingers, nonsteroidal anti-inflammatory drugs (NSAIDs), and in severe cases, surgery.\n5. Achenbach's syndrome is a rare condition.",
    "vicuna-7b_fact": [
      "Achenbach's syndrome is characterized by the formation of blood clots (haematomas) on the palm surface of the fingers.",
      "Dr. Achenbach first described Achenbach's syndrome in 1966.",
      "The cause of Achenbach's syndrome is not fully understood but is thought to be related to finger trauma or blood clotting disorders.",
      "Treatment for Achenbach's syndrome can include rest, immobilization of the fingers, nonsteroidal anti-inflammatory drugs (NSAIDs), and in severe cases, surgery.",
      "Achenbach's syndrome is a rare condition."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by spontaneous bruising, not the formation of blood clots, on the palm surface of the fingers.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "vicuna-7b_response": "The algorithm used for detection of long repeat expansions is the repeat expansion detection (RED) method. The RED method is used to detect expansions of trinucleotide repeats of unknown chromosomal location. The method uses 8-mer oligonucleotides to assess its usefulness in 30 samples from patients with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD), for which the number of CAG/CTG repeats was determined by sequencing. The RED method showed a good correlation between the number of repeats detected by sequencing and those identified by RED. However, in 17% of samples, the RED gave additional fragments for ligation products of different size than the CAG/CTG repeat expansion detected in the sample by sequencing. The same was observed in a group of control subjects (n = 78) without known clinical abnormalities in which products of more than 40 repeats were detected in 27% of them, indicating that CAG/CTG repeat expansions are common in the general population. Further investigation is needed to determine if these correspond to unidentified loci with expansions.",
    "vicuna-7b_fact_raw": "1. The repeat expansion detection (RED) method is used for detection of long repeat expansions.\n2. The RED method is utilized to detect expansions of trinucleotide repeats of unknown chromosomal location.\n3. The method was assessed for its usefulness in 30 samples from patients with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD).\n4. There was a good correlation between the number of repeats detected by sequencing and those identified by the RED method.\n5. In 17% of patient samples, the RED method gave additional fragments for ligation products of different size than the detected CAG/CTG repeat expansion.",
    "vicuna-7b_fact": [
      "The repeat expansion detection (RED) method is used for detection of long repeat expansions.",
      "The RED method is utilized to detect expansions of trinucleotide repeats of unknown chromosomal location.",
      "The method was assessed for its usefulness in 30 samples from patients with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD).",
      "There was a good correlation between the number of repeats detected by sequencing and those identified by the RED method.",
      "In 17% of patient samples, the RED method gave additional fragments for ligation products of different size than the detected CAG/CTG repeat expansion."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: This statement seems to refer to a specific result or finding, but without the original passage's data or context, it's impossible to accurately validate or correct this statement. However, the statement might imply the presence of additional aberrant bands or fragments possibly from somatic mosaicism or technical artifacts, which can occur in some repeat expansion detection methods.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "vicuna-7b_response": "Neuroligin-3 promotes the growth of medulloblastoma (MB) and glioblastoma (GBM) cells. These are the most prevalent malignant brain tumors. The identification of novel therapeutic strategies is crucial for the treatment of MB and GBM patients. A study has discovered 13a-(S)-3-Hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine (PF403) as a potential therapeutic agent for these types of brain tumors. PF403 strongly inhibited the growth of Hedgehog (Hh) pathway-hyperactivated MB and GBM cells with a 50% inhibitory concentration (IC50) of 0.01nM. The prodrug of PF403, called CAT3, was designed and synthesized and displayed significant in vivo efficacy against MB and GBM. The study revealed that CAT3 inhibited the growth of these tumors by interrupting the Hh signaling pathway. At the molecular level, PF403 inhibited the cell surface accumulation of the Smoothened (Smo) receptor by directly binding or enhancing the interaction of Smo with the repressor Ptch1. Additionally, PF403 significantly repressed the accumulation of Gli1 in the nucleus and transcription, promoting Sufu-Gli1 and PKA-Gli1 interactions. Overall, the study supports the hypothesis that CAT3 is a promising therapeutic agent for the treatment of Hh-driven MB and GBM.",
    "vicuna-7b_fact_raw": "1. Neuroligin-3 promotes the growth of medulloblastoma (MB) and glioblastoma (GBM) cells.\n2. A study identified 13a-(S)-3-Hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine (PF403) as a potential therapeutic agent for MB and GBM.\n3. PF403 inhibited the growth of Hedgehog (Hh) pathway-hyperactivated MB and GBM cells with a 50% inhibitory concentration (IC50) of 0.01nM.\n4. The prodrug of PF403, CAT3, was shown to have significant in vivo efficacy against MB and GBM in the study.\n5. PF403 inhibited the cell surface accumulation of the Smoothened (Smo) receptor by either directly binding or enhancing the interaction of Smo with the repressor Ptch1.",
    "vicuna-7b_fact": [
      "Neuroligin-3 promotes the growth of medulloblastoma (MB) and glioblastoma (GBM) cells.",
      "A study identified 13a-(S)-3-Hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine (PF403) as a potential therapeutic agent for MB and GBM.",
      "PF403 inhibited the growth of Hedgehog (Hh) pathway-hyperactivated MB and GBM cells with a 50% inhibitory concentration (IC50) of 0.01nM.",
      "The prodrug of PF403, CAT3, was shown to have significant in vivo efficacy against MB and GBM in the study.",
      "PF403 inhibited the cell surface accumulation of the Smoothened (Smo) receptor by either directly binding or enhancing the interaction of Smo with the repressor Ptch1."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: Neuroligin-3 has been implicated in promoting the growth of various types of cancer cells, including medulloblastoma (MB) and glioblastoma (GBM), by modulating synaptic and non-synaptic signaling mechanisms.\n\n2. UNKNOWN: Without access to the specific study, we cannot confirm whether PF403, with the chemical structure 13a-(S)-3-Hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, was identified as a potential therapeutic agent for MB and GBM. The chemical name given appears to be a detailed and specific compound, but without the actual study or publication, we can't verify its identification as a therapeutic agent.\n\n3. UNKNOWN: Again, due to the lack of specific reference to the study or data, we cannot confirm the IC50 value of PF403 for the growth inhibition of Hedgehog (Hh) pathway-hyperactivated MB and GBM cells. An IC50 of 0.01nM would suggest high potency, but the statement cannot be verified without the source material.\n\n4. UNKNOWN: Without the study details, it's impossible to confirm or refute the in vivo efficacy of the prodrug CAT3 against MB and GBM claimed in the statement. \n\n5. UNKNOWN: The mechanism of action of PF403 on Smoothened (Smo) receptor's cell surface accumulation and its interaction with the repressor Ptch1 cannot be confirmed without the original research data or publication. Such specific details of drug action are typically elucidated through direct experimental evidence.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "vicuna-7b_response": "Based on the information provided in Document-0, gas vesicles in Microcyclus aquaticus appear as transparent areas in whole cells and can be observed using an electron microscope. When collapsed by centrifugation, they are not discernible. However, when suspended in growth medium, small transparent vesicles are detected within 5 minutes, and their number increases to an average of 15 per cell by 15 minutes. The size of the vesicles increases until they reach a maximum diameter of 100 nm, at which point they begin to elongate. This elongation is likely due to the synthesis of the cylindrical midsection of the vesicle. The study also suggests that gas vesicle assembly occurs in two distinct stages, which are subject to genetic mutation. Protein and ribonucleic acid synthesis, as well as adenosine triphosphate formation, are required for gas vesicle assembly. In addition, inhibition of protein or ribonucleic acid synthesis results in a loss of extant gas vesicles. Overall, the size of gas vesicles in Microcyclus aquaticus is approximately 100 nm.",
    "vicuna-7b_fact_raw": "1. Gas vesicles in Microcyclus aquaticus appear as transparent areas and can be observed using an electron microscope.\n2. The maximum diameter of gas vesicles in Microcyclus aquaticus before elongation is approximately 100 nm.\n3. Gas vesicle assembly in Microcyclus aquaticus occurs in two distinct stages.\n4. Protein and ribonucleic acid synthesis, as well as adenosine triphosphate formation, are required for the assembly of gas vesicles in Microcyclus aquaticus.\n5. Inhibition of protein or ribonucleic acid synthesis results in a loss of existing gas vesicles in Microcyclus aquaticus.",
    "vicuna-7b_fact": [
      "Gas vesicles in Microcyclus aquaticus appear as transparent areas and can be observed using an electron microscope.",
      "The maximum diameter of gas vesicles in Microcyclus aquaticus before elongation is approximately 100 nm.",
      "Gas vesicle assembly in Microcyclus aquaticus occurs in two distinct stages.",
      "Protein and ribonucleic acid synthesis, as well as adenosine triphosphate formation, are required for the assembly of gas vesicles in Microcyclus aquaticus.",
      "Inhibition of protein or ribonucleic acid synthesis results in a loss of existing gas vesicles in Microcyclus aquaticus."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - It is correct that gas vesicles can appear as transparent areas and they can be observed with an electron microscope.\n2. FALSE [correction]: The typical diameter of gas vesicles before elongation is not well defined as 'approximately 100 nm' across all species. These structures can vary in size, and the specific maximum diameter for Microcyclus aquaticus is not universally agreed upon. More specific research would be required to make this claim.\n3. TRUE - Gas vesicle assembly is known to occur in multiple stages, including initiation and elongation, which can be considered as distinct stages.\n4. UNKNOWN - While it is known that protein synthesis is necessary for the formation of gas vesicles, the specific requirements for ribonucleic acid synthesis and adenosine triphosphate (ATP) in the assembly of gas vesicles in Microcyclus aquaticus would require more specific research or context to confirm.\n5. UNKNOWN - The statement regarding the inhibition of protein or ribonucleic acid synthesis leading to loss of existing gas vesicles requires specific experimental evidence from studies on Microcyclus aquaticus which isn't provided in this context.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "vicuna-7b_response": "BET proteins, also known as bromodomain and extraterminal proteins, are a family of epigenetic \"readers\" that play a key role in the regulation of gene transcription. The BET proteins BRD2, BRD3, BRD4, and testis-specific BRDT are members of this family. BET proteins have been considered as attractive therapeutic targets for cancer and other human diseases.\nRecently, a new class of small-molecule BET degraders has been designed based on the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. These PROTAC BET degraders are heterobifunctional and have been shown to effectively degrade BRD4 protein in leukemia cell lines at concentrations as low as 30 pM. One of the most promising compounds, 23, has been shown to achieve an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induce rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.",
    "vicuna-7b_fact_raw": "1. The BET protein family includes BRD2, BRD3, BRD4, and BRDT.\n2. BET proteins are involved in the regulation of gene transcription.\n3. BET proteins are considered potential therapeutic targets for cancer and other human diseases.\n4. Small-molecule BET degraders based on the proteolysis targeting chimera (PROTAC) concept have been designed to induce degradation of BET proteins.\n5. A compound known as 23 (BETd-260/ZBC260) has been shown to achieve an IC50 value of 51 pM in inhibiting the growth of RS4;11 cell lines and can induce rapid tumor regression in vivo against RS4;11 xenograft tumors.",
    "vicuna-7b_fact": [
      "The BET protein family includes BRD2, BRD3, BRD4, and BRDT.",
      "BET proteins are involved in the regulation of gene transcription.",
      "BET proteins are considered potential therapeutic targets for cancer and other human diseases.",
      "Small-molecule BET degraders based on the proteolysis targeting chimera (PROTAC) concept have been designed to induce degradation of BET proteins.",
      "A compound known as 23 (BETd-260/ZBC260) has been shown to achieve an IC50 value of 51 pM in inhibiting the growth of RS4;11 cell lines and can induce rapid tumor regression in vivo against RS4;11 xenograft tumors."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements about the BET (bromodomain and extra-terminal motif) protein family and its roles in gene regulation and disease are correct, aligning with established scientific knowledge. PROTAC-based technologies for targeted protein degradation are indeed an active area of research in drug development. However, without additional context on the specific compound and its research results mentioned in statement 5, its accuracy cannot be confirmed; thus, it is marked as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "vicuna-7b_response": "The algorithm for prediction of protein subcellular localization using deep learning is called \"Protein Subcellular Localization Prediction using Deep Learning\" (PSL). It is a comprehensive system that integrates protein sequence-derived data and text-based information. The system is trained on three large datasets that were previously used by leading prediction methods and has been tested on a wide range of eukaryotic subcellular localizations. The results demonstrate that the PSL system performs significantly better than previously reported results.",
    "vicuna-7b_fact_raw": "1. An algorithm for prediction of protein subcellular localization using deep learning is known as \"Protein Subcellular Localization Prediction using Deep Learning\" (PSL).\n2. The PSL system integrates protein sequence-derived data with text-based information.\n3. The PSL system was trained on three large datasets previously used by leading prediction methods.\n4. The PSL system has been tested on a wide range of eukaryotic subcellular localizations.\n5. The results of the PSL system outperform previously reported results for protein subcellular localization prediction.",
    "vicuna-7b_fact": [
      "An algorithm for prediction of protein subcellular localization using deep learning is known as \"Protein Subcellular Localization Prediction using Deep Learning\" (PSL).",
      "The PSL system integrates protein sequence-derived data with text-based information.",
      "The PSL system was trained on three large datasets previously used by leading prediction methods.",
      "The PSL system has been tested on a wide range of eukaryotic subcellular localizations.",
      "The results of the PSL system outperform previously reported results for protein subcellular localization prediction."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage or additional scholarly resources to reference these particular statements about the \"Protein Subcellular Localization Prediction using Deep Learning\" (PSL) system, I cannot verify the accuracy of the statements provided.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "vicuna-7b_response": "MULTOVL is an application suite that detects and statistically analyzes multiple overlaps of genomic regions. It is designed to perform this task in a fast and efficient manner, and it supports the detection of multiple region intersections, unions, and \"solitary\" genomic regions. The significance of the observed overlaps is estimated by comparing them with empirical null distributions generated by random shuffling of the input regions. This allows for the determination of the likelihood that the observed overlaps are due to chance, rather than being a result of a real genetic interaction.",
    "vicuna-7b_fact_raw": "1. MULTOVL is an application suite that detects and analyzes multiple overlaps of genomic regions.\n2. The application is designed for fast and efficient performance.\n3. It supports the detection of multiple region intersections and unions, as well as solitary genomic regions.\n4. MULTOVL estimates the significance of overlaps by comparing them with empirical null distributions from randomly shuffled input regions.\n5. The tool helps determine whether observed overlaps are likely to be due to chance or real genetic interaction.",
    "vicuna-7b_fact": [
      "MULTOVL is an application suite that detects and analyzes multiple overlaps of genomic regions.",
      "The application is designed for fast and efficient performance.",
      "It supports the detection of multiple region intersections and unions, as well as solitary genomic regions.",
      "MULTOVL estimates the significance of overlaps by comparing them with empirical null distributions from randomly shuffled input regions.",
      "The tool helps determine whether observed overlaps are likely to be due to chance or real genetic interaction."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "vicuna-7b_response": "Based on the information provided, it appears that GDF15 may be a biomarker for metformin treatment. Specifically, the SUMMIT cohort study found that GDF15 levels increased by 40% in participants with diabetes who were receiving metformin treatment, and this increase was independent of other major factors. Additionally, the study suggests that the protective cardiovascular effects of metformin may be partly explained by the relatively high bioavailability of GDF15. However, it is important to note that this is based on a single study and further research is needed to confirm the relationship between GDF15 and metformin treatment.",
    "vicuna-7b_fact_raw": "1. GDF15 levels increased by 40% in participants with diabetes who were receiving metformin treatment according to the SUMMIT cohort study.\n2. The increase in GDF15 levels in patients on metformin treatment was independent of other major factors.\n3. The SUMMIT cohort study suggests that metformin's protective cardiovascular effects may be partly due to the bioavailability of GDF15.\n4. The information about GDF15 being a biomarker for metformin treatment is based on a single study.\n5. Further research is needed to confirm the relationship between GDF15 and metformin treatment.",
    "vicuna-7b_fact": [
      "GDF15 levels increased by 40% in participants with diabetes who were receiving metformin treatment according to the SUMMIT cohort study.",
      "The increase in GDF15 levels in patients on metformin treatment was independent of other major factors.",
      "The SUMMIT cohort study suggests that metformin's protective cardiovascular effects may be partly due to the bioavailability of GDF15.",
      "The information about GDF15 being a biomarker for metformin treatment is based on a single study.",
      "Further research is needed to confirm the relationship between GDF15 and metformin treatment."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The statement cannot be verified as true or false because it claims that the information is based on a single study without specifying whether other studies on this matter exist. There may be other studies that have also looked into GDF15 as a biomarker for metformin treatment.\n5. TRUE",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "vicuna-7b_response": "Based on the information provided in Document-0, recursive splicing is a process by which a single intron is removed from pre-mRNA transcripts in multiple distinct segments. It has been observed in a small subset of Drosophila melanogaster introns, but detection of recursive splicing requires observation of splicing intermediates that are inherently unstable, making it difficult to study.\nThe study used computational approaches to identify recursively spliced introns and applied them to nascent RNA sequencing data from Drosophila S2 cells. These approaches identified hundreds of novel sites of recursive splicing, expanding the catalog of recursively spliced fly introns by 4-fold. A subset of the recursive sites were validated by RT-PCR and sequencing.\nThe study found that recursive splicing occurs in most very long (> 40 kb) fly introns, including many genes involved in morphogenesis and development, and tends to occur near the midpoints of introns. Additionally, the study suggests a possible function for recursive splicing, observing that fly introns with recursive sites are spliced more accurately than comparably sized non-recursive introns.\nIn summary, the information provided in Document-0 suggests that recursive splicing is more common in short introns, specifically in very long introns (> 40 kb) and that it tends to occur near the midpoints of introns. Additionally, the study suggests a possible function for recursive splicing, observing that fly introns with recursive sites are spliced more accurately than comparably sized non-recursive introns.",
    "vicuna-7b_fact_raw": "1. Recursive splicing is a process where a single intron is removed from pre-mRNA transcripts in multiple distinct segments.\n2. Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.\n3. The study identified a 4-fold increase in the catalog of recursively spliced fly introns using computational approaches and nascent RNA sequencing data.\n4. Recursive splicing most commonly occurs in very long fly introns that are greater than 40 kilobases (kb) in length.\n5. Fly introns with recursive sites tend to be spliced more accurately than comparably sized non-recursive introns.",
    "vicuna-7b_fact": [
      "Recursive splicing is a process where a single intron is removed from pre-mRNA transcripts in multiple distinct segments.",
      "Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.",
      "The study identified a 4-fold increase in the catalog of recursively spliced fly introns using computational approaches and nascent RNA sequencing data.",
      "Recursive splicing most commonly occurs in very long fly introns that are greater than 40 kilobases (kb) in length.",
      "Fly introns with recursive sites tend to be spliced more accurately than comparably sized non-recursive introns."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE \n5. UNKNOWN\n\nWhile the first two statements about recursive splicing are accurate descriptions of the process, and the fourth statement about the common occurrence in long introns is true (as very long introns often require such complex splicing mechanisms), the third and fifth statements cannot be validated or refuted without specific details of the study referenced and an understanding of splice accuracy between recursive and non-recursive introns, which are not provided here.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "vicuna-7b_response": "The TALE-iD method is used for genome editing and gene regulation applications. It is a liquid phase high-throughput TALE synthesis platform that can produce TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 bp. The platform features a highly efficient reaction scheme, a flexible functionalization platform, and fully automated robotic liquid handling that enable the production of hundreds of expression-ready TALEs within a single day with over 98% assembly efficiency at a material cost of just $5 per TALE. The platform has been used to synthesize and test 90 TALEs, each recognizing 27 bp, without restrictions on their sequence composition. 96% of these TALEs were found to be functional, while sequencing confirmation revealed that the nonfunctional constructs were all correctly assembled.",
    "vicuna-7b_fact_raw": "1. The TALE-iD method is used for genome editing and gene regulation.\n2. It can produce TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 base pairs (bp).\n3. The TALE-iD method can produce hundreds of expression-ready TALEs within a single day.\n4. The assembly efficiency of the TALE-iD method is over 98%.\n5. The material cost for producing a TALE using TALE-iD method is approximately $5.",
    "vicuna-7b_fact": [
      "The TALE-iD method is used for genome editing and gene regulation.",
      "It can produce TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 base pairs (bp).",
      "The TALE-iD method can produce hundreds of expression-ready TALEs within a single day.",
      "The assembly efficiency of the TALE-iD method is over 98%.",
      "The material cost for producing a TALE using TALE-iD method is approximately $5."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: TALEs (Transcription Activator-Like Effectors) can indeed be used for genome editing and gene regulation.\n2. TRUE: TALE nucleases, activators, and repressors can recognize specific DNA sequences, and these sequences are often within the range of 14 to 31 base pairs long.\n3. UNKNOWN: The exact number of TALEs that can be produced within a single day can vary based on the specific method and technology used, and this statement does not provide enough detail to confirm its accuracy.\n4. UNKNOWN: The assembly efficiency rate of over 98% for the TALE-iD method is a specific claim that requires empirical data to confirm, and the statement does not provide such data.\n5. FALSE [correction]: The material cost for producing a single TALE can vary widely depending on a multitude of factors such as the complexity of the TALE, the reagents used, and the method of production. It is unlikely that there is a fixed cost of approximately $5 for all TALEs produced using the TALE-iD method. This statement likely requires more context to accurately determine the cost.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "vicuna-7b_response": "The Lisp framework for image processing that has been developed is FunImageJ. It is built upon the ImageJ software ecosystem and provides a natural functional-style for programming while accounting for the performance requirements necessary in big data processing commonly encountered in biological image analysis. It is a freely available plugin to Fiji and can be installed and used following the instructions available at http://imagej.net/FunImageJ. The developer of the framework is Kevin Harrington and the supplementary data can be found at Bioinformatics online.",
    "vicuna-7b_fact_raw": "1. FunImageJ is a Lisp framework developed for image processing.\n2. FunImageJ is built upon the ImageJ software ecosystem.\n3. FunImageJ is designed for biological image analysis.\n4. The framework is available as a plugin to Fiji.\n5. Kevin Harrington is the developer of FunImageJ.",
    "vicuna-7b_fact": [
      "FunImageJ is a Lisp framework developed for image processing.",
      "FunImageJ is built upon the ImageJ software ecosystem.",
      "FunImageJ is designed for biological image analysis.",
      "The framework is available as a plugin to Fiji.",
      "Kevin Harrington is the developer of FunImageJ."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Curtis Rueden is likely the person you are referring to as a key developer of Fiji, and it is unclear who developed FunImageJ as it could be a collective effort of a research group or community. Kevin Eliceiri is a known figure in biological imaging and was involved in the development of ImageJ and Fiji.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "vicuna-7b_response": "The ancient whole genome duplication in S. cerevisiae resulted in the duplication of approximately 85% of the genes, with most of these duplicates being lost before speciation. Only a small amount of paralogous gene loss occurred after speciation. S. cerevisiae likely lost several hundred genes that were not retained as duplicated paralogs, which could be related to genomic rearrangements that reduced the number of chromosomes from 16 to 9. Other Saccharomyces sensu lato species likely diverged from S. cerevisiae after the duplication, and a thorough analysis of these species will likely reveal other important outcomes of the whole genome duplication.",
    "vicuna-7b_fact_raw": "1. The ancient whole genome duplication in S. cerevisiae involved the duplication of approximately 85% of its genes.\n2. Most of the gene duplicates in S. cerevisiae were lost before speciation.\n3. Only a small amount of paralogous gene loss in S. cerevisiae occurred after speciation.\n4. S. cerevisiae is suggested to have lost several hundred genes that were not retained as duplicated paralogs.\n5. The ancient whole genome duplication event is suggested to have reduced the number of chromosomes from 16 to 9 in S. cerevisiae.",
    "vicuna-7b_fact": [
      "The ancient whole genome duplication in S. cerevisiae involved the duplication of approximately 85% of its genes.",
      "Most of the gene duplicates in S. cerevisiae were lost before speciation.",
      "Only a small amount of paralogous gene loss in S. cerevisiae occurred after speciation.",
      "S. cerevisiae is suggested to have lost several hundred genes that were not retained as duplicated paralogs.",
      "The ancient whole genome duplication event is suggested to have reduced the number of chromosomes from 16 to 9 in S. cerevisiae."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The ancient whole genome duplication (WGD) in Saccharomyces cerevisiae is not known to involve the duplication of an exact percentage of its genes, but it did involve the duplication of the entire genome.\n2. TRUE\n3. FALSE [correction]: Substantial paralogous gene loss in Saccharomyces cerevisiae occurred after speciation, affecting gene balance and leading to the retention of some duplicates.\n4. TRUE\n5. FALSE [correction]: The ancient whole genome duplication event is suggested to have increased the number of chromosomes at the time of the event. S. cerevisiae currently has 16 chromosomes, which likely resulted from rediploidization and rearrangements following the WGD event, not a reduction to 9.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "vicuna-7b_response": "The complex bound by estrogen-related receptor  (Esrrb) is estradiol-pyridine tetra acetate europium(III). This information is based on the detailed 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) bound with this estradiol-derived metal complex, which was reported in Document-0. The structure was determined at 2.6  resolution and provides important information for the design of novel functional ER targeted probes for clinical applications.",
    "vicuna-7b_fact_raw": "1. Estrogen-related receptor  (Esrrb) is bound by the complex estradiol-pyridine tetra acetate europium(III).\n2. The 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) bound with estradiol-pyridine tetra acetate europium(III) was reported in Document-0.\n3. The structure of the ER-LBD bound with estradiol-pyridine tetra acetate europium(III) was determined at a resolution of 2.6 .\n4. The information about the structure is used for the design of novel functional ER targeted probes for clinical applications.",
    "vicuna-7b_fact": [
      "Estrogen-related receptor  (Esrrb) is bound by the complex estradiol-pyridine tetra acetate europium(III).",
      "The 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) bound with estradiol-pyridine tetra acetate europium(III) was reported in Document-0.",
      "The structure of the ER-LBD bound with estradiol-pyridine tetra acetate europium(III) was determined at a resolution of 2.6 .",
      "The information about the structure is used for the design of novel functional ER targeted probes for clinical applications."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n\nThe determination of the truthfulness of the technical statements (1, 2, and 3) about the specific binding of Esrrb and the reporting of the 3D structure at a particular resolution would require access to the mentioned \"Document-0\" or other specific scientific literature to verify the claims. Since no such data has been provided and these details are very specific, their truth cannot be ascertained without access to the source.\n\nStatement 4 is a general statement regarding the use of structural information in drug design and probe development, which is a common practice in biochemical and pharmaceutical research. Therefore, it is reasonably true that the information about the structure of ER-LBD bound with a particular ligand would be used for the design of novel functional estrogen receptor-targeted probes for clinical applications. However, it's important to note that the specific application to \"clinical applications\" can vary widely and the direct use of this particular structure is not guaranteed without further context.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "vicuna-7b_response": "ZCCHC17 is a human nuclear protein that is similar to the yeast protein ZCCHC9. ZCCHC9 is a subunit of the Trf4/Air2/Mtr4 polyadenylation (TRAMP) complex, which is involved in nuclear RNA quality control and degradation in yeast. ZCCHC17 also contains four retroviral-type zinc knuckle motifs and is thought to play a role in RNA quality control in human. The NMR spectral assignment of the zinc knuckle region of ZCCHC17 will allow for further study of its structure and RNA-binding properties. The goal of this study is to investigate the role of ZCCHC17 in human RNA quality control.",
    "vicuna-7b_fact_raw": "1. ZCCHC17 is a human nuclear protein.\n2. ZCCHC17 has a similarity to the yeast protein ZCCHC9.\n3. ZCCHC9 is a subunit of the Trf4/Air2/Mtr4 polyadenylation (TRAMP) complex in yeast.\n4. ZCCHC17 contains four retroviral-type zinc knuckle motifs.\n5. The role of ZCCHC17 is thought to be connected to RNA quality control in humans.",
    "vicuna-7b_fact": [
      "ZCCHC17 is a human nuclear protein.",
      "ZCCHC17 has a similarity to the yeast protein ZCCHC9.",
      "ZCCHC9 is a subunit of the Trf4/Air2/Mtr4 polyadenylation (TRAMP) complex in yeast.",
      "ZCCHC17 contains four retroviral-type zinc knuckle motifs.",
      "The role of ZCCHC17 is thought to be connected to RNA quality control in humans."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ZCCHC17 has a similarity to the yeast protein ZCCHC8.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "vicuna-7b_response": "The proteins that form the nuclear pore basket in human cells are nucleoporins. Nucleoporins are a group of proteins that make up the nuclear pore complex, which is responsible for regulating the transport of molecules between the nucleus and the cytoplasm. The nuclear pore complex is composed of around 30 different proteins, each present at the pore in multiple copies. These proteins work together to create specialized channels that allow for the transport of cargo between the nucleus and the cytoplasm.\nIn the given document, the authors have identified the building blocks of nuclear pores and are studying the assembly process of these proteins into macromolecular pore structures. They have found that many nucleoporins are mislocalized and reduced in level when two pore-associated small ubiquitin-like modifier (SUMO) proteases, SENP1 and SENP2, are codepleted. The results of this study reveal a new role for the pore-associated SENPs in nucleoporin homeostasis and in achieving proper configuration of the nuclear pore complex.",
    "vicuna-7b_fact_raw": "1. Nucleoporins form the nuclear pore basket in human cells.\n2. The nuclear pore complex regulates the transport of molecules between the nucleus and the cytoplasm.\n3. The nuclear pore complex is composed of around 30 different proteins.\n4. The nuclear pore complex proteins create specialized channels that allow transport of cargo between the nucleus and the cytoplasm.\n5. The study mentioned reveals that small ubiquitin-like modifier (SUMO) proteases, SENP1 and SENP2, are involved in nucleoporin homeostasis and proper configuration of the nuclear pore complex.",
    "vicuna-7b_fact": [
      "Nucleoporins form the nuclear pore basket in human cells.",
      "The nuclear pore complex regulates the transport of molecules between the nucleus and the cytoplasm.",
      "The nuclear pore complex is composed of around 30 different proteins.",
      "The nuclear pore complex proteins create specialized channels that allow transport of cargo between the nucleus and the cytoplasm.",
      "The study mentioned reveals that small ubiquitin-like modifier (SUMO) proteases, SENP1 and SENP2, are involved in nucleoporin homeostasis and proper configuration of the nuclear pore complex."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Nucleoporins are the proteins that make up the nuclear pore complex (NPC); however, the nuclear pore basket is a specific structure formed by a subset of nucleoporins called the FG-nucleoporins, not by all nucleoporins.\n2. TRUE\n3. FALSE [correction]: The nuclear pore complex is composed of around 30 distinct protein types, but overall there are approximately 1,000 proteins that make up the entire complex due to multiple copies of each type.\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "vicuna-7b_response": "Gepotidacin is a type IIA topoisomerase inhibitor. It is an antibacterial agent that is effective against many biothreat and conventional pathogens, including Neisseria gonorrhoeae. Gepotidacin works by inhibiting the activity of bacterial topoisomerase enzymes, which are essential for bacterial DNA replication and repair. The reference organism quality control MIC range for gepotidacin is 0.25 to 1 /ml, with 88.8% of MIC results falling within this range when tested at a concentration of 0.5 /ml.",
    "vicuna-7b_fact_raw": "1. Gepotidacin is a type IIA topoisomerase inhibitor.\n2. It is effective against biothreat and conventional pathogens including Neisseria gonorrhoeae.\n3. Gepotidacin inhibits the activity of bacterial topoisomerase enzymes.\n4. The reference organism quality control MIC range for gepotidacin is 0.25 to 1 g/ml.\n5. 88.8% of MIC results fall within the reference range when tested at a concentration of 0.5 g/ml.",
    "vicuna-7b_fact": [
      "Gepotidacin is a type IIA topoisomerase inhibitor.",
      "It is effective against biothreat and conventional pathogens including Neisseria gonorrhoeae.",
      "Gepotidacin inhibits the activity of bacterial topoisomerase enzymes.",
      "The reference organism quality control MIC range for gepotidacin is 0.25 to 1 g/ml.",
      "88.8% of MIC results fall within the reference range when tested at a concentration of 0.5 g/ml."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "vicuna-7b_response": "Canvas SPW is a new tool developed by Illumina for the identification of inherited and de novo copy number variants from pedigree sequencing data. It supports various family structures and provides a range of scoring and filtering options to automate and streamline the identification of de novo variants. Canvas SPW is available for download from GitHub and can be contacted at sivakhno@illumina.com. Supplementary data are available at Bioinformatics online.",
    "vicuna-7b_fact_raw": "1. Canvas SPW is a tool developed by Illumina.\n2. The tool is designed for the identification of inherited and de novo copy number variants from pedigree sequencing data.\n3. Canvas SPW supports various family structures.\n4. Canvas SPW offers scoring and filtering options to identify de novo variants.\n5. Canvas SPW is available for download from GitHub.",
    "vicuna-7b_fact": [
      "Canvas SPW is a tool developed by Illumina.",
      "The tool is designed for the identification of inherited and de novo copy number variants from pedigree sequencing data.",
      "Canvas SPW supports various family structures.",
      "Canvas SPW offers scoring and filtering options to identify de novo variants.",
      "Canvas SPW is available for download from GitHub."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Canvas SPW, also known as Canvas is a tool developed by Microsoft, not Illumina.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "vicuna-7b_response": "STING agonists are a class of drugs that are used to treat conditions such as pain, inflammation, and autoimmune disorders. They work by binding to specific receptors on cells and activating intracellular signaling pathways, leading to the release of chemical messengers that influence the body's immune and inflammatory responses.\nIn the case of the patient described in Document-0, the sting from a Great Weever fish (Echiichthys spp.) resulted in severe pain, swelling, and numbness in the affected region. The patient also developed Raynaud's phenomenon, a condition characterized by the constriction of blood vessels in the affected area, leading to a white or blue discoloration and numbness.\nThere is no specific antidote for Great Weever fish venom, and treatment is mainly supportive and focused on managing symptoms. This may include pain relief medications, anti-inflammatory drugs, and wound care. In some cases, patients may be prescribed STING agonists to help manage pain and inflammation.\nIt is important to note that the patient's symptoms persisted for several months, indicating that the effects of the venom may be long-lasting. Patients who have been stung by a Great Weever fish should be informed of this and should seek medical attention if their symptoms worsen or persist.",
    "vicuna-7b_fact_raw": "1. STING agonists are used to treat pain, inflammation, and autoimmune disorders.\n2. STING agonists work by activating intracellular signaling pathways.\n3. Raynaud's phenomenon is characterized by the constriction of blood vessels leading to discoloration and numbness.\n4. There is no specific antidote for Great Weever fish venom.\n5. The effects of the venom from a Great Weever fish sting may be long-lasting.",
    "vicuna-7b_fact": [
      "STING agonists are used to treat pain, inflammation, and autoimmune disorders.",
      "STING agonists work by activating intracellular signaling pathways.",
      "Raynaud's phenomenon is characterized by the constriction of blood vessels leading to discoloration and numbness.",
      "There is no specific antidote for Great Weever fish venom.",
      "The effects of the venom from a Great Weever fish sting may be long-lasting."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: STING (STimulator of INterferon Genes) agonists are primarily investigated for their role in activating the immune response, particularly in the context of cancer therapy, not specifically for treating pain, inflammation, and autoimmune disorders.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "vicuna-7b_response": "SLIC-CAGE is a dosimetric technique used in radiotherapy to measure the dose delivered to the patient. It involves the use of a scanning liquid-filled ionization chamber (SLIC) electronic portal imaging device. The SLIC is placed in the path of the radiation beam and measures the dose delivered to the patient. The dosimetric characteristics of the SLIC have been investigated, and it has been found that the response of the imaging system is dependent on the incident radiation intensity and can be described to within 1% accuracy on central axis using a square root function.\nThe SLIC is capable of measuring the portal (transmission) dose to within 3% of the ionization chamber results for homogeneous material. For two-dimensional dosimetry applications, the system is calibrated with a 10 cm Perspex block used as beam flattening material on the detector cassette to correct for variations in individual ion chamber sensitivity and the effect of nonuniform beam profiles produced by the flattening filter. Open and wedged dose profiles measured with the SLIC agreed with ion chamber measured profiles to within 3.5% accuracy.\nIn summary, SLIC-CAGE is a dosimetric technique that uses a scanning liquid-filled ionization chamber to measure the dose delivered to the patient in radiotherapy. It has been found that the response of the imaging system is dependent on the incident radiation intensity and can be described to within 1% accuracy on central axis using a square root function. The system is calibrated to correct for variations in individual ion chamber sensitivity and the effect of nonuniform beam profiles produced by the flattening filter, and the results agree with ion chamber measured profiles to within 3.5% accuracy.",
    "vicuna-7b_fact_raw": "1. SLIC-CAGE is a dosimetric technique for measuring the dose delivered to a patient during radiotherapy.\n2. The technique involves the use of a scanning liquid-filled ionization chamber (SLIC) electronic portal imaging device.\n3. The response of the SLIC can be described within 1% accuracy on the central axis using a square root function.\n4. The system's calibration involves using a 10 cm Perspex block to correct for individual ion chamber sensitivity and nonuniform beam profiles.\n5. The SLIC's measured dose profiles agree with ion chamber measured profiles to within 3.5% accuracy.",
    "vicuna-7b_fact": [
      "SLIC-CAGE is a dosimetric technique for measuring the dose delivered to a patient during radiotherapy.",
      "The technique involves the use of a scanning liquid-filled ionization chamber (SLIC) electronic portal imaging device.",
      "The response of the SLIC can be described within 1% accuracy on the central axis using a square root function.",
      "The system's calibration involves using a 10 cm Perspex block to correct for individual ion chamber sensitivity and nonuniform beam profiles.",
      "The SLIC's measured dose profiles agree with ion chamber measured profiles to within 3.5% accuracy."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The statements about the SLIC-CAGE technique's specific calibration processes, response descriptions, and accuracy comparisons with ion chamber profiles require specialized knowledge in the field of medical physics and dosimetry, particularly information that is not commonly known or easily verifiable without access to specific research or technical documents. Therefore, without the relevant context or source material, it is not possible to verify statements 3, 4, and 5.]",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "vicuna-7b_response": "The roles of LEM-3 in AcMNPV infection are not specified in the given information. However, based on the information provided, we can infer that LEM-3 is an essential protein for DNA replication in transient assays. It is also known that P143, a large DNA-binding protein with DNA-unwinding activity, is essential for viral DNA replication in vivo. Both LEF-3 and P143 are found in the nucleus of AcMNPV-infected cells, but only LEF-3 localizes to the nucleus when expressed in transfected cells on its own from a plasmid expression vector. P143 requires LEF-3 as a transporter to enter the nucleus.\nThe study also suggests that the N-terminal 56 amino acid residues of LEF-3 are sufficient for nuclear localization and that this domain, when fused with either the green fluorescent protein reporter gene or P143, is able to direct these proteins to the nucleus. However, it is not clear if this is the only role of LEF-3 or if it performs other essential replication functions once inside the nucleus.\nIn summary, LEM-3 is an essential protein for DNA replication in transient assays, and it is also known to be involved in transporting P143 to the nucleus. However, the exact role of LEM-3 in AcMNPV infection is not specified in the given information.",
    "vicuna-7b_fact_raw": "1. LEM-3 is an essential protein for DNA replication in transient assays.\n2. P143 is a large DNA-binding protein with DNA-unwinding activity that is essential for viral DNA replication in vivo.\n3. Both LEF-3 and P143 are found in the nucleus of AcMNPV-infected cells.\n4. LEF-3 localizes to the nucleus when expressed in transfected cells from a plasmid expression vector on its own.\n5. The N-terminal 56 amino acid residues of LEF-3 are sufficient for nuclear localization.",
    "vicuna-7b_fact": [
      "LEM-3 is an essential protein for DNA replication in transient assays.",
      "P143 is a large DNA-binding protein with DNA-unwinding activity that is essential for viral DNA replication in vivo.",
      "Both LEF-3 and P143 are found in the nucleus of AcMNPV-infected cells.",
      "LEF-3 localizes to the nucleus when expressed in transfected cells from a plasmid expression vector on its own.",
      "The N-terminal 56 amino acid residues of LEF-3 are sufficient for nuclear localization."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nRationale:\n1. The statement might be true in the context of a specific scientific study, but without the context of the study or experimental data, it's not possible to confirm its accuracy.\n2. P143 being a large DNA-binding protein with DNA-unwinding activity, essential for viral DNA replication in vivo, is a very specific claim that requires knowledge of the particular protein and the context within which it operates.\n3. The localization of LEF-3 and P143 in AcMNPV-infected cells requires specific experimental evidence.\n4. This statement is presented as a factual claim likely based on experimental evidence. It is specific and affirmative, suggesting it could be validated in the literature.\n5. The specificity of the amino acid residue requirement for nuclear localization suggests that it's based on experimental evidence. Statements like this are typically well-studied and documented, so it's likely to be true. However, without direct evidence or citation, it is impossible to verify.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "vicuna-7b_response": "The releases of tmVar are not mentioned in the provided information.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "vicuna-7b_response": "The database of somatic mutations in normal cells is NA12878 genome. This genome has been well-characterized with publicly available high-confidence genotype calls, and biological and technological noises can be computationally generalized to the number of sub-clones, the VAFs, the sequencing and mapping qualities. The database consists of 135 simulated tumors from 5 pre-tumors/normals, which vary in sequencing and subsequent mapping error profiles, read length, the number of sub-clones, the VAF, the mutation frequency across the genome and the genomic context. This database can be used to benchmark somatic small variant callers and guide their improvement.",
    "vicuna-7b_fact_raw": "1. The NA12878 genome is a database of somatic mutations in normal cells.\n2. The NA12878 genome includes publicly available high-confidence genotype calls.\n3. The database simulates 135 tumors from 5 pre-tumors/normals.\n4. Variations in the database include sequencing and mapping error profiles, read length, the number of sub-clones, the VAF, and the mutation frequency across the genome.\n5. The NA12878 genome database is used to benchmark somatic small variant callers and guide their improvement.",
    "vicuna-7b_fact": [
      "The NA12878 genome is a database of somatic mutations in normal cells.",
      "The NA12878 genome includes publicly available high-confidence genotype calls.",
      "The database simulates 135 tumors from 5 pre-tumors/normals.",
      "Variations in the database include sequencing and mapping error profiles, read length, the number of sub-clones, the VAF, and the mutation frequency across the genome.",
      "The NA12878 genome database is used to benchmark somatic small variant callers and guide their improvement."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The NA12878 genome is not a database of somatic mutations in normal cells; it is actually a highly studied human reference genome from a female donor that is part of the 1000 Genomes Project and is often used for benchmarking and evaluating the performance of sequencing technologies and bioinformatics pipelines.\n2. TRUE\n3. FALSE [correction]: The statement appears to be confusing the NA12878 genome with a database designed to simulate tumors. The NA12878 genome itself is a reference sample and does not simulate tumors.\n4. FALSE [correction]: This statement seems to refer to the characteristics of a database that simulates tumors, which is not what the NA12878 genome is. In reference to the NA12878, variations characterized would typically be germline variants, not somatic mutations, and would not include these listed specific features of simulated tumors.\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "vicuna-7b_response": "Yes, there are several graph kernel libraries available implemented in Java. Some popular ones include:\n1. JDK8's Graph API: Java 8 introduced a built-in Graph API, which provides a set of classes for working with graphs. The API includes methods for creating and manipulating graph data structures, as well as algorithms for computing graph kernels.\n2. JUNG: JUNG is a popular Java library for working with graphs. It provides a set of classes for creating and manipulating graph data structures, as well as algorithms for computing graph kernels. JUNG also includes support for various graph kernels, such as the random walk kernel and the shortest path kernel.\n3. igraph: igraph is a popular C library for working with graphs. It provides a set of functions for creating and manipulating graph data structures, as well as algorithms for computing graph kernels. igraph also includes support for various graph kernels, such as the random walk kernel and the shortest path kernel.\nAll of these libraries can be used to compute graph kernels in Java, and can be integrated with other Java-based machine learning libraries, such as Weka or Deeplearning4j.",
    "vicuna-7b_fact_raw": "1. Java 8 includes a built-in Graph API that allows for the creation and manipulation of graph data structures and computing graph kernels.\n2. JUNG is a Java library that provides classes for creating, manipulating graph data structures, and computing graph kernels.\n3. JUNG supports various graph kernels, including the random walk kernel and the shortest path kernel.\n4. Igraph is a C library for graph manipulation and computation that also includes support for various graph kernels.\n5. The igraph library's functionality can be utilized in Java applications.",
    "vicuna-7b_fact": [
      "Java 8 includes a built-in Graph API that allows for the creation and manipulation of graph data structures and computing graph kernels.",
      "JUNG is a Java library that provides classes for creating, manipulating graph data structures, and computing graph kernels.",
      "JUNG supports various graph kernels, including the random walk kernel and the shortest path kernel.",
      "Igraph is a C library for graph manipulation and computation that also includes support for various graph kernels.",
      "The igraph library's functionality can be utilized in Java applications."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Java 8 does not include a built-in Graph API. It includes features such as lambda expressions and a new Date and Time API, but not a specific Graph API.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE [note]: While igraph is primarily a C library, it does have interfaces for other languages, including R and Python. Java applications can use the igraph functionality through these language interfaces or by employing native calls to the C library. However, it is more common for Java applications to use Java libraries such as JUNG for graph-related tasks. So, while it's technically true, it may not be trivial to utilize igraph directly from Java.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "vicuna-7b_response": "The four advances integrated into the SHERLOCKv2 platform are:\n1. Four-channel single-reaction multiplexing with orthogonal CRISPR enzymes: This feature allows for the simultaneous detection of multiple targets in a single reaction, using different CRISPR enzymes.\n2. Quantitative measurement of input as low as 2 attomolar: SHERLOCKv2 can detect very low concentrations of nucleic acids, making it suitable for a wide range of diagnostic and biotechnological applications.\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6: This enhancement in sensitivity allows for the detection of even low concentrations of nucleic acids.\n4. Lateral-flow readout: SHERLOCKv2 can be used for rapid and portable detection of nucleic acids using lateral-flow technology, making it suitable for point-of-care testing. The platform has been shown to be capable of detecting Dengue or Zika virus single-stranded RNA as well as mutations in patient liquid biopsy samples.",
    "vicuna-7b_fact_raw": "1. SHERLOCKv2 integrates four-channel single-reaction multiplexing with orthogonal CRISPR enzymes for simultaneous detection of multiple targets.\n2. SHERLOCKv2 has the capability to quantitatively measure input concentrations as low as 2 attomolar.\n3. The platform combines Cas13 with Csm6 for a 3.5-fold increase in signal sensitivity.\n4. SHERLOCKv2 uses lateral-flow readout for rapid and portable nucleic acid detection.\n5. The platform can detect single-stranded RNA from viruses such as Dengue or Zika and mutations in patient liquid biopsy samples.",
    "vicuna-7b_fact": [
      "SHERLOCKv2 integrates four-channel single-reaction multiplexing with orthogonal CRISPR enzymes for simultaneous detection of multiple targets.",
      "SHERLOCKv2 has the capability to quantitatively measure input concentrations as low as 2 attomolar.",
      "The platform combines Cas13 with Csm6 for a 3.5-fold increase in signal sensitivity.",
      "SHERLOCKv2 uses lateral-flow readout for rapid and portable nucleic acid detection.",
      "The platform can detect single-stranded RNA from viruses such as Dengue or Zika and mutations in patient liquid biopsy samples."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nSHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) version 2 is an improved version of the original SHERLOCK platform, which leverages CRISPR technology for the detection of nucleic acid sequences. The statements provided are in line with the capabilities of SHERLOCKv2, integrating multiplexing with CRISPR enzymes, quantitative measurement capabilities, increased signal sensitivity, and lateral-flow readout for portability, as well as the ability to detect single-stranded RNA from viruses and mutations in liquid biopsy samples.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "vicuna-7b_response": "The Bartender algorithm is a novel approach to the cocktail party problem that uses a cortronic artificial neural network architecture as the front end of a speech processing system. The algorithm is designed to provide preprocessing for a pattern recognition system, rather than separating one or more of the mixed sources explicitly. The neural network model employed in the algorithm is more biologically feasible than most other approaches to the cocktail party problem. The algorithm was developed using a detailed knowledge of the signals in the cocktail party environment and can be applied to other areas of information processing.",
    "vicuna-7b_fact_raw": "1. The Bartender algorithm is an approach to the cocktail party problem.\n2. It uses a cortronic artificial neural network architecture for speech processing.\n3. The Bartender algorithm provides preprocessing for a pattern recognition system.\n4. The neural network model used in the Bartender algorithm is considered more biologically feasible than most others for the cocktail party problem.\n5. The algorithm was developed with detailed knowledge of the signals in cocktail party environments.",
    "vicuna-7b_fact": [
      "The Bartender algorithm is an approach to the cocktail party problem.",
      "It uses a cortronic artificial neural network architecture for speech processing.",
      "The Bartender algorithm provides preprocessing for a pattern recognition system.",
      "The neural network model used in the Bartender algorithm is considered more biologically feasible than most others for the cocktail party problem.",
      "The algorithm was developed with detailed knowledge of the signals in cocktail party environments."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided refer to a specific algorithm named the \"Bartender algorithm\". Without additional context or widely-recognized information regarding this algorithm, its functions, or its development, it is not possible to determine the truthfulness of the given statements. If the \"Bartender algorithm\" is a proprietary, theoretical, or less well-known concept in speech processing or machine learning, information may not be readily available to confirm or refute these assertions.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "vicuna-7b_response": "There are several web-based pedigree editors available, including:\n1. Pedigreejs: This is an interactive graphical pedigree editor written in JavaScript that uses standard pedigree nomenclature. It provides an easily configurable, extensible, and lightweight pedigree editor that makes use of an open-source Javascript library to define a hierarchical layout and to produce images in scalable vector graphics (SVG) format that can be viewed and edited in web browsers. The software is freely available under the GPL license (<https://ccge-boadicea.github.io/pedigreejs/>).\n2. GenomeWeb's Pedigree Viewer: This is a web-based tool that allows users to view and edit pedigree data in a graphical format. It supports a variety of pedigree types and can be customized to meet specific needs.\n3. Genome Mate Pro: This is a desktop application that allows users to create and edit pedigree charts. It also provides a web-based pedigree viewer that can be accessed from a web browser.\n4. Family Tree Builder: This is a desktop application that allows users to create and edit pedigree charts. It also provides a web-based pedigree viewer that can be accessed from a web browser.\nThese are just a few examples of web-based pedigree editors available. It is important to note that the availability and features of these tools may vary, and users should carefully evaluate their needs before selecting a particular tool.",
    "vicuna-7b_fact_raw": "1. Pedigreejs is an interactive graphical pedigree editor written in JavaScript.\n2. Pedigreejs uses standard pedigree nomenclature and produces images in SVG format.\n3. GenomeWeb's Pedigree Viewer is a web-based tool for viewing and editing pedigree data in a graphical format.\n4. Genome Mate Pro provides a web-based pedigree viewer accessible from a web browser.\n5. Family Tree Builder offers a web-based pedigree viewer that can be accessed from a web browser.",
    "vicuna-7b_fact": [
      "Pedigreejs is an interactive graphical pedigree editor written in JavaScript.",
      "Pedigreejs uses standard pedigree nomenclature and produces images in SVG format.",
      "GenomeWeb's Pedigree Viewer is a web-based tool for viewing and editing pedigree data in a graphical format.",
      "Genome Mate Pro provides a web-based pedigree viewer accessible from a web browser.",
      "Family Tree Builder offers a web-based pedigree viewer that can be accessed from a web browser."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll these statements seem consistent with what the programs and tools are designed to do based on their descriptions. Family Tree Builder, Genome Mate Pro, and GenomeWeb's Pedigree Viewer are all known to offer tools for viewing and editing pedigree data, often accessible online. Pedigreejs, as a JavaScript pedigree editor, is likely to match the description given; however, without specific knowledge of each tool's current features as of my knowledge cutoff date, detailed verification of each feature can't be provided.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "vicuna-7b_response": "There are several curated databases that exist for spider venom toxins. One such database is the Spider Toxin Database, which is a comprehensive resource for spider venom toxins. This database contains information on the toxins found in various species of spiders, including their chemical structure, biological activity, and other relevant information. Another database is the Scorpion Venom Database, which contains information on the venomous species of scorpions and their toxins. Additionally, the Venomous Animals Database is a comprehensive resource for venomous animals, including spiders, scorpions, and other arachnids, and contains information on the toxins produced by these animals.",
    "vicuna-7b_fact_raw": "1. The Spider Toxin Database is a resource for information on spider venom toxins.\n2. The Spider Toxin Database includes information on chemical structure and biological activity of spider toxins.\n3. The Scorpion Venom Database contains information on venomous species of scorpions and their toxins.\n4. The Venomous Animals Database is a resource that covers venomous animals including spiders, scorpions, and other arachnids.\n5. The Venomous Animals Database includes information on the toxins produced by these venomous animals.",
    "vicuna-7b_fact": [
      "The Spider Toxin Database is a resource for information on spider venom toxins.",
      "The Spider Toxin Database includes information on chemical structure and biological activity of spider toxins.",
      "The Scorpion Venom Database contains information on venomous species of scorpions and their toxins.",
      "The Venomous Animals Database is a resource that covers venomous animals including spiders, scorpions, and other arachnids.",
      "The Venomous Animals Database includes information on the toxins produced by these venomous animals."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "vicuna-7b_response": "Based on the information provided, the answer to the question \"Does Axitinib prolong survival of Pancreatic Cancer patients?\" is no. The randomized phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients, but the phase 3 trial did not show a benefit of adding axitinib to gemcitabine in terms of overall survival. In fact, the addition of axitinib to gemcitabine did not improve overall survival in advanced pancreatic cancer. It is important to note that this is just one study and further research is needed to fully understand the effectiveness of axitinib in the treatment of pancreatic cancer.",
    "vicuna-7b_fact_raw": "1. A randomized phase 2 trial suggested increased overall survival in advanced pancreatic cancer patients treated with axitinib.\n2. A subsequent phase 3 trial did not show a benefit of adding axitinib to gemcitabine in terms of overall survival for advanced pancreatic cancer patients.\n3. The addition of axitinib to gemcitabine did not improve overall survival in advanced pancreatic cancer according to the phase 3 trial results.\n4. Further research is necessary to understand the effectiveness of axitinib in the treatment of pancreatic cancer.",
    "vicuna-7b_fact": [
      "A randomized phase 2 trial suggested increased overall survival in advanced pancreatic cancer patients treated with axitinib.",
      "A subsequent phase 3 trial did not show a benefit of adding axitinib to gemcitabine in terms of overall survival for advanced pancreatic cancer patients.",
      "The addition of axitinib to gemcitabine did not improve overall survival in advanced pancreatic cancer according to the phase 3 trial results.",
      "Further research is necessary to understand the effectiveness of axitinib in the treatment of pancreatic cancer."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n\n[Without access to specific study results or scientific data and given that these statements are related to specific clinical trial outcomes, the verification of statements 1, 2, and 3 would require access to the actual trial data or publications. However, statement 4 is generally true as the field of cancer research typically requires continuous study to better understand the effectiveness of treatments.]",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "vicuna-7b_response": "MLP regulates F-actin dynamics through its N-terminal LIM domain. MLP autonomously binds to, stabilizes, and bundles actin filaments (AFs) in the cytoplasmic compartment. MLP self-associates through its N-terminal LIM domain, and it binds to AFs through its C-terminal LIM domain. MLP contributes to the maintenance of cardiomyocyte cytoarchitecture by a mechanism involving its self-association and actin filament cross-linking.",
    "vicuna-7b_fact_raw": "1. MLP regulates F-actin dynamics through its N-terminal LIM domain.\n2. MLP binds to, stabilizes, and bundles actin filaments in the cytoplasmic compartment.\n3. MLP self-associates through its N-terminal LIM domain.\n4. MLP binds to actin filaments through its C-terminal LIM domain.\n5. MLP contributes to the maintenance of cardiomyocyte cytoarchitecture by self-association and actin filament cross-linking.",
    "vicuna-7b_fact": [
      "MLP regulates F-actin dynamics through its N-terminal LIM domain.",
      "MLP binds to, stabilizes, and bundles actin filaments in the cytoplasmic compartment.",
      "MLP self-associates through its N-terminal LIM domain.",
      "MLP binds to actin filaments through its C-terminal LIM domain.",
      "MLP contributes to the maintenance of cardiomyocyte cytoarchitecture by self-association and actin filament cross-linking."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MLP (Muscle LIM Protein) binds to actin filaments through its N-terminal LIM domain, not its C-terminal LIM domain.\n5. TRUE",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "vicuna-7b_response": "There are 2 pseudokinases in the human kinome: T-kinin and Met-T-kinin. These kinases were identified from the release of bradykinin from T-kininogen by cathepsin D and 72 kDa protease in rats with carrageenin-induced inflammation.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "vicuna-7b_response": "1. ApoE mimetic peptide possesses the putative receptor binding domain 141-150 (LRKLRKRLLR) of apoE covalently linked to the class A amphipathic helical peptide 18A. It dramatically reduces plasma cholesterol in dyslipidemic mouse and rabbit models. Recycling of apoE mimetic peptide increases the duration of pre-HDL formation leading to extended anti-inflammatory and atheroprotective properties.\n2. ApoE mimetic peptide is a synthetic peptide that mimics the structure and function of the apolipoprotein E (apoE) protein. It is composed of the putative receptor binding domain 141-150 (LRKLRKRLLR) of apoE covalently linked to the class A amphipathic helical peptide 18A. It has been shown to reduce plasma cholesterol levels in dyslipidemic mouse and rabbit models, and to increase the duration of pre-HDL formation, leading to extended anti-inflammatory and atheroprotective properties.\n3. ApoE mimetic peptide is a synthetic peptide that mimics the structure and function of the apolipoprotein E (apoE) protein. It is composed of the putative receptor binding domain 141-150 (LRKLRKRLLR) of apoE covalently linked to the class A amphipathic helical peptide 18A. It has been shown to reduce plasma cholesterol levels in dyslipidemic mouse and rabbit models, and to increase the duration of pre-HDL formation, leading to extended anti-inflammatory and atheroprotective properties.",
    "vicuna-7b_fact_raw": "1. An apoE mimetic peptide includes the receptor binding domain 141-150 (LRKLRKRLLR) of apoE.\n2. This mimetic peptide is covalently linked to a class A amphipathic helical peptide known as 18A.\n3. The apoE mimetic peptide has been shown to dramatically reduce plasma cholesterol in dyslipidemic mouse and rabbit models.\n4. The recycling of apoE mimetic peptide leads to a longer duration of pre-HDL formation.\n5. Extended pre-HDL formation from the apoE mimetic peptide contributes to anti-inflammatory and atheroprotective properties.",
    "vicuna-7b_fact": [
      "An apoE mimetic peptide includes the receptor binding domain 141-150 (LRKLRKRLLR) of apoE.",
      "This mimetic peptide is covalently linked to a class A amphipathic helical peptide known as 18A.",
      "The apoE mimetic peptide has been shown to dramatically reduce plasma cholesterol in dyslipidemic mouse and rabbit models.",
      "The recycling of apoE mimetic peptide leads to a longer duration of pre-HDL formation.",
      "Extended pre-HDL formation from the apoE mimetic peptide contributes to anti-inflammatory and atheroprotective properties."
    ],
    "vicuna-7b_judge_raw": "1. TRUE - An apoE mimetic peptide commonly includes the receptor-binding region of apoE, which is the region 141-150 (LRKLRKRLLR).\n2. TRUE - The mimetic peptide can indeed be linked to a class A amphipathic helical peptide such as 18A to mimic the structure and function of the full-length protein.\n3. TRUE - Studies have shown that apoE mimetic peptides can reduce plasma cholesterol levels in various animal models.\n4. UNKNOWN - Without specific references to supporting studies, it's unclear if the recycling of apoE mimetic peptide specifically leads to a longer duration of pre-HDL formation.\n5. UNKNOWN - While apoE and its mimetic peptides may have anti-inflammatory and atheroprotective properties due to their role in lipid metabolism, without specific references, it's unclear whether the extended pre-HDL formation from these peptides contributes to those properties.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "vicuna-7b_response": "Document-0 suggests that there are sex differences in the sensitization of the locomotor activity and stereotypy produced by repeated intermittent amphetamine (AMPH) treatment. Specifically, female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior than males. Additionally, prior exposure to AMPH was associated with an elevation in resting striatal dihydroxyphenlacetic acid (DOPAC) to dopamine (DA) ratios in female rats, suggesting a sex difference in one neurochemical correlate of sensitization. However, it is noted that males were more variable and heterogeneous in their response to repeated AMPH treatment, with a suggestion that this may make it more difficult to identify neurochemical correlates of sensitization in males. The study suggests that there is a sex difference in the responsiveness of brain DA systems to repetitive activation, and this contributes to individual variation in the susceptibility to sensitization.",
    "vicuna-7b_fact_raw": "1. Female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior than male rats after repeated intermittent amphetamine (AMPH) treatment.\n2. Prior exposure to amphetamine (AMPH) was associated with an elevation in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats.\n3. The study indicated that there is a sex difference in the neurochemical correlate of sensitization to amphetamine (AMPH).\n4. Male rats exhibited more variability and heterogeneity in their response to repeated amphetamine (AMPH) treatment compared to females.\n5. There is a suggested sex difference in the responsiveness of brain dopamine (DA) systems to repetitive activation.",
    "vicuna-7b_fact": [
      "Female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior than male rats after repeated intermittent amphetamine (AMPH) treatment.",
      "Prior exposure to amphetamine (AMPH) was associated with an elevation in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats.",
      "The study indicated that there is a sex difference in the neurochemical correlate of sensitization to amphetamine (AMPH).",
      "Male rats exhibited more variability and heterogeneity in their response to repeated amphetamine (AMPH) treatment compared to females.",
      "There is a suggested sex difference in the responsiveness of brain dopamine (DA) systems to repetitive activation."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the statements are very specific and pertain to scientific findings, without the actual research study or passage as a reference, it is not possible to determine the truthfulness of these statements. They would require specialized knowledge of the study's findings or access to the findings themselves.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "vicuna-7b_response": "Based on the information provided, it appears that RUNX2 plays a role in the differentiation of odontoblastic and ameloblastic cells. RUNX2 mutations have been linked to Cleidocranial dysplasia (CCD), a condition characterized by abnormal development of bone and teeth. In this study, the researchers investigated the effect of a specific microRNA, mmu-miR-1963, on the differentiation of ameloblasts in LS8 cells. They found that mmu-miR-1963 had a suppressive effect on ameloblast differentiation and that it did this by targeting the 3'UTR of a protein called Smoc2. The study also found that Smoc2 itself could promote ameloblast differentiation. The results of this study suggest that mmu-miR-1963 may play a role in the development of enamel hypoplasia in patients with CCD.",
    "vicuna-7b_fact_raw": "1. RUNX2 is implicated in the differentiation of odontoblastic and ameloblastic cells.\n2. Mutations in RUNX2 have been linked to Cleidocranial dysplasia (CCD), which affects bone and teeth development.\n3. The study in question investigated the effects of microRNA mmu-miR-1963 on ameloblast differentiation in LS8 cells.\n4. The study found that mmu-miR-1963 suppresses ameloblast differentiation by targeting the 3'UTR of Smoc2 protein.\n5. Smoc2 was found to promote ameloblast differentiation according to the study.",
    "vicuna-7b_fact": [
      "RUNX2 is implicated in the differentiation of odontoblastic and ameloblastic cells.",
      "Mutations in RUNX2 have been linked to Cleidocranial dysplasia (CCD), which affects bone and teeth development.",
      "The study in question investigated the effects of microRNA mmu-miR-1963 on ameloblast differentiation in LS8 cells.",
      "The study found that mmu-miR-1963 suppresses ameloblast differentiation by targeting the 3'UTR of Smoc2 protein.",
      "Smoc2 was found to promote ameloblast differentiation according to the study."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: RUNX2 is a gene that is indeed implicated in the differentiation of odontoblasts, which are cells related to the formation of dentin, as well as ameloblasts, which are involved in the formation of enamel, both essential for tooth development. \n2. TRUE: Mutations in RUNX2 are known to cause Cleidocranial dysplasia (CCD), a genetic disorder that affects the development of bones and teeth due to changes in osteoblast differentiation and function.\n3. UNKNOWN: Without more context it is impossible to confirm the specifics of a study. \"mmu-miR-1963\" and its effects on \"LS8 cells\" are very specific details not typically known without access to the particular research referenced.\n4. UNKNOWN: Again, without access to the referenced study, it is not possible to confirm the findings regarding \"mmu-miR-1963\" and its supposed targeting of the 3'UTR of Smoc2 protein.\n5. UNKNOWN: Without having the specific study, we cannot verify that \"Smoc2\" was found to promote ameloblast differentiation according to the study.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "vicuna-7b_response": "The Cobb-Stainsby excision arthroplasty would be performed in the spine. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat spinal arteriovenous malformations (AVMs). The procedure involves removing the malformation and surrounding tissue, which helps to prevent recurrence. The authors of the article describe a case where the procedure was performed on a 17-year-old boy with Cobb syndrome, which is a rare condition that involves concurrent findings of a metameric spinal vascular malformation and a cutaneous vascular malformation. The patient had a right gluteal angioma and was found to have a spinal AVM. Multiple embolizations failed to prevent neurological deterioration, and the patient eventually became wheelchair dependent. However, after surgical excision of the malformation, the patient's neurological function partially recovered, and at the latest follow-up, 52 months postoperatively, the patient was able to ambulate independently. Therefore, the Cobb-Stainsby excision arthroplasty would be performed in the spine to treat spinal AVMs in patients with Cobb syndrome.",
    "vicuna-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat spinal arteriovenous malformations (AVMs).\n2. This procedure entails removing the malformation and the surrounding tissue.\n3. Cobb-Stainsby excision arthroplasty can be used in patients with Cobb syndrome.\n4. Cobb syndrome involves concurrent findings of a metameric spinal vascular malformation and a cutaneous vascular malformation.\n5. The case mentioned describes a 17-year-old boy with Cobb syndrome who partially recovered neurological function after the surgical excision of the malformation and was able to ambulate independently 52 months postoperatively.",
    "vicuna-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat spinal arteriovenous malformations (AVMs).",
      "This procedure entails removing the malformation and the surrounding tissue.",
      "Cobb-Stainsby excision arthroplasty can be used in patients with Cobb syndrome.",
      "Cobb syndrome involves concurrent findings of a metameric spinal vascular malformation and a cutaneous vascular malformation.",
      "The case mentioned describes a 17-year-old boy with Cobb syndrome who partially recovered neurological function after the surgical excision of the malformation and was able to ambulate independently 52 months postoperatively."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is not used to treat spinal arteriovenous malformations (AVMs); it is a procedure used in orthopedic surgery, particularly for the hip joint, not for the spine.\n2. TRUE: In general, when the term \"excision arthroplasty\" is used, it refers to a surgical procedure that involves removing a joint or a part of it, along with the surrounding tissue. However, it should be noted that this statement is true in the context of orthopedic surgery, not neurosurgery for AVMs.\n3. FALSE [correction]: Cobb-Stainsby excision arthroplasty would not be used in patients with Cobb syndrome as it is an orthopedic procedure, not a neurosurgical one. Cobb syndrome requires treatment directed at the vascular malformations associated with the syndrome.\n4. TRUE: This description of Cobb syndrome is correct. It is a nonhereditary congenital condition characterized by the presence of both a spinal vascular malformation and a cutaneous vascular malformation within the same metameric segment.\n5. UNKNOWN: Without additional specific information from the passage about the details of this case, we cannot determine the truth of this statement.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "vicuna-7b_response": "Based on the information provided, it appears that overexpression of GRHL2 (a.k.a. LOXL2) can lead to EMT. GRHL2 is a transcription factor that is known to be involved in EMT, and overexpression of GRHL2 has been shown to induce EMT in various cell types. In addition, GRHL2 has been shown to promote its accumulation in the endoplasmic reticulum, where it interacts with HSPA5 and activates the IRE1-XBP1 signalling pathway of the ER-stress response. This activation of the IRE1-XBP1 pathway leads to the upregulation of several EMT-TFs, including SNAI1, SNAI2, ZEB2, and TCF3, which are direct transcriptional targets of XBP1. These findings suggest that overexpression of GRHL2 can lead to EMT through the activation of the IRE1-XBP1 pathway and the upregulation of EMT-TFs.",
    "vicuna-7b_fact_raw": "1. GRHL2 overexpression can lead to epithelial-mesenchymal transition (EMT).\n2. GRHL2, also known as LOXL2, is a transcription factor involved in EMT.\n3. Overexpression of GRHL2 induces EMT in various cell types.\n4. GRHL2 overexpression promotes its accumulation in the endoplasmic reticulum and interaction with HSPA5, activating the IRE1-XBP1 signalling pathway.\n5. Activation of the IRE1-XBP1 pathway by GRHL2 overexpression leads to the upregulation of EMT transcription factors (EMT-TFs) such as SNAI1, SNAI2, ZEB2, and TCF3.",
    "vicuna-7b_fact": [
      "GRHL2 overexpression can lead to epithelial-mesenchymal transition (EMT).",
      "GRHL2, also known as LOXL2, is a transcription factor involved in EMT.",
      "Overexpression of GRHL2 induces EMT in various cell types.",
      "GRHL2 overexpression promotes its accumulation in the endoplasmic reticulum and interaction with HSPA5, activating the IRE1-XBP1 signalling pathway.",
      "Activation of the IRE1-XBP1 pathway by GRHL2 overexpression leads to the upregulation of EMT transcription factors (EMT-TFs) such as SNAI1, SNAI2, ZEB2, and TCF3."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: GRHL2, also known as Grainyhead-like 2, is a transcription factor involved in EMT, not LOXL2, which stands for Lysyl Oxidase-Like 2 and is a different protein involved in extracellular matrix remodeling.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWhile statements 1 and 3 are consistent with general knowledge about GRHL2's role in EMT, statement 2 incorrectly identifies GRHL2 as LOXL2. Statements 4 and 5 refer to specific biochemical pathways and interactions that require more specialized knowledge or context to confirm as true or false, and without access to the specific passage or current research, they must be deemed UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "vicuna-7b_response": "Based on the information provided, the T-UCR uc.306 has been implicated in the development of lung cancer. However, the information does not specifically mention lung cancer. The information provided is about the role of uc.306 in the prognosis of hepatitis B (HBV)-related hepatocellular carcinoma (HCC). It is important to note that while T-UCRs are involved in the development of cancer, further research is needed to determine the specific role of uc.306 in lung cancer.",
    "vicuna-7b_fact_raw": "1. T-UCR uc.306 has been implicated in the development of lung cancer.\n2. The information provided also relates to the role of uc.306 in the prognosis of hepatitis B (HBV)-related hepatocellular carcinoma (HCC).\n\n(Note: While the response implies a connection of uc.306 with lung cancer, it appears contradictory as it then states that the information does not specifically mention lung cancer. Therefore, the first point should be taken with caution and further investigation is needed to verify it.)",
    "vicuna-7b_fact": [
      "T-UCR uc.306 has been implicated in the development of lung cancer.",
      "The information provided also relates to the role of uc.306 in the prognosis of hepatitis B (HBV)-related hepatocellular carcinoma (HCC).",
      "ote: While the response implies a connection of uc.306 with lung cancer, it appears contradictory as it then states that the information does not specifically mention lung cancer. Therefore, the first point should be taken with caution and further investigation is needed to verify it.)"
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n\n(Note: The original statements for point 3 seem like commentary or instructions rather than a factual statement to be verified, so it is marked as UNKNOWN. Additionally, there is no visible contradiction in the provided statements as implied by the commentary in point 3, meaning the verification of the first point remains inconclusive with the given information.)",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "vicuna-7b_response": "GPR151 is an orphan G protein-coupled receptor (GPCR) whose function is currently unknown. It is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion. The homology with the galanin family of receptors implies a role in nociception.\nA study was conducted to investigate the role of GPR151 in neuropathic pain using the spared nerve injury model. The results showed a significant 49.92-fold increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after the injury. However, measures of acute, inflammatory, and neuropathic pain behaviors were not significantly different in GPR151 loss-of-function mutant mice and wild-type controls. Additionally, galanin at concentrations between 100nM and 10M did not induce calcium signaling responses in ND7/23 cells transfected with GPR151.\nThese results suggest that GPR151 is not involved in the modulation of pain-related behaviors in the spared nerve injury model of neuropathic pain and that galanin is unlikely to be an endogenous ligand for GPR151. Further research is needed to elucidate the function of GPR151 in the nervous system.",
    "vicuna-7b_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor (GPCR) with an unknown function.\n2. GPR151 is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion.\n3. There was a 49.92-fold increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after a spared nerve injury.\n4. In a study, GPR151 loss-of-function mutant mice did not show significant differences in pain behaviors compared to wild-type controls in the context of neuropathic pain.\n5. In the study mentioned, galanin did not induce calcium signaling responses in ND7/23 cells transfected with GPR151 at concentrations between 100nM and 10M.",
    "vicuna-7b_fact": [
      "GPR151 is an orphan G protein-coupled receptor (GPCR) with an unknown function.",
      "GPR151 is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion.",
      "There was a 49.92-fold increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after a spared nerve injury.",
      "In a study, GPR151 loss-of-function mutant mice did not show significant differences in pain behaviors compared to wild-type controls in the context of neuropathic pain.",
      "In the study mentioned, galanin did not induce calcium signaling responses in ND7/23 cells transfected with GPR151 at concentrations between 100nM and 10M."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nFor statements 3 to 5, the information provided is very specific, and without the context of the cited study or literature, it is not possible to assess the veracity of these statements. If the source for these statements is a scientific study or publication, one would need to reference that material directly to confirm or correct the claims made about GPR151 expression changes, pain behaviors in mutant mice, and the effects of galanin on calcium signaling in cells transfected with GPR151.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "vicuna-7b_response": "The Fluzone intradermal quadrivalent vaccine contains four live attenuated viruses: influenza virus type A (H1N1), influenza virus type A (H3N2), influenza virus type B/Yamagata, and influenza virus type B/Victoria.",
    "vicuna-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains live attenuated viruses.\n2. The vaccine includes an attenuated form of influenza virus type A (H1N1).\n3. It also includes an attenuated form of influenza virus type A (H3N2).\n4. Influenza virus type B/Yamagata is one of the attenuated viruses in the vaccine.\n5. Influenza virus type B/Victoria is another attenuated virus contained in the Fluzone intradermal quadrivalent vaccine.",
    "vicuna-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains live attenuated viruses.",
      "The vaccine includes an attenuated form of influenza virus type A (H1N1).",
      "It also includes an attenuated form of influenza virus type A (H3N2).",
      "Influenza virus type B/Yamagata is one of the attenuated viruses in the vaccine.",
      "Influenza virus type B/Victoria is another attenuated virus contained in the Fluzone intradermal quadrivalent vaccine."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not live attenuated viruses.\n2. FALSE [correction]: Although the vaccine includes antigens from influenza virus type A (H1N1), these are not in an attenuated form; they are inactivated.\n3. FALSE [correction]: As with H1N1, the vaccine includes antigens from influenza virus type A (H3N2), but these are inactivated, not attenuated.\n4. TRUE: Influenza virus type B/Yamagata lineage is included in the vaccine.\n5. TRUE: Influenza virus type B/Victoria lineage is also included in the vaccine.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "vicuna-7b_response": "The TNFR2 gene, which is also known as the TNF receptor 2 gene, has been shown to be genetically associated with Systemic Lupus Erythematosus (SLE) through a study that examined the restriction fragment length polymorphism (RFLP) of the TNF-alpha and -beta genes using restriction endonuclease NcoI. The study found that the frequency of a 5.5 kb NcoI fragment from SLE patients was significantly higher than that from normal controls, suggesting that the polymorphic TNF genes may be involved in the pathogenesis of SLE. The TNFR2 gene is located on chromosome 6p21.3 and encodes a protein that plays a key role in the regulation of the immune response. The TNFR2 gene has been implicated in the development of several autoimmune diseases, including SLE, rheumatoid arthritis, and psoriasis.",
    "vicuna-7b_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE) through a genetic study involving restriction fragment length polymorphism (RFLP).\n2. The study found a higher frequency of a 5.5 kb NcoI fragment in SLE patients compared to normal controls.\n3. The TNFR2 gene is located on chromosome 6p21.3.\n4. The TNFR2 gene encodes a protein that is involved in the regulation of the immune response.\n5. The TNFR2 gene has been implicated in the development of autoimmune diseases such as SLE, rheumatoid arthritis, and psoriasis.",
    "vicuna-7b_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE) through a genetic study involving restriction fragment length polymorphism (RFLP).",
      "The study found a higher frequency of a 5.5 kb NcoI fragment in SLE patients compared to normal controls.",
      "The TNFR2 gene is located on chromosome 6p21.3.",
      "The TNFR2 gene encodes a protein that is involved in the regulation of the immune response.",
      "The TNFR2 gene has been implicated in the development of autoimmune diseases such as SLE, rheumatoid arthritis, and psoriasis."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: Without a specific reference to a study, it's impossible to confirm the association of the TNFR2 gene with Systemic Lupus Erythematosus (SLE) through restriction fragment length polymorphism (RFLP) analysis.\n2. UNKNOWN: Similarly, the finding of a higher frequency of a 5.5 kb NcoI fragment in SLE patients compared to normal controls cannot be confirmed without a reference to the specific study.\n3. TRUE: The TNFR2 gene is indeed located on chromosome 6p21.3.\n4. TRUE: The TNFR2 gene encodes the tumor necrosis factor receptor 2 which is involved in the regulation of the immune response.\n5. TRUE: The TNFR2 gene has been implicated in the development of autoimmune diseases such as SLE, rheumatoid arthritis, and psoriasis through various studies indicating a role in immune system regulation.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "vicuna-7b_response": "Yes, there is a vaccine for peanut allergy. According to the information provided, researchers have been exploring the potential application of poly(anhydride) nanoparticles (NPs) as immunoadjuvants for peanut oral immunotherapy. This type of immunotherapy aims to desensitize individuals with peanut allergy by gradually exposing them to increasing amounts of peanut protein over time. The research suggests that oral immunization with NPs loaded with peanut proteins can induce a balanced T(H)1 and T(H)2 antibody response, accompanied by low specific IgE induction. In addition, oral immunization with spray-dried NPs loaded with peanut proteins was associated with a significant decrease in splenic T(H)2 cytokines (IL-4, IL-5, and IL-6) and enhancement of both T(H)1 (gamma interferon [IFN-) and regulatory (IL-10) cytokines. This suggests that oral immunotherapy with NPs may be a promising approach for treating peanut allergy.",
    "vicuna-7b_fact_raw": "1. Researchers have explored the use of poly(anhydride) nanoparticles (NPs) as immunoadjuvants for peanut oral immunotherapy.\n2. The goal of peanut oral immunotherapy is to desensitize individuals with peanut allergy by gradually exposing them to increasing amounts of peanut protein.\n3. Oral immunization with nanoparticles loaded with peanut proteins can induce a balanced T(H)1 and T(H)2 antibody response.\n4. This immunotherapy with nanoparticles is accompanied by low specific IgE induction.\n5. Oral immunization with spray-dried nanoparticles loaded with peanut proteins led to a significant decrease in splenic T(H)2 cytokines and enhanced T(H)1 and regulatory cytokines.",
    "vicuna-7b_fact": [
      "Researchers have explored the use of poly(anhydride) nanoparticles (NPs) as immunoadjuvants for peanut oral immunotherapy.",
      "The goal of peanut oral immunotherapy is to desensitize individuals with peanut allergy by gradually exposing them to increasing amounts of peanut protein.",
      "Oral immunization with nanoparticles loaded with peanut proteins can induce a balanced T(H)1 and T(H)2 antibody response.",
      "This immunotherapy with nanoparticles is accompanied by low specific IgE induction.",
      "Oral immunization with spray-dried nanoparticles loaded with peanut proteins led to a significant decrease in splenic T(H)2 cytokines and enhanced T(H)1 and regulatory cytokines."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\nThe first four statements align with the general concepts and goals in the field of immunotherapy using nanoparticles, especially for the treatment of allergies like a peanut allergy. Nanoparticles are indeed researched as immunoadjuvants, and the aim of oral immunotherapy for peanut allergies is to desensitize individuals to peanuts. The idea of inducing a balanced immune response and doing so with low specific IgE induction is consistent with the overarching goals of reducing allergic responses while building up tolerance.\n\nHowever, without specific studies or scientific results to reference for the fifth statement, it is not possible to verify the effects on cytokine levels in the spleen or the impact on T(H)1 and regulatory cytokines. Therefore, this statement is marked as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "vicuna-7b_response": "The mouse Fxy gene is located on the minute short arm of the mouse Y chromosome. The gene controls primary sex determination and expresses the male-specific antigen H-Y. The gene is located on the same chromosomal position as the mouse Fxy gene.",
    "vicuna-7b_fact_raw": "1. The mouse Fxy gene is located on the short arm of the mouse Y chromosome.\n2. The Fxy gene is involved in controlling primary sex determination.\n3. The Fxy gene is responsible for expressing the male-specific antigen H-Y.",
    "vicuna-7b_fact": [
      "The mouse Fxy gene is located on the short arm of the mouse Y chromosome.",
      "The Fxy gene is involved in controlling primary sex determination.",
      "The Fxy gene is responsible for expressing the male-specific antigen H-Y."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The mouse Fxy gene (also known as Sry in mice) is located on the Y chromosome, but more specifically, it's located on the short arm of chromosome 11, which is not the Y chromosome.\n2. TRUE\n3. FALSE [correction]: The Sry gene (Sex-determining Region Y), which the Fxy gene corresponds to in the context of sex determination in mice, is responsible for initiating male sex determination by triggering the development of testes. The male-specific antigen H-Y is associated with a different set of genetic determinants and is not exclusively controlled by the Sry/Fxy gene.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "vicuna-7b_response": "The basis of the MPE-seq method is the use of Methidiumpropyl-EDTA (MPE) as a synthetic DNA intercalator that cleaves DNA in the presence of ferrous ion and oxygen. This method is used for protection analysis, also known as footprinting, to identify the nucleotides involved in a protein-DNA interaction. MPE does not exhibit sequence specificity, making it a better choice for protection analysis. The method is generally applicable for identifying specific DNA-protein complexes from a crude nuclear extract. The MPE-seq method has been used to identify the nucleotides of the immunoglobulin (Ig) heavy chain promoter region that are involved in complex formation with a protein that binds the octameric sequence ATGCAAAT, and the results are compared to those obtained using DNase I.",
    "vicuna-7b_fact_raw": "1. Methidiumpropyl-EDTA (MPE) is used as a synthetic DNA intercalator in MPE-seq method.\n2. MPE-seq method uses cleavage of DNA in the presence of ferrous ion and oxygen.\n3. MPE-seq is used for protection analysis to determine nucleotides involved in protein-DNA interactions.\n4. MPE does not exhibit sequence specificity during protection analysis.\n5. The MPE-seq method has been utilized to study the nucleotides of the immunoglobulin (Ig) heavy chain promoter region.",
    "vicuna-7b_fact": [
      "Methidiumpropyl-EDTA (MPE) is used as a synthetic DNA intercalator in MPE-seq method.",
      "MPE-seq method uses cleavage of DNA in the presence of ferrous ion and oxygen.",
      "MPE-seq is used for protection analysis to determine nucleotides involved in protein-DNA interactions.",
      "MPE does not exhibit sequence specificity during protection analysis.",
      "The MPE-seq method has been utilized to study the nucleotides of the immunoglobulin (Ig) heavy chain promoter region."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nMethidiumpropyl-EDTA (MPE) indeed functions as a synthetic DNA intercalator used in certain sequencing methods, such as MPE-seq. The MPE-seq method entails the cleavage of DNA using ferrous ion and oxygen. Moreover, it is used for footprinting or protection analysis where it helps to identify DNA nucleotide sequences involved in protein-DNA interactions. MPE is typically not sequence-specific, which allows for a broader application in protection analysis. Finally, MPE-seq has been employed to study various DNA regions, including the immunoglobulin heavy chain promoter region, making the last statement likely true given the method's applications.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "vicuna-7b_response": "The programming language used for implementing GWAR (Guidelines, Workflows, and Alerts in the EHR) is not specified in the given information. However, it is likely that GWAR was implemented using a programming language that is compatible with the FHIR (Fast Healthcare Interoperability Resources) standard, which is a standard for exchanging healthcare information electronically.\nGWAR is a tool that allows clinicians to create and manage decision support rules and workflows within the EHR system. It is designed to help clinicians make more informed decisions by providing relevant patient information from various data sources.\nIt is possible that GWAR was implemented using a programming language that is specifically designed for building decision support systems, such as Rule Engine or Drools. However, without more information, it is not possible to determine the exact programming language used for implementing GWAR.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "vicuna-7b_response": "Based on the information provided, it appears that xaliproden, a drug with neurotrophic effect, was studied in two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies in patients with clinically probable or definite ALS of more than 6 months and less than 5 years duration. The two primary endpoints were time to death, tracheostomy, or permanent assisted ventilation (DTP) and time to vital capacity (VC)<50% or DTP.\nIn Study 1, the primary outcome measures did not reach statistical significance, but there was a trend in favor of the 2 mg xaliproden group compared to the placebo group for time to VC<50% (RRR 30% [95% CI: 8.46, P=0.009]). In Study 2, no significant results were obtained, but there was a trend in favor of the add-on 1 mg dose of xaliproden vs. placebo for time to VC<50% (RRR 15% [CI: -6.31, ns]) and time to VC<50% or DTP (RRR 12% [CI: -6.27, ns]).\nThe studies found that xaliproden had a good tolerability and dose-dependent side effects were largely associated with the serotonergic properties of xaliproden. Xaliproden also had a small effect on functional parameters, especially VC, but these effects did not reach statistical significance.\nIn summary, the studies suggest that xaliproden may have a small effect on the progression of ALS, but the effects were not statistically significant. The studies also found that xaliproden was well-tolerated and had dose-dependent side effects.",
    "vicuna-7b_fact_raw": "1. Xaliproden was studied in two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies for patients with amyotrophic lateral sclerosis (ALS).\n2. The studies included patients with clinically probable or definite ALS of more than 6 months and less than 5 years duration.\n3. The primary outcome measures for Study 1 did not reach statistical significance.\n4. In Study 2, no significant results were obtained for the add-on 1 mg dose of xaliproden compared to placebo.\n5. The studies reported that xaliproden was well-tolerated and side effects were dose-dependent and largely associated with its serotonergic properties.",
    "vicuna-7b_fact": [
      "Xaliproden was studied in two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies for patients with amyotrophic lateral sclerosis (ALS).",
      "The studies included patients with clinically probable or definite ALS of more than 6 months and less than 5 years duration.",
      "The primary outcome measures for Study 1 did not reach statistical significance.",
      "In Study 2, no significant results were obtained for the add-on 1 mg dose of xaliproden compared to placebo.",
      "The studies reported that xaliproden was well-tolerated and side effects were dose-dependent and largely associated with its serotonergic properties."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the specificity and detail of the statements, they are most likely true if faithfully representing the outcomes of the mentioned clinical studies. Clinical studies such as these are often very precise about their inclusion criteria, outcomes, and findings. However, without access to the original study data or publications, it is not possible to verify the absolute accuracy of these statements beyond reasonable acceptance of detail provided.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "vicuna-7b_response": "The LiPS-A3S line has transgenes inserted in chromosome 2.",
    "vicuna-7b_fact_raw": "1. The LiPS-A3S line has transgenes inserted in chromosome 2.",
    "vicuna-7b_fact": [
      "The LiPS-A3S line has transgenes inserted in chromosome 2."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN",
    "vicuna-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "vicuna-7b_response": "DeepSynergy is a deep learning-based tool for predicting drug synergy. It uses chemical and genomic information as input and employs conical layers to model drug synergies. DeepSynergy was compared to other machine learning methods on the largest publicly available synergy dataset and significantly outperformed the other methods, achieving an improvement of 7.2% over the second best method. DeepSynergy was found to have a high predictive performance for novel drug combinations within the space of explored drugs and cell lines, with a mean Pearson correlation coefficient of 0.73 and an AUC of 0.90. The tool is available via [www.bioinf.jku.at/software/DeepSynergy](http://www.bioinf.jku.at/software/DeepSynergy) and can be contacted at [klambauer@bioinf.jku.at](mailto:klambauer@bioinf.jku.at). Supplementary information is available at Bioinformatics online.",
    "vicuna-7b_fact_raw": "1. DeepSynergy is a tool that uses deep learning to predict drug synergy.\n2. DeepSynergy uses chemical and genomic information as its input for models.\n3. DeepSynergy was tested on the largest publicly available synergy dataset and achieved an improvement of 7.2% over the second best method.\n4. The mean Pearson correlation coefficient for DeepSynergy's predictions is 0.73.\n5. DeepSynergy has an AUC (Area Under the Curve) of 0.90 for its predictions.",
    "vicuna-7b_fact": [
      "DeepSynergy is a tool that uses deep learning to predict drug synergy.",
      "DeepSynergy uses chemical and genomic information as its input for models.",
      "DeepSynergy was tested on the largest publicly available synergy dataset and achieved an improvement of 7.2% over the second best method.",
      "The mean Pearson correlation coefficient for DeepSynergy's predictions is 0.73.",
      "DeepSynergy has an AUC (Area Under the Curve) of 0.90 for its predictions."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without the specific quantitative results from the original publication or source material for DeepSynergy, statements 3, 4, and 5 can't be verified as true or false, thus the responses are marked as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "vicuna-7b_response": "The cloud-based platform that has been developed for comparing GWAS is the GWAtoolbox. The GWAtoolbox is an R package that standardizes and accelerates the handling of data from genome-wide association studies (GWAS), particularly in the context of large-scale GWAS meta-analyses. The GWAtoolbox has the ability to perform quality control (QC) of any number of files in a matter of minutes. The implemented workflow checks three particular data quality aspects: data formatting, quality of the GWAS results, and data consistency across studies. The output consists of an extensive list of quality statistics and plots which allow inspection of individual files and between-study comparison to identify systematic bias. The GWAtoolbox is available at <http://www.eurac.edu/GWAtoolbox> and can be contacted at <cfuchsb@umich.edu; daniel.taliun@eurac.edu>. Supplementary data are available at Bioinformatics online.",
    "vicuna-7b_fact_raw": "1. GWAtoolbox is a cloud-based platform developed for comparing GWAS (genome-wide association studies).\n2. GWAtoolbox is an R package designed to standardize and accelerate the handling of GWAS data.\n3. GWAtoolbox includes a feature for performing quality control of any number of files quickly.\n4. The output of GWAtoolbox includes quality statistics and plots for data inspection and between-study comparison.\n5. GWAtoolbox is hosted at http://www.eurac.edu/GWAtoolbox.",
    "vicuna-7b_fact": [
      "GWAtoolbox is a cloud-based platform developed for comparing GWAS (genome-wide association studies).",
      "GWAtoolbox is an R package designed to standardize and accelerate the handling of GWAS data.",
      "GWAtoolbox includes a feature for performing quality control of any number of files quickly.",
      "The output of GWAtoolbox includes quality statistics and plots for data inspection and between-study comparison.",
      "GWAtoolbox is hosted at http://www.eurac.edu/GWAtoolbox."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: Without additional context or reference about a tool called \"GWAtoolbox,\" it is not possible to determine if this statement is true or false.\n2. TRUE: \"GWAtoolbox\" sounds like it could be the name of an R package since R packages are commonly used for such scientific analyses, but without specific knowledge about every R package or tool named \"GWAtoolbox,\" this statement cannot be verified. Assuming \"GWAtoolbox\" is indeed an R package designed for GWAS data, the statement would be correct.\n3. TRUE: It is plausible for an R package like \"GWAtoolbox\" to include a feature for performing quality control of files quickly, as this is a common requirement in handling GWAS data.\n4. TRUE: The provision of quality statistics and plots for data inspection and comparison is typical functionality expected from a GWAS data handling tool or R package.\n5. FALSE [correction]: Without specific knowledge of the hosting site for \"GWAtoolbox,\" this URL cannot be verified. Moreover, an official tool or package would typically be hosted on a more recognizable platform related to bioinformatics, like Bioconductor, CRAN (if it is an R package), or a research institute's repository, but not necessarily the domain cited here. As of my last update, the mentioned URL does not seem to represent a valid address for GWAtoolbox. Official hosting sites for bioinformatics tools often end in .org, .gov, .edu, or .com, but the exact URL would need to be verified for accuracy.",
    "vicuna-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "vicuna-7b_response": "Based on the information provided, it appears that CMB305 (ZIMET 3164) has been shown to inhibit the growth of sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma in a mouse model. However, it was not effective in prolonging the survival time of mice bearing Ehrlich ascites carcinoma or the leukemias L1210 and LAJ-I. Additionally, CMB305 was found to be effective when given on days -2 to +2 relative to the antigenic stimulus, but administration exclusively prior to immunization only induced moderate immunosuppression, while injection afterwards failed to affect the primary response at all. Overall, CMB305 was found to be less effective than cyclophosphamide, but more effective than chlorambucil. Therefore, it is possible that CMB305 may be effective against sarcomas, but more research is needed to confirm its efficacy in this context.",
    "vicuna-7b_fact_raw": "1. CMB305 (ZIMET 3164) has been shown to inhibit the growth of sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma in a mouse model.\n2. CMB305 was not effective in prolonging the survival time of mice with Ehrlich ascites carcinoma or the leukemias L1210 and LAJ-I.\n3. CMB305 was effective when administered on days -2 to +2 relative to an antigenic stimulus.\n4. Administering CMB305 exclusively prior to immunization induced moderate immunosuppression.\n5. CMB305 was found to be less effective than cyclophosphamide but more effective than chlorambucil.",
    "vicuna-7b_fact": [
      "CMB305 (ZIMET 3164) has been shown to inhibit the growth of sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma in a mouse model.",
      "CMB305 was not effective in prolonging the survival time of mice with Ehrlich ascites carcinoma or the leukemias L1210 and LAJ-I.",
      "CMB305 was effective when administered on days -2 to +2 relative to an antigenic stimulus.",
      "Administering CMB305 exclusively prior to immunization induced moderate immunosuppression.",
      "CMB305 was found to be less effective than cyclophosphamide but more effective than chlorambucil."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided relate to highly specific scientific findings regarding the efficacy of a particular compound (CMB305) in various experimental settings. Without access to relevant scientific data or publications that discuss these outcomes, it's not possible to verify the accuracy of these statements.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "vicuna-7b_response": "The Saint's Triad is a medical condition characterized by the presence of three specific pathologies: cholelithiasis (gallstones), diverticulosis (the presence of diverticula in the colon), and hiatal hernia (a protrusion of the stomach into the chest through the diaphragm). The incidence of the Saint's Triad is relatively low, with an expected rate of 0.2-0.3% in the general population. However, a study conducted on 684 patients who underwent radiological examinations revealed a higher incidence of 1.02%, with 7 cases of Saint's Triad and 86 cases of bifocal associations. Specifically, there were 59 cases of cholelithiasis and diverticulosis, 17 cases of cholelithiasis and hiatal hernia, and 10 cases of diverticulosis and hernia. These findings suggest that the incidence of the Saint's Triad may be higher than previously thought, and further research is needed to confirm this.",
    "vicuna-7b_fact_raw": "1. The Saint's Triad is characterized by cholelithiasis, diverticulosis, and hiatal hernia.\n2. The general population has an expected Saint's Triad incidence rate of 0.2-0.3%.\n3. A study involving 684 patients who underwent radiological examinations found an incidence of 1.02% for the Saint's Triad.\n4. In the study, there were 7 cases of Saint's Triad and 86 cases of bifocal associations.\n5. The study reported 59 cases of cholelithiasis and diverticulosis, 17 cases of cholelithiasis and hiatal hernia, and 10 cases of diverticulosis and hernia.",
    "vicuna-7b_fact": [
      "The Saint's Triad is characterized by cholelithiasis, diverticulosis, and hiatal hernia.",
      "The general population has an expected Saint's Triad incidence rate of 0.2-0.3%.",
      "A study involving 684 patients who underwent radiological examinations found an incidence of 1.02% for the Saint's Triad.",
      "In the study, there were 7 cases of Saint's Triad and 86 cases of bifocal associations.",
      "The study reported 59 cases of cholelithiasis and diverticulosis, 17 cases of cholelithiasis and hiatal hernia, and 10 cases of diverticulosis and hernia."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN (Without specific data regarding the current incidence rate in the general population, it is difficult to confirm the accuracy of this statement.)\n3. UNKNOWN (Assuming the number of patients and incidence rate provided are from a credible study, it would need to be verified directly from the source.)\n4. UNKNOWN (The specific numbers of cases for Saint's Triad and bifocal associations would need to be verified with the study referenced.)\n5. UNKNOWN (The distribution of cases among the different combinations of the triad conditions needs to be verified against the study data.)",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "vicuna-7b_response": "Based on the information provided, it is not clear if overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients. However, it is mentioned that overexpression of PLK1 is associated with a poor prognosis in many tumors, including SCLC. The selective PLK1 inhibitor BI 6727 was found to significantly inhibit proliferation and induce apoptosis in SCLC cell lines, and this was associated with an increase in the population of cells in the G2/M phase and activation of the ATR/ATM-Chk1/Chk2 checkpoint pathway. These findings suggest that BI 6727 may have therapeutic potential for SCLC patients.",
    "vicuna-7b_fact_raw": "1. Overexpression of PLK1 is associated with a poor prognosis in many tumors, including SCLC.\n2. The selective PLK1",
    "vicuna-7b_fact": [
      "Overexpression of PLK1 is associated with a poor prognosis in many tumors, including SCLC.",
      "The selective PLK1"
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN",
    "vicuna-7b_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "vicuna-7b_response": "Based on the information provided in Document-0, the following Cdk targets are dephosphorylated during cytokinesis in budding yeast:\n* Aip1\n* Ede1\n* Inn1\nThese proteins are identified as cytokinetic regulators that are required for the execution of cytokinesis. The dephosphorylation of these targets is coordinated by the master cell cycle regulator Cdk and its counteracting phosphatase Cdc14, which together control each of the sequential steps of cytokinesis.",
    "vicuna-7b_fact_raw": "1. Aip1 is dephosphorylated during cytokinesis in budding yeast.\n2. Ede1 is dephosphorylated during cytokinesis in budding yeast.\n3. Inn1 is dephosphorylated during cytokinesis in budding yeast.\n4. Cdk coordinates the dephosphorylation of certain targets during cytokinesis.\n5. The phosphatase Cdc14 is involved in the dephosphorylation process during cytokinesis in budding yeast.",
    "vicuna-7b_fact": [
      "Aip1 is dephosphorylated during cytokinesis in budding yeast.",
      "Ede1 is dephosphorylated during cytokinesis in budding yeast.",
      "Inn1 is dephosphorylated during cytokinesis in budding yeast.",
      "Cdk coordinates the dephosphorylation of certain targets during cytokinesis.",
      "The phosphatase Cdc14 is involved in the dephosphorylation process during cytokinesis in budding yeast."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nReasoning:\nWithout specific details from the passage regarding the phosphorylation status of Aip1, Ede1, and Inn1 during cytokinesis in budding yeast, I cannot accurately determine the truthfulness of statements 1, 2, and 3. These would require specific scientific knowledge or context.\n\nHowever, statement 4 is generally true as Cdk (Cyclin-dependent kinases) are known to coordinate various processes during the cell cycle, including phosphorylation and dephosphorylation of targets.\n\nStatement 5 is true as well since Cdc14 is a well-studied phosphatase involved in the dephosphorylation process during cytokinesis in budding yeast.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "vicuna-7b_response": "Xanamem is not mentioned in the provided information. It is possible that Xanamem is a different medication or a brand name for a medication that is not mentioned in the information provided.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "vicuna-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in yeast cytokinesis. Hof1 is a protein that is involved in the partitioning of the cytoplasm during cytokinesis, which is the process of dividing the cytoplasm of a cell into two daughter cells. In budding yeast, Hof1 forms a ring at the bud neck, which is distinct from the actomyosin ring, and this zone is active in septum deposition. The Hof1-Cyk3 interaction is important for the recruitment of Hof1 to the bud neck and for the proper functioning of the cytokinesis process. The Vrp1 fragment, which is the yeast Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) ortholog, interacts with Hof1 and facilitates Hof1 recruitment to the bud neck. The Vrp1 fragment, which is the yeast Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) ortholog, interacts with Hof1 and facilitates Hof1 recruitment to the bud neck. The ability of the Vrp1 fragment to bind the Hof1 SH3 domain via its Hof one trap (HOT) domain is critical for cytokinesis. The Hof1 SH3 domain itself is not required for cytokinesis and indeed appears to negatively regulate cytokinesis. The Vrp1 HOT domain promotes cytokinesis by binding to the Hof1 SH3 domain and counteracting its inhibitory effect.",
    "vicuna-7b_fact_raw": "1. The Hof1-Cyk3 interaction is involved in cytokinesis in yeast.\n2. Hof1 is a protein responsible for partitioning the cytoplasm during cytokinesis in yeast.\n3. In budding yeast, Hof1 forms a ring at the bud neck that is involved in septum deposition.\n4. The Vrp1 fragment is a yeast WASP-interacting protein ortholog that facilitates the recruitment of Hof1 to the bud neck.\n5. The Vrp1 HOT domain promotes cytokinesis by binding to the Hof1 SH3 domain and counteracting its inhibitory effect.",
    "vicuna-7b_fact": [
      "The Hof1-Cyk3 interaction is involved in cytokinesis in yeast.",
      "Hof1 is a protein responsible for partitioning the cytoplasm during cytokinesis in yeast.",
      "In budding yeast, Hof1 forms a ring at the bud neck that is involved in septum deposition.",
      "The Vrp1 fragment is a yeast WASP-interacting protein ortholog that facilitates the recruitment of Hof1 to the bud neck.",
      "The Vrp1 HOT domain promotes cytokinesis by binding to the Hof1 SH3 domain and counteracting its inhibitory effect."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: The Hof1-Cyk3 interaction has been reported to be involved in cytokinesis in yeast, which is the process where the cytoplasm divides to form two daughter cells.\n2. TRUE: Hof1 is a protein known to play a role in cytokinesis, and it is involved in the partitioning of the cytoplasm during this process in yeast.\n3. TRUE: In budding yeast, Hof1 is known to form a ring at the bud neck, and this structure is indeed involved in septum formation which is crucial for cytokinesis.\n4. TRUE: Vrp1 (Verprolin) is a protein in yeast that interacts with WASP (Wiskott-Aldrich Syndrome Protein) homologs, and it has been implicated in the recruitment of various proteins such as Hof1 to the bud neck during cytokinesis.\n5. UNKNOWN: Without additional information or context regarding the \"HOT\" domain or its relationship to Vrp1 and the Hof1 SH3 domain, it's challenging to determine the accuracy of this statement. The specific terms \"HOT domain\" and \"inhibitory effect\" are not standard descriptors readily associable with Vrp1 and Hof1 interaction in the existing literature up to the knowledge cutoff date.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "vicuna-7b_response": "UCH-L1 is a deubiquitinating enzyme that has been implicated in the development and progression of gastric cancer. A study conducted on gastric cardiac adenocarcinoma (GCA) specimens found that UCH-L1 expression was increased in GCA compared to normal tissues, and that overexpression of UCH-L1 was tightly correlated with tumor size and overall TNM stage. The study also found that UCH-L1 overexpression was a negative predictor of prognosis in GCA, along with advanced TNM stage. Additionally, silencing of UCH-L1 reduced the ability of gastric cancer cells to proliferate, form colonies, migrate and invade. These findings suggest that UCH-L1 may be a promising prognostic biomarker for GCAs and may play a role in the carcinogenesis of gastric cancer.",
    "vicuna-7b_fact_raw": "1. UCH-L1 is a deubiquitinating enzyme implicated in the development and progression of gastric cancer.\n2. A study found that UCH-L1 expression was increased in gastric cardiac adenocarcinoma (GCA) specimens compared to normal tissues.\n3. Overexpression of UCH-L1 in GCA was tightly correlated with tumor size and overall TNM stage.\n4. High levels of UCH-L1 were found to be a negative predictor of prognosis in GCA.\n5. Silencing of UCH-L1 reduced the proliferative, colony-forming, migratory, and invasive abilities of gastric cancer cells.",
    "vicuna-7b_fact": [
      "UCH-L1 is a deubiquitinating enzyme implicated in the development and progression of gastric cancer.",
      "A study found that UCH-L1 expression was increased in gastric cardiac adenocarcinoma (GCA) specimens compared to normal tissues.",
      "Overexpression of UCH-L1 in GCA was tightly correlated with tumor size and overall TNM stage.",
      "High levels of UCH-L1 were found to be a negative predictor of prognosis in GCA.",
      "Silencing of UCH-L1 reduced the proliferative, colony-forming, migratory, and invasive abilities of gastric cancer cells."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAssuming the research is accurate and the context provided comes from a reliable study or source, the statements appear consistent with typical discussions about the role and effects of certain enzymes or proteins such as UCH-L1 in cancer. However, without the actual study or empirical data to reference, these would constitute a general scientific understanding, which may vary depending on the specific nature of current research discoveries.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "vicuna-7b_response": "The Lupus Severity Index (LSI) is a measure of the distribution of sulfur colloid in the liver and spleen, as determined by single-photon-emission computerized tomography (SPECT). The LSI is calculated by comparing the counts between the liver and spleen, adjusted for spleen size. The LSI is used as a quantitative test of hepatic function and is often used in conjunction with other tests, such as the liver-bone marrow index (LBI) and the Child-Pugh classification, to assess the severity of liver disease. In this study, the LSI and LBI were found to be highly correlated (r = 0.753) and the arithmetic mean of the two scores was defined as the severity score. The severity score was found to be highly correlated with hepatic fibrosis (r = -0.694) and the Child-Pugh classification (r = 0.78) in patients with liver disease. The severity score was also found to be highly correlated with the LBI in patients with benign liver disease who had recent biopsies.",
    "vicuna-7b_fact_raw": "1. The Lupus Severity Index (LSI) measures the distribution of sulfur colloid in the liver and spleen using single-photon-emission computerized tomography (SPECT).\n2. The LSI is calculated by comparing the counts between the liver and spleen, with adjustments for spleen size.\n3. The LSI is used as a quantitative test to assess hepatic function.\n4. The liver-bone marrow index (LBI) and the Child-Pugh classification are other tests used in conjunction with the LSI to assess the severity of liver disease.\n5. In a study, the LSI and LBI were highly correlated with a correlation coefficient (r) of 0.753.",
    "vicuna-7b_fact": [
      "The Lupus Severity Index (LSI) measures the distribution of sulfur colloid in the liver and spleen using single-photon-emission computerized tomography (SPECT).",
      "The LSI is calculated by comparing the counts between the liver and spleen, with adjustments for spleen size.",
      "The LSI is used as a quantitative test to assess hepatic function.",
      "The liver-bone marrow index (LBI) and the Child-Pugh classification are other tests used in conjunction with the LSI to assess the severity of liver disease.",
      "In a study, the LSI and LBI were highly correlated with a correlation coefficient (r) of 0.753."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The Lupus Severity Index (LSI) does not measure the distribution of sulfur colloid in the liver and spleen. The name suggests it might relate to lupus severity assessment, not liver or spleen imaging. The use of single-photon-emission computerized tomography (SPECT) for measuring sulfur colloid distribution in the liver and spleen relates to a liver scan, which would not be labeled as LSI.\n2. UNKNOWN: Since the first statement about the Lupus Severity Index (LSI) relating to measurements in the liver and spleen is incorrect, the truth of this statement cannot be determined based on the given context. Additionally, liver and spleen counts can be compared in other types of tests, but without the proper context, it's not possible to correct or confirm this regarding the LSI.\n3. UNKNOWN: Given that the Lupus Severity Index (LSI) does not measure hepatic function through sulfur colloid distribution, it's unclear what the true purpose of LSI is based on the provided statements. Therefore, whether or not it's used to assess hepatic function cannot be determined.\n4. UNKNOWN: Since the LSI does not pertain to liver imaging or function as mentioned in the first statement and there is no information provided about what LSI actually is or assesses, we cannot determine the truth of the statement regarding the use of the liver-bone marrow index (LBI) and the Child-Pugh classification in conjunction with LSI.\n5. UNKNOWN: Due to the lack of correct context for what the Lupus Severity Index (LSI) is and its purpose, a study asserting a correlation between LSI and LBI cannot be verified. Furthermore, without knowing what LSI measures, the reported correlation coefficient is not interpretable in this context.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "vicuna-7b_response": "Based on the information provided, it appears that de novo mutations in ZSWIM6 can cause both acromelic frontonasal dysostosis (AFND) and severe-profound intellectual disability with additional central and peripheral nervous system symptoms, but without frontonasal or limb malformations. The study suggests that the c.2737C>T variant in the penultimate exon of ZSWIM6 does not trigger nonsense-mediated decay of the ZSWIM6 mRNA, which supports the existence of a truncated ZSWIM6 protein lacking the Sin3-like domain. This dominant-negative effect could be responsible for the additional symptoms observed in individuals with this variant. The study also suggests that ZSWIM6 has a key role in neuronal development and function, in addition to its putative roles in limb and craniofacial development.",
    "vicuna-7b_fact_raw": "1. De novo mutations in ZSWIM6 can cause acromelic frontonasal dysostosis (AFND).\n2. De novo mutations in ZSWIM6 can cause severe-profound intellectual disability with additional central and peripheral nervous system symptoms.\n3. The c.2737C>T variant in ZSWIM6 does not trigger nonsense-mediated decay of the ZSWIM6 mRNA.\n4. A truncated ZSWIM6 protein lacking the Sin3-like domain could be associated with the symptoms observed in individuals with the c.2737C>T variant.\n5. ZSWIM6 plays a key role in neuronal development and function.",
    "vicuna-7b_fact": [
      "De novo mutations in ZSWIM6 can cause acromelic frontonasal dysostosis (AFND).",
      "De novo mutations in ZSWIM6 can cause severe-profound intellectual disability with additional central and peripheral nervous system symptoms.",
      "The c.2737C>T variant in ZSWIM6 does not trigger nonsense-mediated decay of the ZSWIM6 mRNA.",
      "A truncated ZSWIM6 protein lacking the Sin3-like domain could be associated with the symptoms observed in individuals with the c.2737C>T variant.",
      "ZSWIM6 plays a key role in neuronal development and function."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: De novo mutations in ZSWIM6 have been associated with acromelic frontonasal dysostosis (AFND) in the scientific literature.\n2. TRUE: De novo mutations in ZSWIM6 have been associated with severe-profound intellectual disability and may cause additional central and peripheral nervous system symptoms.\n3. TRUE: The c.2737C>T variant in ZSWIM6 is a nonsense mutation, and such mutations typically do not trigger nonsense-mediated decay if they occur in the last exon, which is the case for this variant. Thus, it does not trigger nonsense-mediated decay of the ZSWIM6 mRNA.\n4. TRUE: A truncated ZSWIM6 protein lacking the Sin3-like domain, resulting from the c.2737C>T variant, could potentially be associated with the symptoms observed in individuals, as the lack of critical protein domains can disrupt protein function and cause disease.\n5. TRUE: ZSWIM6 has been implicated as a gene involved in neuronal development and function, and mutations can lead to neurological disorders.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "vicuna-7b_response": "The Koos Classification is a system used to classify early onset scoliosis (EOS). The classification system is based on the etiology of the disease and the degree of curvature of the spine. The classification system is reliable and can be used as a tool for clinical communication and research. The study shows that the C-EOS scheme has excellent interobserver and intraobserver agreement. The results of the study suggest that the C-EOS scheme can be used as a reliable tool for classifying EOS patients.",
    "vicuna-7b_fact_raw": "1. The Koos Classification is used to classify early onset scoliosis (EOS).\n2. The classification system takes into account the etiology of the disease and the degree of curvature of the spine.\n3. The Koos Classification is intended for use in clinical communication and research.\n4. The C-EOS scheme within the Koos Classification demonstrates excellent interobserver agreement.\n5. The C-EOS scheme also shows excellent intraobserver agreement.",
    "vicuna-7b_fact": [
      "The Koos Classification is used to classify early onset scoliosis (EOS).",
      "The classification system takes into account the etiology of the disease and the degree of curvature of the spine.",
      "The Koos Classification is intended for use in clinical communication and research.",
      "The C-EOS scheme within the Koos Classification demonstrates excellent interobserver agreement.",
      "The C-EOS scheme also shows excellent intraobserver agreement."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: It should be the \"Cobb angle,\" not \"Koos Classification,\" which is used to classify the degree of spinal curvature in scoliosis.\n2. TRUE: A classification system for early onset scoliosis (EOS) would typically take into account the etiology of the disease and the degree of curvature of the spine.\n3. TRUE: Classification systems are generally intended for use in clinical communication and research to categorize and describe conditions consistently.\n4. UNKNOWN: Without specific research or validation studies presented for the \"C-EOS scheme\" within a so-called Koos Classification, it's not possible to confirm the level of interobserver agreement for the scheme.\n5. UNKNOWN: Similar to statement 4, without specific sources or statistics on the \"C-EOS scheme\" within a so-called Koos Classification, it's not possible to confirm the level of intraobserver agreement.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "vicuna-7b_response": "AZD8601 is a modified mRNA that encodes vascular endothelial growth factor A (VEGF-A) and has the potential to produce paracrine factors at a physiologically beneficial level, in a spatiotemporally controlled manner, and with low toxicity. It is highly promising in cardiovascular medicine and wound healing. In this study, the in vivo effects of AZD8601 were longitudinally and comprehensively characterized in mice using multi-parametric photoacoustic microscopy. The results showed that intradermal injection of AZD8601 formulated in a biocompatible vehicle resulted in pronounced, sustained, and dose-dependent vasodilation, blood flow upregulation, and neovessel formation, in contrast to recombinant human VEGF-A protein, a non-translatable variant of AZD8601, and citrate/saline vehicle. Additionally, AZD8601 was evaluated in a mouse model of diabetic wound healing, and sequential dosing of AZD8601 improved vascularization and tissue oxygenation of the wound bed, leading to accelerated re-epithelialization during the early phase of diabetic wound healing. Overall, these results suggest that AZD8601 has the potential to be an effective therapeutic for cardiovascular and wound healing diseases.",
    "vicuna-7b_fact_raw": "1. AZD8601 is a modified mRNA that encodes vascular endothelial growth factor A (VEGF-A).\n2. AZD8601 is indicated to have potential benefits in cardiovascular medicine and wound healing.\n3. In vivo effects of AZD8601 were studied in mice using multi-parametric photoacoustic microscopy.\n4. Intradermal injection of AZD8601 in mice resulted in vasodilation, blood flow upregulation, and neovessel formation.\n5. Sequential dosing of AZD8601 in a mouse model of diabetic wound healing improved vascularization and tissue oxygenation, leading to faster re-epithelialization.",
    "vicuna-7b_fact": [
      "AZD8601 is a modified mRNA that encodes vascular endothelial growth factor A (VEGF-A).",
      "AZD8601 is indicated to have potential benefits in cardiovascular medicine and wound healing.",
      "In vivo effects of AZD8601 were studied in mice using multi-parametric photoacoustic microscopy.",
      "Intradermal injection of AZD8601 in mice resulted in vasodilation, blood flow upregulation, and neovessel formation.",
      "Sequential dosing of AZD8601 in a mouse model of diabetic wound healing improved vascularization and tissue oxygenation, leading to faster re-epithelialization."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about AZD8601 are consistent with the type of research and experimental interventions that might be conducted with a therapy designed to stimulate angiogenesis via VEGF-A. However, without specific reference to published studies or clinical trials, the verification of the specific in vivo studies, their outcomes (statements 3, 4, and 5), and whether these studies were conducted in mice, remain unknown.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "vicuna-7b_response": "SAHFs, or senescence associated heterochromatic foci, are structures that form in human diploid fibroblasts (HDFs) as a result of cellular senescence. These structures are formed through the spatial repositioning of the genome, rather than through the spreading of heterochromatin. The formation of SAHFs is influenced by factors such as HMGA proteins and structural components of SAHFs, but the involvement of epigenetic marks in SAHF formation is not yet clear. Our recent study, using microscopy and ChIP-seq approaches, revealed that SAHFs are formed through the segregation of certain chromatin features, including H3K9me3 and H3K27me3, which are associated with, but do not require, these repressive marks. These repressive marks are segregated from each other within SAHFs, forming layered high-order chromatin structures (HOCS). During the dynamic change in HOCS as SAHFs form, the linear epigenomic profiles of these repressive marks are highly static, in contrast to the spreading of repressive marks during embryonic cell differentiation. The layered HOCS of SAHFs is likely achieved mainly through the spatial rearrangement of pre-existing heterochromatin, rather than the spreading of heterochromatin. The co-association of similar types of chromatin is also emerging, and SAHFs may provide a unique model system to study the correlation between HOCS and chromatin types, which are readily visible and regulable.",
    "vicuna-7b_fact_raw": "1. SAHFs, or senescence associated heterochromatic foci, form in human diploid fibroblasts as a result of cellular senescence.\n2. The formation of SAHFs is influenced by factors such as HMGA proteins and structural components of SAHFs.\n3. SAHFs are formed through the segregation of certain chromatin features, including H3K9me3 and H3K27me3.\n4. During the formation of SAHFs, these repressive marks form layered high-order chromatin structures (HOCS) and are segregated from each other.\n5. The spatial rearrangement of pre-existing heterochromatin contributes to the layered HOCS of SAHFs, rather than the spreading of heterochromatin.",
    "vicuna-7b_fact": [
      "SAHFs, or senescence associated heterochromatic foci, form in human diploid fibroblasts as a result of cellular senescence.",
      "The formation of SAHFs is influenced by factors such as HMGA proteins and structural components of SAHFs.",
      "SAHFs are formed through the segregation of certain chromatin features, including H3K9me3 and H3K27me3.",
      "During the formation of SAHFs, these repressive marks form layered high-order chromatin structures (HOCS) and are segregated from each other.",
      "The spatial rearrangement of pre-existing heterochromatin contributes to the layered HOCS of SAHFs, rather than the spreading of heterochromatin."
    ],
    "vicuna-7b_judge_raw": "1. TRUE: SAHFs, or senescence-associated heterochromatic foci, do form in human diploid fibroblasts as a result of cellular senescence.\n2. TRUE: The formation of SAHFs is influenced by factors such as High Mobility Group A (HMGA) proteins, which are indeed structural components of SAHFs.\n3. TRUE: SAHFs are formed through the segregation of certain chromatin features, including the histone marks H3K9me3 and H3K27me3, which are associated with transcriptional repression.\n4. FALSE [correction]: During the formation of SAHFs, repressive marks such as H3K9me3 contribute to the formation of high-order chromatin structures (HOCS); however, the statement about them being segregated from each other requires more specific context to verify, as typically these marks co-localize to form the SAHF structure.\n5. TRUE: The spatial rearrangement of pre-existing heterochromatin does contribute to the layered HOCS of SAHFs, and this rearrangement is crucial in forming SAHFs rather than a simple spreading of heterochromatin.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "vicuna-7b_response": "The PDZ domain of SATB1 plays a critical role in its in vivo function as a global repressor. The N-terminal PDZ-like domain of SATB1 mediates interactions with several chromatin proteins, but lacks DNA binding activity. Overexpression of the PDZ-like domain results in de-repression of genes regulated by SATB1, indicating that it exerts a dominant negative effect on these genes. To study the effect of sequestration of the interaction partners on the global gene regulation by SATB1, a stable dominant negative model was developed in human embryonic kidney (HEK) 293T cells. Transcripts from induced and uninduced clones were subjected to gene expression profiling, which revealed that 600 out of 19000 genes were significantly upregulated upon overexpression of the PDZ-like domain. These studies demonstrate that the PDZ domain of SATB1 is involved in global gene regulation presumably through its interaction with other cellular proteins.",
    "vicuna-7b_fact_raw": "1. The PDZ domain of SATB1 plays a role as a global repressor.\n2. The N-terminal PDZ-like domain of SATB1 mediates interactions with chromatin proteins but does not bind DNA.\n3. Overexpression of the PDZ-like domain of SATB1 leads to de-repression of genes regulated by SATB1.\n4. A stable dominant negative model involving the PDZ-like domain of SATB1 was developed in human embryonic kidney (HEK) 293T cells.\n5. Gene expression profiling showed that 600 out of 19000 genes were significantly upregulated upon overexpression of the PDZ-like domain of SATB1.",
    "vicuna-7b_fact": [
      "The PDZ domain of SATB1 plays a role as a global repressor.",
      "The N-terminal PDZ-like domain of SATB1 mediates interactions with chromatin proteins but does not bind DNA.",
      "Overexpression of the PDZ-like domain of SATB1 leads to de-repression of genes regulated by SATB1.",
      "A stable dominant negative model involving the PDZ-like domain of SATB1 was developed in human embryonic kidney (HEK) 293T cells.",
      "Gene expression profiling showed that 600 out of 19000 genes were significantly upregulated upon overexpression of the PDZ-like domain of SATB1."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: Without specific information about SATB1 and its functions in the provided context, it is not possible to ascertain the accuracy of this statement.\n2. UNKNOWN: Similarly to statement 1, without additional context, the specific role of the N-terminal PDZ-like domain of SATB1 cannot be confirmed.\n3. UNKNOWN: Whether overexpression of the PDZ-like domain of SATB1 leads to the de-repression of genes is not something that can be determined without contextual data.\n4. UNKNOWN: The development of a stable dominant negative model using the PDZ-like domain of SATB1 in HEK 293T cells requires specific scientific research evidence to confirm.\n5. UNKNOWN: Gene expression profiling results are very specific and require the context of the experimental data to confirm the accuracy of the number of genes upregulated upon overexpression of SATB1's PDZ-like domain.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "vicuna-7b_response": "The BLISS technique is based on the use of Blissymbols, a system of symbols that represent words or concepts. The technique aims to facilitate communication for individuals with aphasia and severe verbal apraxia by using Blissymbols as an alternative means of communication. The basis of the BLISS technique is that individuals with good auditory comprehension, visual-perceptual skills, and a high level of motivation are more successful in using Blissymbols as a facilitating technique. The use of Blissymbols is found to encourage verbal language and writing skills, even though not stressed. The group therapy approach provides needed motivation and proves beneficial.",
    "vicuna-7b_fact_raw": "1. The BLISS technique uses Blissymbols, a system of symbols that represent words or concepts.\n2. The BLISS technique is intended to aid communication for individuals with aphasia and severe verbal apraxia.\n3. Success in using Blissymbols is associated with individuals having good auditory comprehension, visual-perceptual skills, and a high level of motivation.\n4. Blissymbols usage is thought to encourage verbal language and writing skills.\n5. Group therapy is part of the BLISS technique and is deemed to provide needed motivation.",
    "vicuna-7b_fact": [
      "The BLISS technique uses Blissymbols, a system of symbols that represent words or concepts.",
      "The BLISS technique is intended to aid communication for individuals with aphasia and severe verbal apraxia.",
      "Success in using Blissymbols is associated with individuals having good auditory comprehension, visual-perceptual skills, and a high level of motivation.",
      "Blissymbols usage is thought to encourage verbal language and writing skills.",
      "Group therapy is part of the BLISS technique and is deemed to provide needed motivation."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe fifth statement is difficult to evaluate without specific text or context confirming the use of group therapy as part of the BLISS technique and whether it is considered to provide motivation. Group therapy could be a strategy used in some implementations of the BLISS technique, but without a specific reference, it's not possible to accurately determine the truth of this statement.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "vicuna-7b_response": "1. Compound 1: A C3-alkylsulfoxide substituted quinoline with excellent NK3 functional activity, good selectivity, and drug-like properties. It has been reported to have good in vitro/in vivo DMPK characteristics and is active in a gerbil locomotor activity model.\n2. Compound 2: Another C3-alkylsulfoxide substituted quinoline with excellent NK3 functional activity, good selectivity, and drug-like properties. It has been reported to have good in vitro/in vivo DMPK characteristics and is active in a gerbil locomotor activity model.\n3. Compound 3: A third C3-alkylsulfoxide substituted quinoline with excellent NK3 functional activity, good selectivity, and drug-like properties. It has been reported to have good in vitro/in vivo DMPK characteristics and is active in a gerbil locomotor activity model.",
    "vicuna-7b_fact_raw": "1. Compound 1 is a C3-alkylsulfoxide substituted quinoline that shows excellent NK3 functional activity.\n2. Compound 1 has demonstrated good in vitro/in vivo drug metabolism and pharmacokinetics (DMPK) characteristics.\n3. Compound 1 is reported to be active in a gerbil locomotor activity model.\n4. Compounds 2 and 3 are also C3-alkylsulfoxide substituted quinolines with excellent NK3 functional activity and good in vitro/in vivo DMPK characteristics.\n5. All three compounds (Compound 1, 2, and 3) are indicated to have drug-like properties and good selectivity.",
    "vicuna-7b_fact": [
      "Compound 1 is a C3-alkylsulfoxide substituted quinoline that shows excellent NK3 functional activity.",
      "Compound 1 has demonstrated good in vitro/in vivo drug metabolism and pharmacokinetics (DMPK) characteristics.",
      "Compound 1 is reported to be active in a gerbil locomotor activity model.",
      "Compounds 2 and 3 are also C3-alkylsulfoxide substituted quinolines with excellent NK3 functional activity and good in vitro/in vivo DMPK characteristics.",
      "All three compounds (Compound 1, 2, and 3) are indicated to have drug-like properties and good selectivity."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truthfulness of these statements cannot be verified without the specific scientific study or literature that describes the properties and activities of Compound 1, Compound 2, and Compound 3. Without such context, the statements remain unclear.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "vicuna-7b_response": "The drug that is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is compound 47. Compound 47 is a chemotype of ghrelin inverse agonists that was discovered through chimeric design based on molecular scaffolds known as growth-hormone secretagogue receptor (GHSR) modulators but with divergent pharmacodynamic and pharmacokinetic properties. It has been shown to display potent human GHSR antagonism and inverse agonism in cellular assays, with an IC50 of 68 nM and an EC50 of 29 nM. It also has moderate oral bioavailability and notable brain penetration in rats, leading to effective reduction of food intake in mice after oral or parenteral administration. Further preclinical studies are needed to evaluate the most suitable mode of administration with the aim of promoting a first central-acting ghrelin inverse agonist molecule to development, which would represent a significant step toward therapeutic agents to treat metabolic disorders related to obesity, such as type 2 diabetes mellitus.",
    "vicuna-7b_fact_raw": "1. Compound 47 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Compound 47 exhibited potent human GHSR antagonism and inverse agonism in cellular assays with an IC50 of 68 nM.\n3. Compound 47 had an EC50 of 29 nM in cellular assays.\n4. The drug has moderate oral bioavailability and notable brain penetration in rats.\n5. Compound 47 effectively reduced food intake in mice after both oral and parenteral administration.",
    "vicuna-7b_fact": [
      "Compound 47 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Compound 47 exhibited potent human GHSR antagonism and inverse agonism in cellular assays with an IC50 of 68 nM.",
      "Compound 47 had an EC50 of 29 nM in cellular assays.",
      "The drug has moderate oral bioavailability and notable brain penetration in rats.",
      "Compound 47 effectively reduced food intake in mice after both oral and parenteral administration."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information regarding \"Compound 47,\" its trials, or efficacy, it is impossible to determine the veracity of these technical statements. They seem specific and could be true within a particular scientific context, however, without access to the relevant scientific studies or data, their truth value cannot be ascertained.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "vicuna-7b_response": "Vaxchora is a cholera vaccine that is effective in providing protection against moderate to severe cholera. A study conducted in Guinea found that two doses of Shanchol, the oral cholera vaccine used in Vaxchora, were associated with an 86.6% effectiveness in preventing cholera when used as part of an integrated response to a cholera outbreak. The study also supports the use of vaccination as part of emergency response strategies to prevent and control cholera outbreaks.",
    "vicuna-7b_fact_raw": "1. Vaxchora is a cholera vaccine.\n2. Vaxchora provides protection against moderate to severe cholera.\n3. A study in Guinea found that two doses of Shanchol have an 86.6% effectiveness in preventing cholera.\n4. The study indicates the oral cholera vaccine used in Vaxchora is Shanchol.\n5. The study supports vaccination as part of emergency response strategies for cholera outbreaks.",
    "vicuna-7b_fact": [
      "Vaxchora is a cholera vaccine.",
      "Vaxchora provides protection against moderate to severe cholera.",
      "A study in Guinea found that two doses of Shanchol have an 86.6% effectiveness in preventing cholera.",
      "The study indicates the oral cholera vaccine used in Vaxchora is Shanchol.",
      "The study supports vaccination as part of emergency response strategies for cholera outbreaks."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (Without specific reference to this study, the exact effectiveness percentage cannot be confirmed)\n4. FALSE [correction]: Vaxchora and Shanchol are different vaccines; Vaxchora contains a live, attenuated strain of the Vibrio cholerae bacterium, while Shanchol is an inactivated vaccine containing killed bacteria. They are not the same product.\n5. TRUE (Generally, studies supporting the use of oral cholera vaccines would support vaccination as part of emergency response strategies for cholera outbreaks, but without specific reference to the study, this cannot be confirmed as related to that particular study)",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "vicuna-7b_response": "The first cholera vaccine approved in the US was the oral live cholera vaccine CVD 103-HgR (Orochol, Mutachol), which was launched in 1993 in Switzerland. This vaccine was considered to be an ideal cholera vaccine as it was a single-dose, provided protection against moderate to severe cholera with efficacy of 80-100%, acted within 8 days and had excellent safety, indistinguishable from placebo. However, the vaccine faced several challenges, including downplaying of the indication for cholera vaccines by experts and a moratorium on genetically modified organisms (GMOs) by the European Commission in 1997, which blocked its registration in the European Union. As a result, demand for this vaccine remained low and it was taken off the market in 2003 for economic reasons. However, after a decade in obscurity, the vaccine has resurfaced again, now produced in the US and equipped with a US FDA license (June 10, 2016). The vaccine, now known as Vaxchora, is now available for at-risk populations and travelers alike.",
    "vicuna-7b_fact_raw": "1. The first cholera vaccine approved in the US was CVD 103-HgR, also known as Orochol and Mutachol.\n2. CVD 103-HgR was launched in 1993 in Switzerland.\n3. The vaccine CVD 103-HgR had an efficacy of 80-100% against moderate to severe cholera and acted within 8 days.\n4. A moratorium on genetically modified organisms by the European Commission in 1997 impacted the registration of the vaccine in the European Union.\n5. The vaccine CVD 103-HgR was taken off the market in 2003 but resurfaced with a US FDA license on June 10, 2016, and is now known as Vaxchora.",
    "vicuna-7b_fact": [
      "The first cholera vaccine approved in the US was CVD 103-HgR, also known as Orochol and Mutachol.",
      "CVD 103-HgR was launched in 1993 in Switzerland.",
      "The vaccine CVD 103-HgR had an efficacy of 80-100% against moderate to severe cholera and acted within 8 days.",
      "A moratorium on genetically modified organisms by the European Commission in 1997 impacted the registration of the vaccine in the European Union.",
      "The vaccine CVD 103-HgR was taken off the market in 2003 but resurfaced with a US FDA license on June 10, 2016, and is now known as Vaxchora."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE: However, it's important to note that the efficacy might vary depending on several factors, but reports suggest an efficacy in this range for CVD 103-HgR.\n4. UNKNOWN: While there was a moratorium on genetically modified organisms in Europe, its direct impact on the registration of the cholera vaccine CVD 103-HgR in the European Union is not clearly established without more specific information.\n5. TRUE: CVD 103-HgR was indeed taken off the market due to manufacturing problems and was later approved by the US FDA under the name Vaxchora on June 10, 2016.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "vicuna-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is Fc receptor deficiency. This is based on the information provided in Document-0, which describes a patient with CVID who developed renal granulomatous disease and was treated with corticosteroid treatment and intravenous immunoglobulin infusions. The pathogenesis of granulomatous disease in CVID is unclear, but it may involve monocyte and T-cell abnormalities. Fc receptor deficiency is one of the most common monogenic causes of CVID in Europeans, and it is characterized by a decreased serum immunoglobulin level, recurrent infections, and the occurrence of various autoimmune diseases.",
    "vicuna-7b_fact_raw": "1. Fc receptor deficiency is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. Patients with CVID may develop renal granulomatous disease.\n3. Treatment for patients with CVID can include corticosteroid treatment and intravenous immunoglobulin infusions.\n4. The pathogenesis of granulomatous disease in CVID may involve monocyte and T-cell abnormalities.\n5. Fc receptor deficiency is characterized by decreased serum immunoglobulin levels, recurrent infections, and the occurrence of various autoimmune diseases.",
    "vicuna-7b_fact": [
      "Fc receptor deficiency is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "Patients with CVID may develop renal granulomatous disease.",
      "Treatment for patients with CVID can include corticosteroid treatment and intravenous immunoglobulin infusions.",
      "The pathogenesis of granulomatous disease in CVID may involve monocyte and T-cell abnormalities.",
      "Fc receptor deficiency is characterized by decreased serum immunoglobulin levels, recurrent infections, and the occurrence of various autoimmune diseases."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: The most common monogenic cause of CVID in Europeans is not well-established; however, mutations in genes such as ICOS, TNFRSF13B (TACI), and TNFRSF13C (BAFF-R) can contribute to the condition.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "vicuna-7b_response": "The IFIT1 gene has not been reported to have a direct role in Systemic Lupus Erythematosus (SLE). However, the IFIT1 gene has been shown to play a role in regulating the expression of cytokines such as interferon-gamma (IFNG), which is known to play a key role in controlling the immunity and inflammation in SLE. The IFNG gene has been previously reported to be associated with SLE, and its polymorphisms may affect the expression levels of IFNG among individuals.\nIn the provided document, the frequency of a polymorphism in the IFNG gene intron (+874) was investigated in a case-control study of 154 Systemic Lupus Erythematosus (SLE) patients and 154 healthy control subjects with similar ethnic backgrounds. The results showed that the allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects. However, there was a significant association between the A allele of the IFNG (+874) gene polymorphism and arthritis in SLE patients in the Thai population.\nIn summary, while the IFIT1 gene has not been directly implicated in SLE, the IFNG gene, which is regulated by the IFIT1 gene, has been shown to play a role in the disease. The IFNG (+874) gene polymorphism has been reported to be associated with SLE, and the A allele of this polymorphism may be a marker for SLE susceptibility with arthritis in the Thai population.",
    "vicuna-7b_fact_raw": "1. The IFIT1 gene regulates the expression of cytokines such as interferon-gamma (IFNG).\n2. Interferon-gamma (IFNG) plays a key role in controlling immunity and inflammation in Systemic Lupus Erythematosus (SLE).\n3. Polymorphisms in the IFNG gene have been associated with Systemic Lupus Erythematosus (SLE).\n4. A case-control study involved 154 Systemic Lupus Erythematosus (SLE) patients and 154 healthy control subjects with similar ethnic backgrounds.\n5. The A allele of the IFNG (+874) gene polymorphism has been found to be significantly associated with arthritis in SLE patients in the Thai population.",
    "vicuna-7b_fact": [
      "The IFIT1 gene regulates the expression of cytokines such as interferon-gamma (IFNG).",
      "Interferon-gamma (IFNG) plays a key role in controlling immunity and inflammation in Systemic Lupus Erythematosus (SLE).",
      "Polymorphisms in the IFNG gene have been associated with Systemic Lupus Erythematosus (SLE).",
      "A case-control study involved 154 Systemic Lupus Erythematosus (SLE) patients and 154 healthy control subjects with similar ethnic backgrounds.",
      "The A allele of the IFNG (+874) gene polymorphism has been found to be significantly associated with arthritis in SLE patients in the Thai population."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\n1. The IFIT1 gene is indeed involved in the response to viral infections, including the regulation of interferon-stimulated genes, which can include those related to cytokines such as interferon-gamma (IFNG).\n2. Interferon-gamma (IFNG) is a key cytokine in the immune response and has been implicated in the pathogenesis of autoimmune diseases such as Systemic Lupus Erythematosus (SLE).\n3. Genetic variations, or polymorphisms, in the IFNG gene have been studied in various populations to understand their association with SLE and other diseases.\n4. & 5. The details provided in statements 4 and 5 about a specific study, including the exact number of patients and control subjects as well as findings related to the A allele of the IFNG gene in Thai SLE patients, require access to specific study data or publications to confirm their accuracy. Since such specific details are not commonly known without reference to the particular research, I categorized these as UNKNOWN.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "vicuna-7b_response": "The Liverpool Elbow Score (LES) is a validated elbow-specific score that consists of a patient-answered questionnaire (PAQ) and a clinical assessment. The purpose of this study was to determine whether the PAQ portion of the LES could be used independently as a postal questionnaire for the assessment of outcome after total elbow arthroplasty. The study included 51 total elbow replacements, with patients answering the postal questionnaire and then attending the clinic for assessment by use of both the LES and the Mayo Elbow Performance Score (MEPS). The results showed good correlation between the LES and the MEPS (Spearman correlation coefficient, 0.84; P < .001) and between the PAQ portion of the LES and the MEPS (Spearman correlation coefficient, 0.76; P < .001). The study concluded that there is good correlation between the LES PAQ component and the MEPS, suggesting that outcome assessment is possible by postal questionnaire.",
    "vicuna-7b_fact_raw": "1. The Liverpool Elbow Score (LES) includes a patient-answered questionnaire (PAQ) and a clinical assessment.\n2. The study investigated if the PAQ portion of the LES could be used as a postal questionnaire for outcome assessment after total elbow arthroplasty.\n3. The study included 51 total elbow replacements.\n4. There was a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with a Spearman correlation coefficient of 0.84 (P < .001).\n5. There was also a good correlation between the PAQ portion of the LES and the MEPS with a Spearman correlation coefficient of 0.76 (P < .001).",
    "vicuna-7b_fact": [
      "The Liverpool Elbow Score (LES) includes a patient-answered questionnaire (PAQ) and a clinical assessment.",
      "The study investigated if the PAQ portion of the LES could be used as a postal questionnaire for outcome assessment after total elbow arthroplasty.",
      "The study included 51 total elbow replacements.",
      "There was a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with a Spearman correlation coefficient of 0.84 (P < .001).",
      "There was also a good correlation between the PAQ portion of the LES and the MEPS with a Spearman correlation coefficient of 0.76 (P < .001)."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements refer to specific details about the Liverpool Elbow Score and its correlation with the Mayo Elbow Performance Score, which are very domain-specific and require access to the relevant study or data to verify. Without that information, the truth of statements 3, 4, and 5 cannot be determined in this format.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "vicuna-7b_response": "The 100,000 Genomes Project is a large-scale initiative aimed at sequencing the genomes of 100,000 people in the UK. The project was launched with the goal of advancing our understanding of genetic variation and improving the diagnosis and treatment of rare diseases. As part of the project, the UK Biobank, a large-scale study of the genetics and health of 500,000 people, was also integrated into the project.\nOne of the primary goals of the 100,000 Genomes Project is to create a deep catalog of human genetic variation. This catalog will include information on the types of genetic variations that exist in the population, as well as the frequency of those variations. This information will be used to better understand the genetic basis of disease and to develop new diagnostic tools.\nIn addition to the primary scientific goals of the project, the 100,000 Genomes Project also makes all of its data publicly available. This means that researchers from around the world can access the data and use it to advance our understanding of genetics and disease. The project has developed several tools to enable widespread data access, including a web portal and a suite of analysis tools.\nThe 100,000 Genomes Project has made significant progress in advancing our understanding of genetic variation and its role in disease. The project has also made it easier for researchers around the world to access and use this data to advance their own research.",
    "vicuna-7b_fact_raw": "1. The 100,000 Genomes Project aims at sequencing the genomes of 100,000 people in the UK.\n2. The UK Biobank, a study of the genetics and health of 500,000 people, was integrated into the 100,000 Genomes Project.\n3. A goal of the 100,000 Genomes Project is to create a catalog of human genetic variation.\n4. The 100,000 Genomes Project's data is publicly available to researchers worldwide.\n5. The project provides a web portal and tools to facilitate access to its genetic data.",
    "vicuna-7b_fact": [
      "The 100,000 Genomes Project aims at sequencing the genomes of 100,000 people in the UK.",
      "The UK Biobank, a study of the genetics and health of 500,000 people, was integrated into the 100,000 Genomes Project.",
      "A goal of the 100,000 Genomes Project is to create a catalog of human genetic variation.",
      "The 100,000 Genomes Project's data is publicly available to researchers worldwide.",
      "The project provides a web portal and tools to facilitate access to its genetic data."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The UK Biobank is a separate project from the 100,000 Genomes Project, albeit both are large-scale biomedical databases in the UK.\n3. TRUE\n4. FALSE [correction]: The 100,000 Genomes Projects data is available for researchers, but typically access is controlled and there may be restrictions based on consent, intended use, and user qualifications.\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "vicuna-7b_response": "Yes, protein ALEX1 contains armadillo repeats. ALEX1 is a protein that contains two armadillo repeat domains and is expressed differently in normal and cancerous tissues. Several studies have found that ALEX1 protein is lost in tumors that originate in epithelial tissues, including cervical cancer. The results of one study showed that ALEX1 protein expression is significantly increased in cervical cancer tissues compared to non-cancerous tissues, suggesting that it may play a role in tumorigenesis and may serve as a potential diagnostic biomarker for cervical cancer.",
    "vicuna-7b_fact_raw": "1. Protein ALEX1 contains two armadillo repeat domains.\n2. Protein ALEX1 is expressed differently in normal and cancerous tissues.\n3. ALEX1 protein is lost in tumors that originate in epithelial tissues.\n4. ALEX1 protein expression is significantly increased in cervical cancer tissues compared to non-cancerous tissues.\n5. ALEX1 may serve as a potential diagnostic biomarker for cervical cancer.",
    "vicuna-7b_fact": [
      "Protein ALEX1 contains two armadillo repeat domains.",
      "Protein ALEX1 is expressed differently in normal and cancerous tissues.",
      "ALEX1 protein is lost in tumors that originate in epithelial tissues.",
      "ALEX1 protein expression is significantly increased in cervical cancer tissues compared to non-cancerous tissues.",
      "ALEX1 may serve as a potential diagnostic biomarker for cervical cancer."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Protein ALEX1 (ARMCX1) contains ARM domain repeats, but it is not described as having two armadillo repeat domains.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: If ALEX1 protein is lost in tumors originating from epithelial tissues, which cervical cancer is, it would not be correct to say its expression is increased in these cancerous tissues compared to non-cancerous tissues.\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "vicuna-7b_response": "Document-0 provides information on histone deacetylases (HDACs), which are enzymes that remove acetyl groups from the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones. There are 18 potential deacetylase enzymes in humans that are responsible for the removal of acetyl groups and maintenance of the equilibrium of lysine acetylation on histones. HDACs can also modify non-histone proteins. The article provides up-to-date, easy-to-follow approaches and techniques specifically for the assay of HDAC enzymatic activities.",
    "vicuna-7b_fact_raw": "1. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from the amino groups of lysine residues in histone proteins.\n2. There are 18 potential deacetylase enzymes in humans that are involved in histone modification.\n3. HDACs are responsible for the maintenance of the equilibrium of lysine acetylation on histones.\n4. HDACs have the capability to modify non-histone proteins.",
    "vicuna-7b_fact": [
      "Histone deacetylases (HDACs) are enzymes that remove acetyl groups from the amino groups of lysine residues in histone proteins.",
      "There are 18 potential deacetylase enzymes in humans that are involved in histone modification.",
      "HDACs are responsible for the maintenance of the equilibrium of lysine acetylation on histones.",
      "HDACs have the capability to modify non-histone proteins."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE - While the exact number can vary slightly depending on the classification criteria used in research, 18 is commonly accepted.\n3. TRUE - HDACs are indeed involved in maintaining the balance of lysine acetylation on histones, working in opposition to histone acetyltransferases (HATs).\n4. TRUE - HDACs are also known to modify non-histone proteins, affecting various cellular functions beyond chromatin remodeling.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "vicuna-7b_response": "Based on the information provided, it appears that head CT scans may increase the risk of benign brain tumors in children. The study found that the frequency of CT examination was strongly correlated with the subsequent risk of malignancy and benign brain tumors. However, it is important to note that the study was limited by its retrospective design and the relatively small sample size. Therefore, further research is needed to confirm these findings and to better understand the potential risks and benefits of head CT scans in children.",
    "vicuna-7b_fact_raw": "1. Head CT scans may increase the risk of benign brain tumors in children.\n2. The frequency of CT examination was strongly correlated with the subsequent risk of malignancy and benign brain tumors according to the study mentioned.\n3. The study discussed was of retrospective design.\n4. The study discussed had a relatively small sample size.\n5. The answer suggests that further research is needed to confirm the findings related to head CT scans and brain tumor risks in children.",
    "vicuna-7b_fact": [
      "Head CT scans may increase the risk of benign brain tumors in children.",
      "The frequency of CT examination was strongly correlated with the subsequent risk of malignancy and benign brain tumors according to the study mentioned.",
      "The study discussed was of retrospective design.",
      "The study discussed had a relatively small sample size.",
      "The answer suggests that further research is needed to confirm the findings related to head CT scans and brain tumor risks in children."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "vicuna-7b_response": "Otx2 is associated with primed pluripotency.",
    "vicuna-7b_fact_raw": "1. Otx2 is associated with primed pluripotency.",
    "vicuna-7b_fact": [
      "Otx2 is associated with primed pluripotency."
    ],
    "vicuna-7b_judge_raw": "1. TRUE",
    "vicuna-7b_judge": [
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "vicuna-7b_response": "Based on the information provided, there are 11 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region.",
    "vicuna-7b_fact_raw": "1. There are 11 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region.",
    "vicuna-7b_fact": [
      "There are 11 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region."
    ],
    "vicuna-7b_judge_raw": "UNKNOWN\n\nThe specificity of the number of DNaseI hypersensitive sites (DHS) within the murine beta globin locus region would require detailed scientific knowledge or data which is not provided in the context. This level of detail can vary based on the experimental conditions and the resolution of the assays used to map DHS. Therefore, without further information, the truth of this statement cannot be established.",
    "vicuna-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "vicuna-7b_response": "Here is a list of European influenza vaccines:\n1. AstraZeneca FluMist Quadrivalent (Influenza Virus Vaccine, Live, Quadrivalent)\n2. Seqirus Fluvirin Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n3. GlaxoSmithKline FluLaval Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n4. Sanofi Pasteur Fluzone Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n5. Seqirus Afluria Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n6. AstraZeneca Fluad Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n7. Novartis Flucelvax Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n8. Seqirus Fluarix Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n9. GlaxoSmithKline Fluarix Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\n10. Sanofi Pasteur Fluzone High-Dose Quadrivalent (Influenza Virus Vaccine, Quadrivalent)\nNote: This list is not exhaustive and may not be up-to-date. It is recommended to check with the relevant authorities for the most recent information on influenza vaccines available in Europe.",
    "vicuna-7b_fact_raw": "1. AstraZeneca FluMist Quadrivalent is an influenza virus vaccine that is available in Europe.\n2. Seqirus Fluvirin Quadrivalent is a quadrivalent influenza virus vaccine offered in Europe.\n3. GlaxoSmithKline FluLaval Quadrivalent is another quadrivalent influenza virus vaccine provided in European countries.\n4. Sanofi Pasteur Fluzone Quadrivalent is a quadrivalent influenza virus vaccine found in Europe.\n5. Sanofi Pasteur Fluzone High-Dose Quadrivalent is a high-dose influenza virus vaccine available in Europe.",
    "vicuna-7b_fact": [
      "AstraZeneca FluMist Quadrivalent is an influenza virus vaccine that is available in Europe.",
      "Seqirus Fluvirin Quadrivalent is a quadrivalent influenza virus vaccine offered in Europe.",
      "GlaxoSmithKline FluLaval Quadrivalent is another quadrivalent influenza virus vaccine provided in European countries.",
      "Sanofi Pasteur Fluzone Quadrivalent is a quadrivalent influenza virus vaccine found in Europe.",
      "Sanofi Pasteur Fluzone High-Dose Quadrivalent is a high-dose influenza virus vaccine available in Europe."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: AstraZeneca's FluMist Quadrivalent is a live attenuated influenza vaccine primarily available in the United States. Though it may have been approved in some European countries, it is not widely available across Europe.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Sanofi Pasteur Fluzone High-Dose Quadrivalent is a high-dose influenza virus vaccine mainly available in the United States and not widely available in Europe.",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "vicuna-7b_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses have a nonsegmented negative-stranded RNA genome, which is segmented. Each genomic segment is flanked by authentic NDV 3' and 5' noncoding termini allowing for efficient replication and transcription. The rescued viruses grew well and were stable in embryonated chicken eggs over multiple passages. The reporter genes encoding green fluorescent protein (GFP) and red fluorescent protein dsRed were inserted into one segment, and a chimeric virus expressing GFP and the severe acute respiratory syndrome-associated coronavirus spike S protein was also rescued, which extended the coding capacity of NDV by 30%.",
    "vicuna-7b_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. Paramyxovirus genomes have nonsegmented negative-stranded RNA.\n3. Each genomic segment of Paramyxovirus has NDV 3' and 5' noncoding termini.\n4. Rescued Paramyxoviruses can replicate in embryonated chicken eggs over multiple passages.\n5. The coding capacity of NDV (Newcastle Disease Virus) can be extended by 30%.",
    "vicuna-7b_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "Paramyxovirus genomes have nonsegmented negative-stranded RNA.",
      "Each genomic segment of Paramyxovirus has NDV 3' and 5' noncoding termini.",
      "Rescued Paramyxoviruses can replicate in embryonated chicken eggs over multiple passages.",
      "The coding capacity of NDV (Newcastle Disease Virus) can be extended by 30%."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Since Paramyxovirus genomes are nonsegmented, the statement about each \"genomic segment\" having NDV 3' and 5' noncoding termini is incorrect. Instead, there is one negative-sense RNA genome with 3' and 5' noncoding regions.\n4. TRUE\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "vicuna-7b_response": "Roflumilast Cream is effective for the treatment of cerebral inflammation following subarachnoid hemorrhage (SAH) as shown by a study that investigated the effects of roflumilast on the rat SAH model. The study found that subcutaneous administration of roflumilast (3 mg/kg) significantly improved neurological deficits, reduced blood-brain barrier permeability and brain edema, and decreased levels of inflammatory cytokines and the number of apoptotic neurons in the brain. Therefore, Roflumilast Cream is effective for treating cerebral inflammation following SAH.",
    "vicuna-7b_fact_raw": "1. Roflumilast Cream is used for the treatment of cerebral inflammation following subarachnoid hemorrhage (SAH).\n2. A study on the rat SAH model showed that roflumilast improves neurological deficits.\n3. In the study, roflumilast reduced blood-brain barrier permeability and brain edema.\n4. The study found that roflumilast decreased levels of inflammatory cytokines in the brain.\n5. Roflumilast was observed to reduce the number of apoptotic neurons in the brain following SAH.",
    "vicuna-7b_fact": [
      "Roflumilast Cream is used for the treatment of cerebral inflammation following subarachnoid hemorrhage (SAH).",
      "A study on the rat SAH model showed that roflumilast improves neurological deficits.",
      "In the study, roflumilast reduced blood-brain barrier permeability and brain edema.",
      "The study found that roflumilast decreased levels of inflammatory cytokines in the brain.",
      "Roflumilast was observed to reduce the number of apoptotic neurons in the brain following SAH."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Roflumilast is a drug used to treat chronic obstructive pulmonary disease (COPD), not cerebral inflammation following subarachnoid hemorrhage (SAH).\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction and determination of the first statement are based on the known use of Roflumilast as of my knowledge cutoff date. The unknowns for statements 2-5 are due to the lack of context or reference to a specific study which would provide details necessary to evaluate the truthfulness of these statements.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "vicuna-7b_response": "There are several bioinformatics tools that have been developed for identifying and visualizing ncRNA promoters. One such tool is the database RiboGap, which is a primary tool for finding known ncRNAs and uncovering simple sequence motifs with regulatory roles. RiboGap can also be used to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes. Additionally, RiboGap can be used to extend analysis and choose the best candidate ncRNAs for experimental validation.\nAnother tool for identifying ncRNA promoters is the program called \"PromoterPredict\". This tool uses a machine learning approach to predict the presence of promoters in ncRNA sequences. It can also be used to predict the transcription start site and the direction of transcription.\nAnother tool is called \"RNAhybrid\" which is a tool for the discovery of new ncRNAs and the identification of their promoters. It uses a combination of computational and experimental approaches to identify ncRNAs and their promoters.\nIn addition, there are also tools like \"RNA-seq analysis tools\" which are used to analyze RNA-seq data and identify ncRNA promoters. These tools can be used to identify the transcription start site, the direction of transcription, and the promoter region of ncRNAs.\nIt's worth noting that these are just a few examples of the many tools that have been developed for identifying and visualizing ncRNA promoters. The choice of tool will depend on the specific research question and the available data.",
    "vicuna-7b_fact_raw": "1. RiboGap is a database used for finding known ncRNAs as well as identifying simple sequence motifs with regulatory roles.\n2. RiboGap can be utilized to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes.\n3. PromoterPredict is a program that uses machine learning to predict the presence of promoters in ncRNA sequences.\n4. RNAhybrid is a tool that combines computational and experimental approaches for the discovery of new ncRNAs and the identification of their promoters.\n5. RNA-seq analysis tools are used to analyze RNA-seq data to identify the transcription start site, direction of transcription, and promoter regions of ncRNAs.",
    "vicuna-7b_fact": [
      "RiboGap is a database used for finding known ncRNAs as well as identifying simple sequence motifs with regulatory roles.",
      "RiboGap can be utilized to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes.",
      "PromoterPredict is a program that uses machine learning to predict the presence of promoters in ncRNA sequences.",
      "RNAhybrid is a tool that combines computational and experimental approaches for the discovery of new ncRNAs and the identification of their promoters.",
      "RNA-seq analysis tools are used to analyze RNA-seq data to identify the transcription start site, direction of transcription, and promoter regions of ncRNAs."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: RiboGap is a method for designing ribozyme gapmers, which are molecules used to specifically target and cleave RNA. It is not a database for finding known ncRNAs or identifying simple sequence motifs with regulatory roles.\n2. FALSE [correction]: Since RiboGap is not a database, it cannot be utilized to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures; it is a method relating to ribozyme gapmers.\n3. TRUE: PromoterPredict is indeed a program that utilizes machine learning algorithms to predict the presence of bacterial promoters in DNA sequences, which could include non-coding RNA (ncRNA) sequences.\n4. FALSE [correction]: RNAhybrid is a tool that predicts potential microRNA binding sites in an mRNA or ncRNA target sequence by finding the energetically most favorable hybridization sites for a given microRNA; it does not combine computational and experimental approaches for discovery of new ncRNAs or identification of promoters.\n5. TRUE: RNA-seq analysis tools are indeed used to analyze RNA-seq data which can help identify the transcription start site, direction of transcription, and promoter regions among other genomic features.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "vicuna-7b_response": "The SWIM tool has identified 137 up-regulated and 63 down-regulated genes in gliomas and glioblastoma. The up-regulated genes are associated with the PI3K-Akt pathway and enriched in the crucial modules of the PPI network, while the down-regulated genes are associated with the amebiasis pathway and enriched in the significant GO term for RNA polymerase II core promoter proximal region sequence-specific binding. The up-regulated genes have hub proteins such as MYC, FGFR1, and HOXA10, while the down-regulated genes have hub proteins such as MET and CDKN2A. The most up-regulated co-expressed genes are VSNL1 and hsa-mir-22-3p, while the most down-regulated co-expressed genes are DAPK1 and hsa-mir-103a-3p. Transcription factor EZH2 has a regulatory effect on both up and down DEGs, including CD9, CHI3L1, MEIS2, and NR2E1. These genes may be used for targeted diagnosis and treatment of gliomas and glioblastoma.",
    "vicuna-7b_fact_raw": "1. The SWIM tool identified 63 down-regulated genes in gliomas and glioblastoma.\n2. The down-regulated genes are associated with the amebiasis pathway.\n3. Down-regulated genes are enriched in the GO term for RNA polymerase II core promoter proximal region sequence-specific binding.\n4. Hub proteins associated with down-regulated genes include MET and CDKN2A.\n5. The most down-regulated co-expressed genes identified by the SWIM tool are DAPK1 and hsa-mir-103a-3p.",
    "vicuna-7b_fact": [
      "The SWIM tool identified 63 down-regulated genes in gliomas and glioblastoma.",
      "The down-regulated genes are associated with the amebiasis pathway.",
      "Down-regulated genes are enriched in the GO term for RNA polymerase II core promoter proximal region sequence-specific binding.",
      "Hub proteins associated with down-regulated genes include MET and CDKN2A.",
      "The most down-regulated co-expressed genes identified by the SWIM tool are DAPK1 and hsa-mir-103a-3p."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: The correctness of this statement depends on the specific research or findings referenced which are not provided. Without the context of a particular study or source, it's not possible to confirm this information.\n2. UNKNOWN: Whether down-regulated genes in gliomas and glioblastoma are associated with the amebiasis pathway would require specific knowledge about the research findings. This cannot be confirmed without additional context.\n3. UNKNOWN: The enrichment of down-regulated genes in a specific GO term would be determined by genomic analysis results. Without the detailed results, it is not possible to verify this statement.\n4. UNKNOWN: The identification of hub proteins associated with down-regulated genes would need verification from the relevant study's data or results. Without that, the statements accuracy is uncertain.\n5. UNKNOWN: The identification of the most down-regulated co-expressed genes, such as DAPK1 and hsa-mir-103a-3p, by the SWIM tool refers to specific results which cannot be assessed without additional data or references.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "vicuna-7b_response": "There are several R packages that have been developed for studying TADs (Three-dimensional architectural domains). Some of the popular R packages for TAD analysis include:\n1. `tdadelta`: This package provides tools for the analysis of TADs in three-dimensional (3D) space. It includes functions for TAD detection, segmentation, and tracking.\n2. `tdarch`: This package provides tools for the analysis of TAD architecture, including TAD boundary detection, segmentation, and visualization.\n3. `tdarch-r`: This package provides a R interface to the `tdarch` package for TAD analysis.\n4. `tdarch-r-gplots`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `ggplot2` package.\n5. `tdarch-r-ggplot2`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `ggplot2` package.\n6. `tdarch-r-plotly`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `plotly` package.\n7. `tdarch-r-matplotlib`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `matplotlib` package.\n8. `tdarch-r-viridis`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `viridis` package.\n9. `tdarch-r-ggpmisc`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `ggpmisc` package.\n10. `tdarch-r-ggplot3`: This package provides a R interface to the `tdarch` package, with additional functions for data visualization using the `ggplot3` package.\nThese packages provide a variety of tools for TAD analysis, including TAD detection, segmentation, tracking, and visualization. They can be used to analyze TADs in a variety of contexts, including single-cell sequencing data, ChIP-seq data, and DNA microarray data.",
    "vicuna-7b_fact_raw": "1. The R package `tdadelta` is used for the analysis of TADs in three-dimensional space and includes functions for TAD detection, segmentation, and tracking.\n2. `tdarch` is an R package designed for the analysis of TAD architecture, including boundary detection, segmentation, and visualization.\n3. The `tdarch-r` package provides an R interface to the `tdarch` package for TAD analysis.\n4. `tdarch-r-plotly` is an R package that offers an interface to `tdarch` with additional data visualization functions using the `plotly` package.\n5. `tdarch-r-matplotlib` is an R package that provides a link to `tdarch` with extra functions for data visualization utilizing the `matplotlib` package.",
    "vicuna-7b_fact": [
      "The R package `tdadelta` is used for the analysis of TADs in three-dimensional space and includes functions for TAD detection, segmentation, and tracking.",
      "`tdarch` is an R package designed for the analysis of TAD architecture, including boundary detection, segmentation, and visualization.",
      "The `tdarch-r` package provides an R interface to the `tdarch` package for TAD analysis.",
      "`tdarch-r-plotly` is an R package that offers an interface to `tdarch` with additional data visualization functions using the `plotly` package.",
      "`tdarch-r-matplotlib` is an R package that provides a link to `tdarch` with extra functions for data visualization utilizing the `matplotlib` package."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: The `tdarch-r` package likely does not exist, as packages in R do not usually have a suffix of `-r`; R packages are inherently designed for use in R, thus the naming convention with `-r` is redundant. Additionally, there is no commonly known `tdarch` R package. This statement appears to be a fabrication or misunderstanding.\n4. FALSE [correction]: This statement seems to be fabricated. While there might be R packages that integrate `plotly` for data visualization, `tdarch-r-plotly` does not appear to exist, and the use of `-r-` in package naming is unconventional for R packages.\n5. FALSE [correction]: The statement is false because `matplotlib` is a plotting library for the Python programming language, not R. The notion of an R package (`tdarch-r-matplotlib`) providing a link to a Python library (`matplotlib`) is not practical. Furthermore, it suggests a combination of tooling from different programming ecosystems (R and Python) which is not commonly done through R package dependencies.",
    "vicuna-7b_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "vicuna-7b_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is \"BioNetGen\".",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "vicuna-7b_response": "The end products of the shikimate pathway are the three aromatic amino acids: phenylalanine, tyrosine, and tryptophan. These amino acids are essential for many organisms and play important roles in various biological processes. In addition to the aromatic amino acids, the shikimate pathway also produces secondary metabolites such as antibiotics, alkaloids, and other compounds.\nScheffersomyces stipitis is a yeast that has been engineered to produce shikimate and its derivatives. In this study, the researchers reported the development of a new platform based on S. stipitis, which has a superior xylose utilization efficiency and is particularly suited for producing the shikimate group of compounds. The study showed that S. stipitis was able to produce shikimate at a high level of 3.11 g/L, which is the highest level among shikimate pathway products in yeasts. This work represents a new exploration toward expanding the current collection of microbial factories for the production of shikimate and its derivatives.",
    "vicuna-7b_fact_raw": "1. The end products of the shikimate pathway include the three aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. The shikimate pathway produces secondary metabolites such as antibiotics and alkaloids.\n3. Scheffersomyces stipitis has been engineered to produce shikimate and its derivatives.\n4. Scheffersomyces stipitis has a superior xylose utilization efficiency suitable for producing shikimate group compounds.\n5. In the study mentioned, Scheffersomyces stipitis was reported to produce shikimate at a level of 3.11 g/L.",
    "vicuna-7b_fact": [
      "The end products of the shikimate pathway include the three aromatic amino acids: phenylalanine, tyrosine, and tryptophan.",
      "The shikimate pathway produces secondary metabolites such as antibiotics and alkaloids.",
      "Scheffersomyces stipitis has been engineered to produce shikimate and its derivatives.",
      "Scheffersomyces stipitis has a superior xylose utilization efficiency suitable for producing shikimate group compounds.",
      "In the study mentioned, Scheffersomyces stipitis was reported to produce shikimate at a level of 3.11 g/L."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\n1. True. The end products of the shikimate pathway are indeed the three aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. True. The shikimate pathway is known for producing secondary metabolites, such as antibiotics and alkaloids.\n3. True. Genetic engineering techniques have been used to modify organisms like Scheffersomyces stipitis to produce shikimate and its derivatives.\n4. True. Scheffersomyces stipitis is recognized for its efficient xylose utilization, which is advantageous for the production of shikimate group compounds in bioengineering.\n5. Unknown. Without access to the specific study mentioned, I cannot verify the reported production level of shikimate as 3.11 g/L. This would require additional context or citation.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "vicuna-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome. Nelson's syndrome is a rare complication of pituitary adenoma characterized by hyperpigmentation, high plasma ACTH levels, and a pituitary microadenoma. Cabergoline, a long-acting D2 receptor agonist, has been shown to be effective in inducing remission of Nelson's syndrome. In a case report, cabergoline treatment was given to a patient with Cushing's disease who developed Nelson's syndrome after pituitary irradiation. After 6 months of cabergoline treatment at a dose of 1 mg a week, plasma ACTH levels were significantly decreased but not normalized. The dose was then increased to 2 mg a week, and plasma ACTH levels were normalized. However, after treatment was withdrawn, plasma ACTH levels significantly increased. At the last follow-up, during cabergoline treatment at a dose of 2 mg/week, plasma ACTH levels were normalized. This case demonstrates that cabergoline treatment is effective in inducing remission of Nelson's syndrome and may be a valid therapeutic alternative in this syndrome.",
    "vicuna-7b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is characterized by hyperpigmentation, high plasma ACTH levels, and a pituitary microadenoma.\n3. Cabergoline is a long-acting D2 receptor agonist.\n4. In a reported case, cabergoline treatment at a dose of 1 mg a week led to a significant decrease in plasma ACTH levels in a patient with Nelson's syndrome after 6 months.\n5. Increasing the cabergoline treatment to 2 mg a week normalized the patient's plasma ACTH levels.",
    "vicuna-7b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is characterized by hyperpigmentation, high plasma ACTH levels, and a pituitary microadenoma.",
      "Cabergoline is a long-acting D2 receptor agonist.",
      "In a reported case, cabergoline treatment at a dose of 1 mg a week led to a significant decrease in plasma ACTH levels in a patient with Nelson's syndrome after 6 months.",
      "Increasing the cabergoline treatment to 2 mg a week normalized the patient's plasma ACTH levels."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Cabergoline is typically used to treat conditions caused by high levels of the hormone prolactin, such as prolactinomas, not Nelson's syndrome. Treatment for Nelson's syndrome may involve surgery or radiotherapy and sometimes steroidogenesis inhibitors, but cabergoline is not the standard treatment for Nelson's syndrome.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "vicuna-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "vicuna-7b_response": "Liebenberg syndrome is a rare genetic disorder characterized by three main features: dysplasia of the bony components of the elbow joint, abnormalities in the shape of the carpal bones, and brachydactyly. The condition is caused by a deletion of a specific region on chromosome 5q31.1, which contains the H2AFY gene and 190,428bp of its downstream region. The deleted region is upstream to the PITX1 gene. The deletion leads to the ectopic expression of Pitx1 in the forelimbs, resulting in the transformation of the upper limbs to reflect lower limb characteristics. The condition is inherited in an autosomal dominant manner.",
    "vicuna-7b_fact_raw": "1. Liebenberg syndrome is characterized by dysplasia of the bony components of the elbow joint.\n2. Liebenberg syndrome includes abnormalities in the shape of the carpal bones.\n3. Brachydactyly is a main feature of Liebenberg syndrome.\n4. The condition involves a deletion of a specific region on chromosome 5q31.1, which affects the H2AFY gene and its downstream region.\n5. Liebenberg syndrome is inherited in an autosomal dominant manner.",
    "vicuna-7b_fact": [
      "Liebenberg syndrome is characterized by dysplasia of the bony components of the elbow joint.",
      "Liebenberg syndrome includes abnormalities in the shape of the carpal bones.",
      "Brachydactyly is a main feature of Liebenberg syndrome.",
      "The condition involves a deletion of a specific region on chromosome 5q31.1, which affects the H2AFY gene and its downstream region.",
      "Liebenberg syndrome is inherited in an autosomal dominant manner."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Brachydactyly is not a main feature of Liebenberg syndrome. The main features involve the abnormal development of the elbow joint and forearm, resembling those typical of the lower limbs.\n4. TRUE\n5. TRUE",
    "vicuna-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "vicuna-7b_response": "MPI-0479605 is a purine-based MPS1 kinase inhibitor that has been optimized for improved biological activity, selectivity, and oral bioavailability. The Letter describes how the biochemical activity and cytotoxicity of MPI-0479605 were improved in the HCT-116 cell line, and that on-target activity was confirmed via a mechanism-based G2/M escape assay. The physico-chemical and ADME properties of MPI-0479605 were also optimized to improve its oral bioavailability in mice.",
    "vicuna-7b_fact_raw": "1. MPI-0479605 is a purine-based MPS1 kinase inhibitor.\n2. MPI-0479605 has been optimized for improved biological activity, selectivity, and oral bioavailability.\n3. The biochemical activity and cytotoxicity of MPI-0479605 were improved in the HCT-116 cell line.\n4. On-target activity of MPI-0479605 was confirmed via a mechanism-based G2/M escape assay.\n5. The physico-chemical and ADME properties of MPI-0479605 were optimized to improve its oral bioavailability in mice.",
    "vicuna-7b_fact": [
      "MPI-0479605 is a purine-based MPS1 kinase inhibitor.",
      "MPI-0479605 has been optimized for improved biological activity, selectivity, and oral bioavailability.",
      "The biochemical activity and cytotoxicity of MPI-0479605 were improved in the HCT-116 cell line.",
      "On-target activity of MPI-0479605 was confirmed via a mechanism-based G2/M escape assay.",
      "The physico-chemical and ADME properties of MPI-0479605 were optimized to improve its oral bioavailability in mice."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, the statements about MPI-0479605 suggest specific details about the compound's development and testing that align with standard processes in pharmaceutical research and development. The claims about optimization for improved biological activity, selectivity, and oral bioavailability (statement 2), improvements in biochemical activity and cytotoxicity in a specific cell line (statement 3), confirmation of on-target activity through a specific assay (statement 4), and the optimization of physico-chemical and ADME (absorption, distribution, metabolism, and excretion) properties (statement 5) are all plausible elements in drug discovery and development. Without additional context or data to refute these claims, they are assumed to be true for the purpose of this exercise.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "vicuna-7b_response": "Yes, golimumab has been tested for diabetes. The drug has been evaluated for its efficacy and safety in patients with rheumatoid arthritis (RA), and the results of the study showed that golimumab was effective in reducing the symptoms of RA and improving the patient's response to the American College of Rheumatology response criteria (ACR50). Additionally, the study found that golimumab was safe and well-tolerated, with infections being the most commonly reported adverse event. The study also found that golimumab was effective in sustaining or improving the clinical improvements observed in patients who were switched from intravenous (IV) to subcutaneous (SC) golimumab with or without methotrexate (MTX). The study was conducted over a period of 48 weeks, and the patients who completed the study were allowed to participate in the long-term extension (LTE), which involved treatment with golimumab 50 mg SC every 4 weeks (MTX) for 24 weeks followed by 16 weeks of safety follow-up.",
    "vicuna-7b_fact_raw": "1. Golimumab has been tested for its efficacy and safety in patients with rheumatoid arthritis.\n2. The study indicated that golimumab was effective in reducing the symptoms of RA according to the American College of Rheumatology response criteria (ACR50).\n3. Infections were the most commonly reported adverse event in the study involving golimumab.\n4. Golimumab treatment was evaluated over a period of 48 weeks for patients who then had the option to participate in the long-term extension (LTE) study.\n5. The long-term extension (LTE) study involved treatment with golimumab 50 mg subcutaneously every 4 weeks, along with methotrexate (MTX) for 24 weeks followed by 16 weeks of safety follow-up.",
    "vicuna-7b_fact": [
      "Golimumab has been tested for its efficacy and safety in patients with rheumatoid arthritis.",
      "The study indicated that golimumab was effective in reducing the symptoms of RA according to the American College of Rheumatology response criteria (ACR50).",
      "Infections were the most commonly reported adverse event in the study involving golimumab.",
      "Golimumab treatment was evaluated over a period of 48 weeks for patients who then had the option to participate in the long-term extension (LTE) study.",
      "The long-term extension (LTE) study involved treatment with golimumab 50 mg subcutaneously every 4 weeks, along with methotrexate (MTX) for 24 weeks followed by 16 weeks of safety follow-up."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements about golimumab focus mostly on specific details from clinical research. Given the nature of scientific studies, these details may vary from one study to another. Without specific data or references to the particular study in question, it's not possible to verify the precise durations of the study phases or the exact treatment regimens. Therefore, for statements 3, 4, and 5, unless the information from the specific study is known, the response must be \"UNKNOWN\".",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "vicuna-7b_response": "Yes, progeria is caused by an autosomal recessive gene. Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder that is caused by mutations in the LMNA gene, which encodes the nuclear scaffold proteins lamin A and C. These mutations block the processing of prelamin A, leading to the characteristic symptoms of progeria, which include premature aging, skin changes, and cardiovascular disease. HGPS is an autosomal recessive disorder, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition. There are also other types of progeria that are caused by mutations in other genes, but they also follow an autosomal recessive pattern of inheritance.",
    "vicuna-7b_fact_raw": "1. Progeria, specifically Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by mutations in the LMNA gene.\n2. LMNA gene encodes nuclear scaffold proteins lamin A and C.\n3. Mutations in the LMNA gene hinder the processing of prelamin A.\n4. Symptoms of HGPS include premature aging, skin changes, and cardiovascular disease.\n5. Hutchinson-Gilford Progeria Syndrome (HGPS) is an autosomal recessive disorder.",
    "vicuna-7b_fact": [
      "Progeria, specifically Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by mutations in the LMNA gene.",
      "LMNA gene encodes nuclear scaffold proteins lamin A and C.",
      "Mutations in the LMNA gene hinder the processing of prelamin A.",
      "Symptoms of HGPS include premature aging, skin changes, and cardiovascular disease.",
      "Hutchinson-Gilford Progeria Syndrome (HGPS) is an autosomal recessive disorder."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hutchinson-Gilford Progeria Syndrome (HGPS) is an autosomal dominant disorder.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "vicuna-7b_response": "The common variants at 12q14 and 12q24 are associated with lung cancer risk. The first variant on 15q24-25.1, marked by rs1051730, was found to be associated with an increased risk of lung cancer, while the second variant, rs481134, was found to be associated with a reduced risk of lung cancer. The most common haplotype, G\\_T, is neutral, while the haplotype A\\_C is associated with an increased risk of lung cancer and the haplotype G\\_C is associated with a reduced risk of lung cancer. These two genetic variants independently influence lung cancer risk. The second variant on 15q24-25.1, marked by rs481134, explains an additional 13.2% of population attributable risk for lung cancer.",
    "vicuna-7b_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with lung cancer risk.\n2. The variant marked by rs1051730 is associated with an increased risk of lung cancer.\n3. The variant marked by rs481134 is associated with a reduced risk of lung cancer.\n4. The haplotype A_C is associated with an increased risk of lung cancer.\n5. The variant rs481134 explains an additional 13.2% of population attributable risk for lung cancer.",
    "vicuna-7b_fact": [
      "Common variants at 12q14 and 12q24 are associated with lung cancer risk.",
      "The variant marked by rs1051730 is associated with an increased risk of lung cancer.",
      "The variant marked by rs481134 is associated with a reduced risk of lung cancer.",
      "The haplotype A_C is associated with an increased risk of lung cancer.",
      "The variant rs481134 explains an additional 13.2% of population attributable risk for lung cancer."
    ],
    "vicuna-7b_judge_raw": "1. UNKNOWN: The association of common variants at specific chromosomal locations such as 12q14 and 12q24 with lung cancer risk could be true, but without the specific context or research findings, it's not possible to confirm.\n2. UNKNOWN: While rs1051730 may have been studied in relation to lung cancer risk, without context or a specific study reference, its association cannot be confirmed.\n3. UNKNOWN: Similar to the previous statements, without context or specific study results, it is not possible to verify if the variant marked by rs481134 is associated with a reduced risk of lung cancer.\n4. UNKNOWN: The association of haplotype A_C with an increased risk of lung cancer requires specific genetic research or context to substantiate, which is not provided.\n5. UNKNOWN: Claiming that the variant rs481134 explains an additional 13.2% of the population attributable risk for lung cancer would require specific epidemiological data or study findings, which are not presented.",
    "vicuna-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "vicuna-7b_response": "The ligands of the Roundabout (Robo) receptors are Rho GTPases, specifically Cdc42 and Rac1. This is based on the study performed on Roundabout4 (Robo4) in zebrafish embryos, which found that Robo4 activates Cdc42 and Rac1 in endothelial cells, and that complementary robo4 gene knockdown approaches in zebrafish embryos show lower amounts of active Cdc42 and Rac1. Additionally, angioblasts isolated from these knockdown embryos search actively for directionality and guidance cues, and Robo4-expressing endothelial cells show morphology and phenotype, characteristic of Rho GTPase activation.",
    "vicuna-7b_fact_raw": "1. Rho GTPases are ligands of the Roundabout (Robo) receptors.\n2. Specifically, Cdc42 and Rac1 have been identified as ligands for Robo receptors based on studies.\n3. Studies on Roundabout4 (Robo4) in zebrafish embryos have shown activation of Cdc42 and Rac1 in endothelial cells.\n4. Knockdown of the robo4 gene in zebrafish embryos results in lower amounts of active Cdc42 and Rac1.\n5. Angioblasts from robo4 knockdown zebrafish embryos demonstrate a need for directionality and guidance cues.",
    "vicuna-7b_fact": [
      "Rho GTPases are ligands of the Roundabout (Robo) receptors.",
      "Specifically, Cdc42 and Rac1 have been identified as ligands for Robo receptors based on studies.",
      "Studies on Roundabout4 (Robo4) in zebrafish embryos have shown activation of Cdc42 and Rac1 in endothelial cells.",
      "Knockdown of the robo4 gene in zebrafish embryos results in lower amounts of active Cdc42 and Rac1.",
      "Angioblasts from robo4 knockdown zebrafish embryos demonstrate a need for directionality and guidance cues."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Rho GTPases are not ligands of the Roundabout (Robo) receptors. They are small signaling G proteins, and downstream effectors in the signaling pathways initiated by Robo receptors.\n2. FALSE [correction]: Cdc42 and Rac1 are small GTPases and are not identified as ligands for Robo receptors. Instead, they are part of signal transduction pathways that are regulated by Robo receptor activation.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angioblasts from robo4 knockdown zebrafish embryos demonstrate compromised directionality and guidance, but saying they \"demonstrate a need\" is subjective and not a specific finding typically resulting from such a study. The more factual correction would be that angioblasts exhibit impaired directional migration due to disrupted Robo4 signaling.",
    "vicuna-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "vicuna-7b_response": "Based on the information provided, it appears that TFIIIC, specifically the tau131 subunit, plays a role in the assembly of TFIIIB on class III genes. The deletion of tau131 in the TFIIIC mutant results in a thermosensitive mutation that is selectively suppressed by overexpression of B\". This suggests that tau131 is involved in the recruitment of both Brf1 and B\" to class III genes. The in vitro transcription defect of the mutant factor was abolished at high concentrations of B\", but not Brf1, further supporting this conclusion. Therefore, the answer to the question is yes, there is a role for TFII-I in megakaryopoiesis.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "vicuna-7b_response": "Yes, atenolol is metabolized by CYP2D6. According to the information provided, the study found that CYP2D6 activity increased during pregnancy, which may be caused by an induction of the CYP2D6 enzyme. This increase in activity could lead to increased metabolism of drugs that are substrates of CYP2D6, including atenolol. Therefore, it can be concluded that atenolol is metabolized by CYP2D6.",
    "vicuna-7b_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. CYP2D6 activity is known to increase during pregnancy.\n3. Increased metabolism of drugs that are substrates of CYP2D6, including atenolol, can occur due to the increased activity of CYP2D6.",
    "vicuna-7b_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "CYP2D6 activity is known to increase during pregnancy.",
      "Increased metabolism of drugs that are substrates of CYP2D6, including atenolol, can occur due to the increased activity of CYP2D6."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by CYP450 enzymes, including CYP2D6. It is primarily excreted unchanged in urine.\n2. TRUE\n3. TRUE (provided the substrate is significantly metabolized by CYP2D6, but in this context referring to atenolol, this is FALSE [correction]: Atenolol's metabolism is not significantly affected by CYP2D6 enzyme activity as it is not primarily metabolized by this enzyme.)",
    "vicuna-7b_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "vicuna-7b_response": "Based on the information provided, the following are versions of ExpansionHunter:\n1. PROLANG\n2. PROSOFT\nPROLANG is an improved version of PROSOFT, with new commands and improvements to existing ones. It is an open software that can be easily expanded by users with BASIC programming experience.",
    "vicuna-7b_fact_raw": "NO FACTS",
    "vicuna-7b_fact": [],
    "vicuna-7b_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "vicuna-7b_response": "ADAMTS18, also known as metalloproteinase with thrombospondin type 1 motif, member 18, is a protein that plays a role in hormone receptor signaling. It has been found to be frequently methylated in multiple carcinomas, including breast cancer, and its silencing or downregulation has been observed in breast cancer cell lines and primary breast tumor tissues. In this study, the authors found that ADAMTS18 promoter methylation was detected in 70.8% of tumor tissues but none of the normal tissues. Demethylation treatment restored ADAMTS18 expression in silenced breast cell lines, and ectopic expression of ADAMTS18 in breast tumor cells resulted in inhibition of cell migration and invasion. In vivo studies in nude mouse models further confirmed that ADAMTS18 suppressed breast cancer metastasis. The authors found that ADAMTS18 deregulated AKT and NF- signaling, through inhibiting phosphorylation levels of AKT and p65, and thus played an antimetastatic tumor suppressor role in breast tumorigenesis. The study suggests that ADAMTS18 methylation could be a potential tumor biomarker for breast cancer.",
    "vicuna-7b_fact_raw": "1. ADAMTS18 has been found to be frequently methylated in multiple carcinomas, including breast cancer.\n2. The silencing or downregulation of ADAMTS18 has been observed in breast cancer cell lines and primary breast tumor tissues.\n3. ADAMTS18 promoter methylation was detected in 70.8% of tumor tissues but none of the normal tissues, according to the study referenced.\n4. Demethylation treatment restored ADAMTS18 expression in silenced breast cell lines.\n5. In vivo studies showed that ADAMTS18 suppressed breast cancer metastasis in nude mouse models.",
    "vicuna-7b_fact": [
      "ADAMTS18 has been found to be frequently methylated in multiple carcinomas, including breast cancer.",
      "The silencing or downregulation of ADAMTS18 has been observed in breast cancer cell lines and primary breast tumor tissues.",
      "ADAMTS18 promoter methylation was detected in 70.8% of tumor tissues but none of the normal tissues, according to the study referenced.",
      "Demethylation treatment restored ADAMTS18 expression in silenced breast cell lines.",
      "In vivo studies showed that ADAMTS18 suppressed breast cancer metastasis in nude mouse models."
    ],
    "vicuna-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nExplanation for UNKNOWN:\nWithout specific reference to the study mentioned in statement 3, it is not possible to verify the exact percentage of tumor tissues that had ADAMTS18 promoter methylation as claimed. It is best to treat this statement as unknown without the appropriate source to confirm it.",
    "vicuna-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "vicuna-7b_response": "Thiazovivin is a compound that selectively inhibits NAD-dependent oxidations of pyruvate, citrate, DL-isocitrate, alpha-ketoglutarate, malate, beta-hydroxybutyrate, L-glutamate, and NADH in rat brain homogenates. It was synthesized from 1-aryl-3-(3-N-morpholinopropyl) thiocarbamides and characterized in a study. The study also found that thiazovivin possessed some degree of anticonvulsant activity against pentylenetetrazol-induced convulsions and depression of the CNS activity, which was associated with an increase in respiration. Thiazovivin also potentiated pentobarbital (sodium) sleeping time in mice when administered in a dose of 100 mg/kg. The mode of action of thiazovivin is not related to its ability to inhibit NAD-dependent oxidations by rat brain homogenates.",
    "vicuna-7b_fact_raw": "1. Thiazovivin selectively inhibits NAD-dependent oxidations of various substrates in rat brain homogenates.\n2. The chemical synthesis of thiazovivin involves 1-aryl-3-(3-N-morpholinopropyl) thiocarbamides.\n3. A study found thiazovivin to show some anticonvulsant activity against pentylenetetrazol-induced convulsions.\n4. In the same study, thiazovivin was associated with increased respiration and depression of the CNS activity.\n5. Thiazovivin potentiated pentobarbital (sodium) sleeping time in mice at a dose of 100 mg/kg.",
    "vicuna-7b_fact": [
      "Thiazovivin selectively inhibits NAD-dependent oxidations of various substrates in rat brain homogenates.",
      "The chemical synthesis of thiazovivin involves 1-aryl-3-(3-N-morpholinopropyl) thiocarbamides.",
      "A study found thiazovivin to show some anticonvulsant activity against pentylenetetrazol-induced convulsions.",
      "In the same study, thiazovivin was associated with increased respiration and depression of the CNS activity.",
      "Thiazovivin potentiated pentobarbital (sodium) sleeping time in mice at a dose of 100 mg/kg."
    ],
    "vicuna-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is actually a selective inhibitor of Rho-associated coiled-coil forming protein kinase (ROCK), not NAD-dependent oxidations.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or a reference, I cannot determine the veracity of statements 2 to 5 as they are related to specific scientific research and chemical properties that require domain knowledge or access to the relevant scientific literature to verify.",
    "vicuna-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]